

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
26 August 2004 (26.08.2004)

PCT

(10) International Publication Number
WO 2004/071507 A1

(51) International Patent Classification⁷: **A61K 31/4162**,
C07D 487/04, 209/82, A61P 25/00, 35/00, 37/00

(21) International Application Number:
PCT/EP2004/050071

(22) International Filing Date: 3 February 2004 (03.02.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/448,049 17 February 2003 (17.02.2003) US

(71) Applicant (for all designated States except US): **PHARMACIA ITALIA S.P.A.** [IT/IT]; Via Robert Koch 1.2, I-20152 Milan (IT).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **VANOTTI, Ermes** [CH/IT]; Via Cimabue 4, I-20148 Milan (IT). **CERVI, Giovanni** [IT/IT]; Via Cavallotti 4, I-22100 Como (IT). **PULICI, Maurizio** [IT/IT]; Via T. Sperti 31, I-20040 Caponago (Milan) (IT). **MENICHINCHERI, Maria** [IT/IT]; Via F. Casati 19, I-20124 Milan (IT). **VARASI, Mario** [IT/IT]; Via Moncucco 24/A, I-20142 Milan (IT). **VIANELLO, Paola** [IT/IT]; Via Trebazio 6, I-20145 Milan (IT).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: TETRACYCLIC PYRAZOLE DERIVATIVES AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM

(57) Abstract: The present invention provides a method for treating diseases caused by and/or associated with an altered protein kinase activity which comprises administering to a mammal in need thereof an effective amount of a tetracyclic pyrazole. The invention also provides specific tetracyclic pyrazole derivatives, useful intermediates, a library comprising at least two of them, a process for their preparation and the pharmaceutical compositions containing them, which are useful in the treatment of diseases caused by and/or associated with an altered protein kinase activity such as cancer, cell proliferative disorders, viral infections, autoimmune diseases and neurodegenerative disorders.



WO 2004/071507 A1

TITLE OF THE INVENTION

TETRACYCLIC PYRAZOLE DERIVATIVES AS KINASE INHIBITORS,
PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL
5 COMPOSITIONS COMPRISING THEM

BACKGROUND OF THE INVENTIONField of the Invention

The present invention relates to pyrazole derivatives
10 active as kinase inhibitors and, more in particular, it
relates to tetracyclic pyrazole derivatives, to a process
for their preparation, to pharmaceutical compositions
comprising them and to their use as therapeutic agents,
particularly in the treatment of diseases linked to
15 deregulated protein kinases.

Discussion of the Background

The malfunctioning of protein kinases (PKs) is the hallmark
of numerous diseases.

A large share of the oncogenes and proto-oncogenes are
20 involved in human cancers code for PKs. The enhanced
activities of PKs are also implicated in many non-malignant
diseases such as benign prostate hyperplasia, familial
adenomatosis, polyposis, neuro-fibromatosis, psoriasis,
vascular smooth cell proliferation associated with
25 atherosclerosis, pulmonary fibrosis, arthritis
glomerulonephritis and post-surgical stenosis and
restenosis.

PKs are also implicated in inflammatory conditions and in
the multiplication of viruses and parasites. PKs may also
30 play a major role in the pathogenesis and development of
neurodegenerative disorders.

For a general reference to PKs malfunctioning or
dysregulation see, for instance, *Current Opinion in
Chemical Biology* **1999**, 3, 459-465.

- 2 -

Several pyrazole derivatives and analogues thereof are known in the art, for instance as synthetic intermediates or even as therapeutic agents.

As an example, carboxamido-pyrazoles possessing cdk
5 inhibitory activity have been described in U.S. Patent No. 6,218,418 to Pevarello et al.

Pyrazole derivatives have been described for use in the treatment of inflammation. U.S. Patent No. 5,134,142 to Matsuo et al describes 1,5-diaryl pyrazole derivatives, and
10 specifically, 1-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3-trifluoromethyl pyrazole, as having anti-inflammatory activity.

U.S. Patent No. 3,940,418 to R. Hamilton describes tricyclic 4,5-dihydrobenz[g]indazole derivatives as anti-
15 inflammatory agents. In addition, R. Hamilton [*J. Heterocyclic Chem.*, **13**, 545 (1976)] describes tricyclic 4,5-dihydrobenz[g]indazole derivatives as anti-inflammatory agents. U.S. Patent No. 5,134,155 describes fused tricyclic pyrazole derivatives having a saturated ring
20 bridging the pyrazole and a phenyl radical as HMG-CoA reductase inhibitors. European publication EP 477,049, published Mar. 25, 1992, describes [4,5-dihydro-1-phenyl-1H-benz[g]indazol-3-yl]amides as having antipsychotic activity. European publication EP 347,773, published Dec.
25 27, 1989, describes [4,5-dihydro-1-phenyl-1H-benz[g]indazol-3-yl]propanamide derivatives as immunostimulants. M. Hashem et al [*J. Med. Chem.*, **19**, 229 (1976)] describes fused tricyclic pyrazole derivatives, having a saturated ring bridging the pyrazole and a phenyl
30 radical, as antibiotics.

Certain substituted pyrazolyl-benzenesulfonamide derivatives have been described in the literature as synthetic intermediates. Specifically, 4-[5-(4-chlorophenyl)-3-phenyl-1H-pyrazol-1-yl]benzenesulfonamide

- 3 -

has been prepared from a pyrazoline compound as an intermediate for compounds having hypoglycemic activity [R. Soliman et al, *J. Pharm. Sci.*, **76**, 626 (1987)]. 4-[5-[2-(4-Bromophenyl)-2H-1,2,3-triazol-4-yl]-3-methyl-1H-pyrazol-1-yl]benzenesulfonamide has been prepared from a pyrazoline compound and described as potentially having hypoglycemic activity [H. Mokhtar, *Pak. J. Sci. Ind. Res.*, **31**, 762 (1988)]. Similarly, 4-[4-bromo-5-[2-(4-chlorophenyl)-2H-1,2,3-triazol-4-yl]-3-methyl-1H-pyrazol-1-yl]benzenesulfonamide has been prepared [H. Mokhtar et al, *Pak. J. Sci. Ind. Res.*, **34**, 9 (1991)].

The phytotoxicity of pyrazole derivatives is described [M. Cocco et al, *Il. Farmaco-Ed. Sci.*, **40**, 272 (1985)], specifically for 1-[4-(aminosulfonyl)phenyl]-5-phenyl-1H-pyrazole-3,4-dicarboxylic acid.

The use of styryl pyrazole esters for antidiabetic drugs is described [H. Mokhtar et al, *Pharmazie*, **33**, 649-651 (1978)]. The use of styryl pyrazole carboxylic acids for antidiabetes drugs is described [R. Soliman et al, *Pharmazie*, **33**, 184-5 (1978)]. The use of 4-[3,4,5-trisubstituted-pyrazol-1-yl]benzenesulfonamide derivatives as intermediates for sulfonylurea anti-diabetes agents is described, and specifically, 1-[4-(aminosulfonyl)phenyl]-3-methyl-5-phenyl-1H-pyrazole-4-carboxylic acid [R. Soliman et al, *J. Pharm. Sci.*, **72**, 1004 (1983)]. A series of 4-[3-substituted methyl-5-phenyl-1H-pyrazol-1-yl]benzenesulfonamide derivatives has been prepared as intermediates for anti-diabetes agents, and more specifically, 4-[3-methyl-5-phenyl-1H-pyrazol-1-yl]benzenesulfonamide [H. Feid-Allah, *Pharmazie*, **36**, 754 (1981)]. In addition, 1-(4-[aminosulfonyl]phenyl)-5-phenylpyrazole-3-carboxylic acid has been prepared from the above described 4-[3-methyl-5-phenyl-1H-pyrazol-1-

- 4 -

yl]benzenesulfonamide compound [R. Soliman et al, *J. Pharm. Sci.*, **70**, 602 (1981)].

WO00/27822 discloses tricyclic pyrazole derivatives,

WO00/59901 discloses dihydroindeno pyrazole derivatives,

5 WO95/15315 discloses diphenyl pyrazole compounds,

WO95/15317 discloses triphenyl pyrazole compounds,

WO95/15318 discloses tri-substituted pyrazole compounds,

and WO96/09293 discloses benz[g]indazolyl derivatives.

WO95/15316 discloses substituted pyrazolyl benzenesulfamide

10 derivatives.

SUMMARY OF THE INVENTION

The present inventors have now discovered that some tetracyclic pyrazole derivatives are endowed with multiple protein kinase inhibiting activity and are thus useful in

15 therapy in the treatment of diseases caused by and/or associated with dysregulated protein kinases.

As such, it is an object of the invention to provide compounds useful as therapeutic agents against a host of diseases caused by a dysregulated protein kinase activity.

20 It is another object to provide compounds endowed with multiple protein kinase inhibiting activity.

More specifically, the tetracyclic pyrazole derivatives of this invention are useful in the treatment of a variety of cancers including, but not limited to: carcinoma such as

25 bladder, breast, colon, kidney, liver, lung, including small cell lung cancer, esophagus, gall-bladder, ovary, pancreas, stomach, cervix, thyroid, prostate, and skin, including squamous cell carcinoma; hematopoietic tumors of lymphoid lineage, including leukemia, acute lymphocytic leukemia, acute lymphoblastic leukemia, B-cell lymphoma, T-cell-lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, hairy cell lymphoma and Burkett's lymphoma; hematopoietic tumors of myeloid lineage, including acute and chronic myelogenous leukemias, myelodysplastic syndrome and

- 5 -

promyelocytic leukemia; tumors of mesenchymal origin, including fibrosarcoma and rhabdomyosarcoma; tumors of the central and peripheral nervous system, including astrocytoma, neuroblastoma, glioma and schwannomas; other
5 tumors, including melanoma, seminoma, teratocarcinoma, osteosarcoma, xenoderma pigmentosum, keratocanthoma, thyroid follicular cancer and Kaposi's sarcoma.

Due to the key role of PKs in the regulation of cellular proliferation, these tetracyclic pyrazole derivatives are
10 also useful in the treatment of a variety of cell proliferative disorders such as, for instance, benign prostate hyperplasia, familial adenomatosis, polyposis, neuro-fibromatosis, psoriasis, vascular smooth cell proliferation associated with atherosclerosis, pulmonary
15 fibrosis, arthritis glomerulonephritis and post-surgical stenosis and restenosis.

The compounds of the invention can be useful in the treatment of Alzheimer's disease, as suggested by the fact that cdk5 is involved in the phosphorylation of tau protein
20 (*J. Biochem.*, **1995**, *117*, 741-749).

The compounds of this invention, as modulators of apoptosis, may also be useful in the treatment of cancer, viral infections, prevention of AIDS development in HIV-infected individuals, autoimmune diseases and
25 neurodegenerative disorders.


The compounds of this invention may be useful in inhibiting tumor angiogenesis and metastasis.

The compounds of this invention may also act as inhibitors of other protein kinases, e.g. protein kinase C in
30 different isoforms, Met, PAK-4, PAK-5, ZC-1, STIK-2, DDR-2, Aurora 1, Aurora 2, Bub-1, PLK, Chk1, Chk2, HER2, raf1, MEK1, MAPK, EGF-R, PDGF-R, FGF-R, IGF-R, PI3K, weel kinase, Src, Abl, Akt, ILK, MK-2, IKK-2, Nek, Cdc7, and thus be

- 6 -

effective in the treatment of diseases associated with other protein kinase malfunctioning.

Accordingly, the present invention provides a method for treating diseases caused by and/or associated with an altered protein kinase activity which comprises administering to a mammal in need thereof an effective amount of a tetracyclic pyrazole derivative represented by formula (I):



(I)

10

wherein

R1 and R2, being the same or different, are independently hydrogen or halogen atom, nitro, cyano, hydroxy, carboxy, hydroxyaminocarbonyl group, or an optionally substituted group selected from aminocarbonyl, amino or sulfonamido group, a straight or branched C₁-C₈ alkyl group, a perfluorinated C₁-C₈ alkyl, a straight or branched C₁-C₈ alkoxy C₁-C₆ alkyl group, a saturated or unsaturated C₃-C₇ cycloalkyl, a saturated or unsaturated C₃-C₇ cycloalkyl C₁-C₆ alkyl, a straight or branched C₂-C₈ alkenyl group, a straight or branched C₁-C₈ alkyloxy group, a saturated or unsaturated C₃-C₆ cycloalkyloxy, a straight or branched C₁-C₈ alkyloxy C₁-C₆ alkyloxy group, C₁-C₆ alkyloxycarbonyl, aryloxycarbonyl, aryl C₁-C₆ alkyloxycarbonyl, heteroaryloxycarbonyl, heteroaryl C₁-C₆ alkyloxycarbonyl, C₁-C₆ alkylaminocarbonyl, C₁-C₆ dialkylaminocarbonyl, arylaminocarbonyl, heteroarylaminocarbonyl, C₁-C₆ alkyloxyaminocarbonyl, aryloxyaminocarbonyl, C₁-C₆ alkylcarbonyloxy, arylcarbonyloxy, C₁-C₆ alkylcarbonyl, arylcarbonyl, heterocyclylcarbonyl, aryl, aryl C₁-C₆ alkyl

30

- 7 -

group, aryl C₁-C₆ alkyloxy group, aryloxy, heteroaryl, heteroaryl C₁-C₆ alkyl group, a straight or branched C₁-C₆ alkylthio, C₁-C₆ alkylsulphinyl, C₁-C₆ alkylsulphonyl, arylthio, arylsulphinyl, arylsulphonyl, C₁-C₆ alkylamino, di

5 C₁-C₆ alkylamino, arylamino, aryl C₁-C₆ alkylamino, heteroarylamino, heteroaryl C₁-C₆ alkylamino, C₁-C₆ alkylcarbonylamino, arylcarbonylamino, C₁-C₆ alkyloxycarbonylamino, aryl C₁-C₆ alkyloxycarbonylamino, aryloxycarbonylamino, ureido, thioureido group, C₁-C₆

10 alkylaminocarbonylamino, C₁-C₆ dialkylaminocarbonylamino, arylaminocarbonylamino, C₁-C₆ alkylaminothiocarbonylamino, C₁-C₆ dialkylaminothiocarbonylamino, arylaminothiocarbonyl-amino, C₁-C₆ alkylsulfonylamino, arylsulfonylamino, C₁-C₆ alkylaminosulfonyl and arylaminosulfonyl group;

15 Y is a -(CH₂)_n- group wherein n is 1, 2 or 3, or a carbon-carbon double bond (-CH₂=CH₂-);

R₃ is hydrogen atom, cyano, carboxy, hydroxyaminocarbonyl group, or an optionally substituted group selected from aminocarbonyl, amino or sulfonamido group, a straight or

20 branched C₁-C₈ alkyl group, a perfluorinated C₁-C₈ alkyl, a straight or branched C₁-C₈ alkoxy C₁-C₆ alkyl group, a saturated or unsaturated C₃-C₇ cycloalkyl, a saturated or unsaturated C₃-C₇ cycloalkyl C₁-C₆ alkyl, a straight or branched C₂-C₈ alkenyl group, an aryl, an aryl C₁-C₆ alkyl

25 group, a straight or branched C₁-C₈ alkyloxy group, a saturated or unsaturated C₃-C₆ cycloalkyloxy, a straight or branched C₁-C₈ alkyloxy C₁-C₆ alkyloxy group, C₁-C₆ alkyloxy-carbonyl, aryloxycarbonyl, aryl C₁-C₆ alkyloxycarbonyl, heteroaryloxycarbonyl, heteroaryl C₁-C₆ alkyloxycarbonyl,


30 C₁-C₆ alkylaminocarbonyl, C₁-C₆ dialkylaminocarbonyl, arylaminocarbonyl, C₁-C₆ alkyloxyaminocarbonyl, aryloxyamino carbonyl, C₁-C₆ alkylcarbonyloxy, arylcarbonyloxy,

C₁-C₆ alkylcarbonyl, arylcarbonyl, heterocyclylcarbonyl,

35 aryl C₁-C₆ alkyloxy group, aryloxy, a straight or branched

- 8 -

- C₁-C₆ alkylthio, aryl C₁-C₆ alkylthio, C₁-C₆ alkylsulphinyl group, C₁-C₆ alkylsulphonyl, arylthio, arylsulphinyl, arylsulphonyl, C₁-C₆ alkylamino, di C₁-C₆ alkylamino, arylamino, aryl C₁-C₆ alkylamino, heteroaryl amino, heteroaryl C₁-C₆ alkylamino, C₁-C₆ alkylcarbonylamino, arylcarbonylamino, C₁-C₆ alkyloxycarbonylamino, aryl C₁-C₆ alkyloxycarbonylamino, aryloxycarbonylamino, an ureido, thioureido group, C₁-C₆ alkylaminocarbonylamino, C₁-C₆ dialkylaminocarbonylamino, arylaminocarbonylamino, C₁-C₆ alkylaminothiocabonylamino, C₁-C₆ dialkylaminothiocabonylamino, arylaminothiocabonylamino, C₁-C₆ alkylsulfonylamino, arylsulfonylamino, C₁-C₆ alkylaminosulfonyl, and arylamino-sulfonyl group, or a pharmaceutically acceptable salt thereof.
- The present invention also provides a tetracyclic pyrazole derivative of the formula (I):



(I)

- wherein
- R1 and R2, being the same or different, are independently hydrogen or halogen atom, nitro, cyano, hydroxy, carboxy, hydroxyaminocarbonyl group, or an optionally substituted group selected from aminocarbonyl, amino or sulfonamido group, a straight or branched C₁-C₈ alkyl group, a perfluorinated C₁-C₈ alkyl, a straight or branched C₁-C₈ alkoxy C₁-C₆ alkyl group, a saturated or unsaturated C₃-C₇ cycloalkyl, a saturated or unsaturated C₃-C₇ cycloalkyl C₁-C₆ alkyl, a straight or branched C₂-C₈ alkenyl group, a straight or branched C₁-C₈ alkyloxy group, a saturated or unsaturated C₃-C₆ cycloalkyloxy, a straight or branched C₁-

- 9 -

- C₈ alkyloxy C₁-C₆ alkyloxy group, C₁-C₆ alkyloxycarbonyl, aryloxycarbonyl, aryl C₁-C₆ alkyloxycarbonyl, heteroaryloxycarbonyl, heteroaryl C₁-C₆ alkyloxycarbonyl, C₁-C₆ alkylaminocarbonyl, C₁-C₆ dialkylaminocarbonyl
- 5 arylaminocarbonyl, heteroarylaminocarbonyl, , C₁-C₆ alkyloxyaminocarbonyl, aryloxyaminocarbonyl, C₁-C₆ alkylcarbonyloxy, arylcarbonyloxy, C₁-C₆ alkylcarbonyl, arylcarbonyl, heterocyclylcarbonyl, aryl, aryl C₁-C₆ alkyl group, aryl C₁-C₆ alkyloxy group, aryloxy, heteroaryl,
- 10 heteroaryl C₁-C₆ alkyl group, a straight or branched C₁-C₆ alkylthio, C₁-C₆ alkylsulphanyl, C₁-C₆ alkylsulphonyl, arylthio, arylsulphanyl, arylsulphonyl, C₁-C₆ alkylamino, di C₁-C₆ alkylamino, arylamino, aryl C₁-C₆ alkylamino, heteroarylamino, heteroaryl C₁-C₆ alkylamino, C₁-C₆ alkyl-
- 15 carbonylamino, arylcarbonylamino, C₁-C₆ alkyloxycarbonyl-amino, aryl C₁-C₆ alkyloxycarbonylamino, aryloxycarbonyl-amino, ureido, thioureido group, C₁-C₆ alkylamino-carbonylamino, C₁-C₆ dialkylaminocarbonylamino, arylamino-carbonylamino, C₁-C₆ alkylaminothiocabonylamino, C₁-C₆
- 20 dialkylaminothiocabonylamino, arylaminothiocabonyl-amino, C₁-C₆ alkylsulfonylamino, arylsulfonylamino, C₁-C₆ alkylaminosulfonyl and arylaminosulfonyl group;
- Y is a -(CH₂)_n- group wherein n is 1, 2 or 3, or a carbon-carbon double bond (-CH₂=CH₂-);
- 25 R₃ is hydrogen atom, cyano, carboxy, hydroxyaminocarbonyl group, or an optionally substituted group selected from aminocarbonyl, amino or sulfonamido group, a straight or branched C₁-C₈ alkyl group, a perfluorinated C₁-C₈ alkyl, a straight or branched C₁-C₈ alkoxy C₁-C₆ alkyl group, a
- 30 saturated or unsaturated C₃-C₇ cycloalkyl, a saturated or unsaturated C₃-C₇ cycloalkyl C₁-C₆ alkyl, a straight or branched C₂-C₈ alkenyl group, an aryl, an aryl C₁-C₆ alkyl group, a straight or branched C₁-C₈ alkyloxy group, a saturated or unsaturated C₃-C₆ cycloalkyloxy, a straight or
- 35 branched C₁-C₈ alkyloxy C₁-C₆ alkyloxy group, C₁-C₆

- 10 -

alkyloxy-carbonyl, aryloxy-carbonyl, aryl C₁-C₆ alkyloxy-carbonyl, heteroaryloxy-carbonyl, heteroaryl C₁-C₆ alkyloxy-carbonyl, C₁-C₆ alkylaminocarbonyl, C₁-C₆ dialkylaminocarbonyl, arylaminocarbonyl, C₁-C₆ alkyloxyaminocarbonyl, 5 aryloxyaminocarbonyl, C₁-C₆ alkylcarbonyloxy, arylcarbonyloxy, C₁-C₆ alkylcarbonyl, arylcarbonyl, heterocycl-ylcarbonyl, aryl C₁-C₆ alkyloxy group, aryloxy, a straight or branched C₁-C₆ alkylthio, arylC₁-C₆ alkylthio, C₁-C₆ alkylsulph-10 inyl group, C₁-C₆ alkylsulphonyl, arylthio, arylsulph-10 inyl, arylsulphonyl, C₁-C₆ alkylamino, di C₁-C₆ alkylamino, arylamino, aryl C₁-C₆ alkylamino, heteroarylamino, heteroaryl C₁-C₆ alkylamino, C₁-C₆ alkylcarbonylamino, arylcarbonylamino, C₁-C₆ alkyloxy-carbonylamino, aryl C₁-C₆ alkyloxy-carbonylamino, 15 aryloxy-carbonylamino, an ureido, thioureido group, C₁-C₆ alkylaminocarbonylamino, C₁-C₆ dialkylaminocarbonylamino, arylaminocarbonylamino, C₁-C₆ alkylaminothiocabonylamino, C₁-C₆ dialkylaminothiocabonylamino, arylaminothiocabonyl-20 amino, C₁-C₆ alkylsulfonylamino, arylsulfonylamino, C₁-C₆ alkylaminosulfonyl, and arylaminosulfonyl group, with the proviso that when R₂ and R₃ are both hydrogen atoms and Y is a -CH₂-CH₂- group, then R₁ is not hydrogen or 7-chloro, 7-bromo atom, 7-cyclohexyl or 7-methyl group, or a pharmaceutically acceptable salt thereof.

25 In a preferred embodiment of the method described above, the disease caused by and/or associated with an altered protein kinase activity is selected from the group consisting of cancer, cell proliferative disorders, Alzheimer's disease, viral infections, autoimmune diseases 30 and neurodegenerative disorders.

Specific types of cancer that may be treated according to the invention include carcinoma, squamous cell carcinoma, hematopoietic tumors of myeloid or lymphoid lineage, tumors of mesenchymal origin, tumors of the central and peripheral 35 nervous system, melanoma, seminoma, teratocarcinoma,

- 11 -

osteosarcoma, xeroderma pigmentosum, keratoxanthoma, thyroid follicular cancer and Kaposi's sarcoma.

In another preferred embodiment of the method described above, the cell proliferative disorder is selected from the group consisting of benign prostate hyperplasia, familial adenomatosis polyposis, neuro-fibromatosis, psoriasis, vascular smooth cell proliferation associated with atherosclerosis, pulmonary fibrosis, arthritis glomerulonephritis and post-surgical stenosis and restenosis. In addition, the method object of the present invention provides tumor angiogenesis and metastasis inhibition.

The tetracyclic pyrazole derivatives of formula (I), object of the invention, are obtainable through a synthetic process comprising well known reactions carried out according to conventional techniques, as well as through a new and extremely versatile solid-phase combinatorial process, being both comprised within the scope of the invention.

The present invention also provides a pharmaceutical composition comprising the tetracyclic pyrazole derivatives of formula (I) with the above proviso and at least one pharmaceutically acceptable excipient, carrier or diluent.

A more complete appreciation of the invention and many of the attendant advantages thereof will be readily obtained, as the same becomes better understood by reference to the following detailed description.


DETAILED DESCRIPTION OF THE INVENTION

The compounds of formula (I), object of the present invention, may have asymmetric carbon atoms and may therefore exist either as racemic admixtures or as individual optical isomers. Accordingly, all the possible isomers and their admixtures and of both the metabolites and the pharmaceutically acceptable bio-precursors (otherwise referred to as pro-drugs) of the compounds of

- 12 -

formula (I), as well as any therapeutic method of treatment comprising them, are also within the scope of the present invention.

In addition to the above, as will be readily appreciated, the unsubstituted ring nitrogen pyrazoles in the compounds of the invention are known to rapidly equilibrate, in solution, as admixtures of both tautomers, A and B:



- 10 wherein R1, R2, R3 and Y are as defined above.
- Accordingly, in the present invention and unless otherwise indicated, where only one tautomer A is indicated for the compounds of formula (I), the other, B, is also within the scope of the present invention.
- 15 As used herein, unless otherwise specified, with the term straight or branched C₁-C₈ alkyl, hence also comprising C₁-C₆ alkyl, we intend a group such as, for instance, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, neopentyl, n-hexyl, isohexyl, n-heptyl, 2-methyl-hexyl-2-yl, n-octyl, and the like.
- 20 With the term straight or branched C₂-C₈ alkenyl we intend a group such as, for instance, vinyl, 1- or -2-propenyl, isopropenyl, 1-, 2- or 3-butenyl, pentenyl, hexenyl, heptenyl, octenyl and the like.
- 25 With the term saturated or unsaturated C₃-C₇ cycloalkyl or cycloalkyloxy group we intend, for instance, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopentenyl, cyclohexenyl, cyclopentyloxy, cyclohexyloxy and the like.

- 13 -

With the term aryl we intend an aromatic carbocycle such as, for instance, phenyl, biphenyl, 1-naphthyl, 2-naphthyl, and the like.

With the term heteroaryl we intend an optionally condensed
5 5 or 6 membered heterocycle with 1 to 4 heteroatoms selected among nitrogen, oxygen or sulphur.

With the term 5 or 6 membered heterocycle with 1 to 4 heteroatoms selected among nitrogen, oxygen or sulphur, we intend a saturated, partly unsaturated or fully unsaturated
10 either aromatic or non aromatic heterocycle such as, for instance, thiophene, furan, pyrrole, imidazole, pyrazole, thiazole, isothiazole, oxazole, isoxazole, pyridine, pyrazine, pyrimidine, pyridazine, pyrrolidine, pyrroline, imidazolidine, imidazoline, piperidine, piperazine,
15 morpholine, tetrahydrofuran, tetrahydropyran, tetrahydrothiopyran, and the like. With the term optionally condensed heterocycle and unless otherwise indicated we intend any of the above defined heterocycles further condensed, through any one of the available bonds, with
20 other heterocycle(s) as defined above or benzene ring(s) such as, for instance, quinoline, isoquinoline, chroman, chromene, thionaphthene, indoline, and the like.

In this respect, unless otherwise indicated, with the term halogen atom we intend a fluorine, chlorine, bromine or
25 iodine atom.

With the term perfluorinated C₁-C₈ alkyl we intend any alkyl group as above defined being substituted by two or more fluorine atoms such as, for instance, trifluoromethyl, 2,2,2-trifluoroethyl, 1,1-difluoroethyl, and the like.

30 From all of the above, it is clear to the skilled man that any of the groups or substituents being defined, for instance, as arylalkyl, heteroarylalkyl, alkylaryl, alkoxy, alkoxyalkoxy, arylalkoxy, alkylaminocarbonyl, heteroarylcarbonyl, alkylamino, arylamino, alkylthio,
35 arylthio, alkylsulphonyl, arylsulphonyl and the like, have

- 14 -

to be construed from the names of the groups from which they originate. As an example, unless specifically noted otherwise, any arylalkyloxycarbonylamino group has to be intended as a carbonylamino group being substituted by alkyloxy wherein the alkyl moiety is further substituted by aryl, both aryl and alkyl being as above defined.

The term "optionally substituted" means that the group may be substituted or unsubstituted; the substituents which may be present in the groups in any of the above definitions of R1-R3 include the following:

- halo (i.e., fluoro, bromo, chloro or iodo);
- hydroxy;
- nitro;
- azido;
- mercapto (i.e., -SH), and acetyl or phenylacetyl esters thereof (i.e., -SCOCH₃ and -SCOCH₂C₆H₅);
- amino (i.e., -NH₂ or -NHR^I or -NR^IR^{II}, wherein R^I and R^{II}, which are the same or different, are straight or branched C₁-C₆ alkyl, phenyl, biphenyl (i.e., -C₆H₄-C₆H₅), or benzyl groups, optionally substituted by hydroxy, methoxy, methyl, amino, methylamino, dimethylamino, chloro or fluoro; or R^I and R^{II} taken together with the nitrogen atom to which they are attached form a heterocyclic ring such as morpholino, pyrrolidino, piperidino, pyperazino or N-methylpyperazino;
- guanidino, i.e., -NHC(=NH)NH₂;
- formyl (i.e., -CHO);
- cyano;
- carboxy (i.e., -COOH), or esters thereof (i.e., -COOR^I), or amides thereof (i.e., -CONH₂, -CONHR^I or -CONHR^IR^{II}), wherein R^I and R^{II} are as defined above, and including morpholino-amides, pyrrolidino-amides, and carboxymethylamides -CONHCH₂COOH;
- sulfo (i.e., -SO₃H);
- acyl, i.e., -C(O)R^I, wherein R^I is as defined above, including monofluoroacetyl, difluoroacetyl, trifluoroacetyl;

- 15 -

- carbamoyloxy (i.e., $-\text{OCONH}_2$) and N-methylcarbamoyloxy;
- acyloxy, i.e., $-\text{OC(O)}\text{R}^{\text{I}}$ wherein R^{I} is as defined above, or formyloxy;
- acylamino, i.e., $-\text{NHC(O)}\text{R}^{\text{I}}$, or $-\text{NHC(O)}\text{OR}^{\text{I}}$, wherein R^{I}
- 5 is as defined above or is a group $-(\text{CH}_2)_t\text{COOH}$ where t is 1, 2 or 3;
- ureido, i.e., $-\text{NH(CO)NH}_2$, $-\text{NH(CO)NHR}^{\text{I}}$, $-\text{NH(CO)NR}^{\text{I}}\text{R}^{\text{II}}$, wherein R^{I} and R^{II} are as defined above, including $-\text{NH(CO)}-$
- 10 $-(4\text{-morpholino})$, $-\text{NH(CO)}-(1\text{-pyrrolidino})$, $-\text{NH(CO)}-(1\text{-piperazino})$, $-\text{NH(CO)}-(4\text{-methyl-1-piperazino})$;
- sulfonamido, i.e., $-\text{NHSO}_2\text{R}^{\text{I}}$ wherein R^{I} is as defined above;
- a group $-(\text{CH}_2)_t\text{COOH}$, and esters and amides thereof, i.e., $-(\text{CH}_2)_t\text{COOR}^{\text{I}}$ and $-(\text{CH}_2)_t\text{CONH}_2$, $-(\text{CH}_2)_t\text{CONHR}^{\text{I}}$, $-(\text{CH}_2)_t\text{CONR}^{\text{I}}\text{R}^{\text{II}}$,
- 15 wherein t , R^{I} and R^{II} are as defined above;
- a group $-\text{NH(SO}_2\text{)NH}_2$, $-\text{NH(SO}_2\text{)NHR}^{\text{I}}$, $-\text{NH(SO}_2\text{)NR}^{\text{I}}\text{R}^{\text{II}}$, wherein R^{I} and R^{II} are as defined above, including $-\text{NH(SO}_2\text{)}-$
- 20 $-(4\text{-morpholino})$, $-\text{NH(SO}_2\text{)}-(1\text{-pyrrolidino})$, $-\text{NH(SO}_2\text{)}-(1\text{-piperazino})$, $-\text{NH(SO}_2\text{)}-(4\text{-methyl-1-piperazino})$;
- a group $-\text{OC(O)OR}^{\text{I}}$, wherein R^{I} is as defined above;
- a group $-\text{OR}^{\text{I}}$, wherein R^{I} is as defined above, including $-\text{OCH}_2\text{COOH}$;
- a group $-\text{O-CH}_2\text{-O-}$, methylenedioxy or $-\text{O-CH}_2\text{-CH}_2\text{-O-}$, ethylenedioxy;
- 25 - a group $-\text{SR}^{\text{I}}$, wherein R^{I} is as defined above, including $-\text{SCH}_2\text{COOH}$;
- a group $-\text{S(O)R}^{\text{I}}$, wherein R^{I} is as defined above;
- a group $-\text{S(O}_2\text{)R}^{\text{I}}$, wherein R^{I} is as defined above;
- a group $-\text{SO}_2\text{NH}_2$, $-\text{SO}_2\text{NHR}^{\text{I}}$, or $-\text{SO}_2\text{NR}^{\text{I}}\text{R}^{\text{II}}$, wherein R^{I} and
- 30 R^{II} are as defined above;
- $\text{C}_1\text{-C}_6$ alkyl or $\text{C}_2\text{-C}_6$ alkenyl;
- $\text{C}_3\text{-C}_7$ cycloalkyl;
- substituted methyl selected from chloromethyl, fluoromethyl, difluoromethyl, trifluoromethyl, aminomethyl,
- 35 N,N -dimethylaminomethyl, azidomethyl, cyanomethyl,

- 16 -

carboxymethyl, sulfomethyl, carbamoylmethyl, carbamoyloxymethyl, hydroxymethyl, methoxycarbonylmethyl, ethoxycarbonylmethyl, tert-butoxycarbonylmethyl and guanidinomethyl.

- 5 Most preferred substituents are methoxy, trifluoromethyl, methylenedioxy, dimethylamino, and ethoxycarbonyl groups.

- When present, carboxy, hydroxy, mercapto and amino groups may be either free or in a protected form. Protected forms of said groups are any of those generally known in the art. Preferably, carboxy groups are protected as esters thereof, in particular methyl, ethyl, tert-butyl, benzyl, and 4-nitrobenzyl esters. Preferably, hydroxy groups are protected as silyl-ethers, ethers or esters thereof, in particular trimethyl silyl, tert-butyldiphenyl silyl, triethyl silyl, triisopropyl silyl or tert-butyldimethylsilyl ethers, methoxymethyl ethers, tetrahydropyranyl ethers, benzyl ethers, acetates or benzoates. Preferably, mercapto groups are protected as thioethers or thioesters, in particular tert-butyl thioethers, thioacetates or thiobenzoates. Preferably, amino groups are protected as carbamates, e.g. tert-butoxycarbonyl derivatives, or as amides, e.g. acetamides and benzamides.
- 10
15
20

Furthermore, hydrates, solvates of compounds of formula (I) are included within the scope of the present invention.

- 25 With the term oxo we intend a carbonyl ($>C=O$) group. Pharmaceutically acceptable salts of the compounds of formula (I) are the acid addition salts with inorganic or organic, e.g. nitric, hydrochloric, hydrobromic, sulphuric, perchloric, phosphoric, acetic, trifluoroacetic, propionic, glycolic, lactic, oxalic, malonic, malic, maleic, tartaric, citric, benzoic, cinnamic, mandelic, methanesulphonic, isethionic and salicylic acid, as well as the salts with inorganic or organic bases, e.g. alkali or alkaline-earth metals, especially sodium, potassium, calcium or magnesium hydroxides, carbonates or bicarbonates, acyclic or cyclic
- 30
35

- 17 -

amines, preferably methylamine, ethylamine, diethylamine, triethylamine or piperidine.

Preferred compounds of formula (I) are the compounds wherein R₁ is hydrogen or halogen atom, cyano or hydroxy group, or an optionally substituted group selected from a straight or branched optionally substituted C₁-C₈ alkyl group, a perfluorinated C₁-C₈ alkyl and a saturated or unsaturated C₃-C₇ cycloalkyl group; R₂ is hydrogen or halogen atom, cyano, hydroxy, carboxy, or an optionally substituted group selected from aminocarbonyl, amino, hydroxyaminocarbonyl, sulfonamido, ureido, thioureido group, a straight or branched C₁-C₈ alkyl group, a perfluorinated C₁-C₈ alkyl, a saturated or unsaturated C₃-C₇ cycloalkyl, C₁-C₆ alkyloxycarbonyl, aryloxycarbonyl, heteroaryloxycarbonyl, heteroaryl C₁-C₆ alkyloxycarbonyl, C₁-C₆ alkylaminocarbonyl, C₁-C₆ dialkylaminocarbonyl, arylaminocarbonyl, C₁-C₆ alkoxyaminocarbonyl, aryloxyaminocarbonyl, C₁-C₆ alkylcarbonyloxy, arylcarbonyloxy, C₁-C₆ alkylamino, arylamino, aryl C₁-C₆ alkylamino, heteroarylamino, heteroaryl C₁-C₆ alkylamino, C₁-C₆ alkylcarbonylamino, arylcarbonylamino, C₁-C₆ alkyloxycarbonylamino, aryl C₁-C₆ alkyloxycarbonylamino, aryloxycarbonylamino, C₁-C₆ alkylaminocarbonylamino, aryl C₁-C₆ alkylaminocarbonylamino, C₁-C₆ dialkylaminocarbonylamino, arylaminocarbonylamino, C₁-C₆ alkylsulfonylamino, arylsulfonylamino, C₁-C₆ alkylaminosulfonyl, straight or branched C₁-C₆ alkylthio and arylaminosulfonyl group;

Y is a -(CH₂)_n- group, wherein n is 1, 2 or 3, or a carbon-carbon double bond -CH=CH-;


R₃ is hydrogen atom, carboxy or an optionally substituted group selected from C₁-C₆ straight or branched alkyl, perfluorinated C₁-C₆ alkyl, aryl C₁-C₆ alkyl group, C₁-C₆ alkyloxycarbonyl, aryl C₁-C₆ alkyloxycarbonyl, straight or branched C₁-C₆ alkylthio, C₁-C₆ alkylaminocarbonyl, C₁-C₆

- 18 -

dialkylaminocarbonyl, arylaminocarbonyl and aryl C₁-C₆ alkylaminocarbonyl, with the proviso that when R₂ and R₃ are both hydrogen atoms and Y is a -CH₂-CH₂- group, then R₁ is not hydrogen, 7-chloro or 7-bromo atom or 7-cyclohexyl or 7-methyl group, or a pharmaceutically acceptable salt thereof.

Still more preferred, within this class, are the 1,4,5,10-tetrahydropyrazolo[3,4-a]carbazole derivatives of formula (IA)

10



(IA)


wherein R₁ is halogen atom, cyano, nitro, hydroxy, carboxy, aminocarbonyl, hydroxyaminocarbonyl, amino or sulfonamido group, or an optionally substituted group selected from a straight or branched C₁-C₈ alkyl group, a perfluorinated C₁-C₈ alkyl, a saturated or unsaturated C₃-C₇ cycloalkyl, a straight or branched C₁-C₈ alkoxy group, alkyloxycarbonyl, aryloxycarbonyl, heteroaryloxycarbonyl, heteroaryl C₁-C₆ alkyloxycarbonyl, C₁-C₆ alkylaminocarbonyl, C₁-C₆ dialkylaminocarbonyl, arylaminocarbonyl, C₁-C₆ alkoxyaminocarbonyl, aryloxyaminocarbonyl, C₁-C₆ alkylcarbonyloxy, arylcarbonyloxy, an C₁-C₆ alkylamino, arylamino, aryl C₁-C₆ alkylamino, C₁-C₆ alkylcarbonylamino, arylcarbonylamino, aryloxycarbonylamino, C₁-C₆ alkylaminocarbonylamino, C₁-C₆ dialkylaminocarbonylamino, aryl C₁-C₆ alkylaminocarbonylamino, arylaminocarbonylamino, C₁-C₆ alkylsulfonylamino, arylsulfonylamino, C₁-C₆ alkylaminosulfonyl and arylaminosulfonyl;

R₃ is hydrogen atom, a carboxy group or an optionally substituted group selected from C₁-C₆ straight or branched

- 19 -

alkyl, C₁-C₆ alkyloxycarbonyl, aryl C₁-C₆ alkyloxycarbonyl, C₁-C₆ alkylaminocarbonyl, C₁-C₆ dialkylaminocarbonyl, arylaminocarbonyl and aryl C₁-C₆ alkylaminocarbonyl, with the proviso that when R₃ is hydrogen atom, then R₁ is not
 5 hydrogen or 7-chloro, 7-bromo atom, 7-cyclohexyl or 7-methyl group, or a pharmaceutically acceptable salt thereof.

For clarity, we point out that the framework of the preferred compounds of formula (IA) of the present
 10 invention is numbered as follows:



Specific, not limiting, preferred compounds of formula (IA) of the invention, whenever appropriate in the form of
 15 pharmaceutically acceptable salts, are the following:

- 1 6-fluoro-2,4,5,10-tetrahydropyrazolo[3,4-a]carbazole;
- 2 7-fluoro-2,4,5,10-tetrahydropyrazolo[3,4-a]carbazole;
- 3 8-fluoro-2,4,5,10-tetrahydropyrazolo[3,4-a]carbazole;
- 4 6-chloro-2,4,5,10-tetrahydropyrazolo[3,4-a]carbazole;
- 20 5 8-chloro-2,4,5,10-tetrahydropyrazolo[3,4-a]carbazole;
- 6 6-bromo-2,4,5,10-tetrahydropyrazolo[3,4-a]carbazole;
- 7 8-bromo-2,4,5,10-tetrahydropyrazolo[3,4-a]carbazole;
- 8 6-cyano-2,4,5,10-tetrahydropyrazolo[3,4-a]carbazole;
- 9 7-cyano-2,4,5,10-tetrahydropyrazolo[3,4-a]carbazole;
- 25 10 8-cyano-2,4,5,10-tetrahydropyrazolo[3,4-a]carbazole;
- 11 6-nitro-2,4,5,10-tetrahydropyrazolo[3,4-a]carbazole;
- 12 7-nitro-2,4,5,10-tetrahydropyrazolo[3,4-a]carbazole;
- 13 8-nitro-2,4,5,10-tetrahydropyrazolo[3,4-a]carbazole;
- 14 6-methyl-2,4,5,10-tetrahydropyrazolo[3,4-a]carbazole;
- 30 15 8-methyl-2,4,5,10-tetrahydropyrazolo[3,4-a]carbazole;

- 20 -

- 16 6-trifluoromethyl-2,4,5,10-tetrahydropyrazolo[3,4-a]
carbazole;
- 17 7-trifluoromethyl-2,4,5,10-tetrahydropyrazolo[3,4-a]
carbazole;
- 5 18 8-trifluoromethyl-2,4,5,10-tetrahydropyrazolo[3,4-a]
carbazole;
- 19 6-methoxy-2,4,5,10-tetrahydropyrazolo[3,4-a] carbazole;
- 20 7-methoxy-2,4,5,10-tetrahydropyrazolo[3,4-a] carbazole;
- 21 8-methoxy-2,4,5,10-tetrahydropyrazolo[3,4-a] carbazole;
- 10 22 6-hydroxy-2,4,5,10-tetrahydropyrazolo[3,4-a] carbazole;
- 23 7-hydroxy-2,4,5,10-tetrahydropyrazolo[3,4-a] carbazole;
- 24 8-hydroxy-2,4,5,10-tetrahydropyrazolo[3,4-a] carbazole;
- 25 2,4,5,10-tetrahydropyrazolo[3,4-a]carbazole-6-carboxylic
acid;
- 15 26 2,4,5,10-tetrahydropyrazolo[3,4-a]carbazole-7-carboxylic
acid;
- 27 2,4,5,10-tetrahydropyrazolo[3,4-a]carbazole-8-carboxylic
acid;
- 28 methyl 2,4,5,10-tetrahydropyrazolo[3,4-a]carbazole-6-
20 carboxylate;
- 29 methyl 2,4,5,10-tetrahydropyrazolo[3,4-a]carbazole-7-
carboxylate;
- 30 methyl 2,4,5,10-tetrahydropyrazolo[3,4-a]carbazole-8-
carboxylate;
- 25 31 ethyl 2,4,5,10-tetrahydropyrazolo[3,4-a]carbazole-6-
carboxylate;
- 32 ethyl 2,4,5,10-tetrahydropyrazolo[3,4-a]carbazole-7-
carboxylate;
- 33 ethyl 2,4,5,10-tetrahydropyrazolo[3,4-a]carbazole-8-
30 carboxylate;
- 34 i-butyl 2,4,5,10-tetrahydropyrazolo[3,4-a]carbazole-6-
carboxylate;
- 35 i-butyl 2,4,5,10-tetrahydropyrazolo[3,4-a]carbazole-7-
carboxylate;

- 21 -

- 36 i-butyl 2,4,5,10-tetrahydropyrazolo[3,4-a]carbazole-8-
carboxylate;
- 37 1,4,5,10-tetrahydropyrazolo[3,4-a]carbazole-3-carboxylic
acid
- 5 38 methyl 2,4,5,10-tetrahydropyrazolo[3,4-a]carbazole-3-
carboxylate;
- 39 ethyl 2,4,5,10-tetrahydropyrazolo[3,4-a]carbazole-3-
carboxylate;
- 40 propyl 2,4,5,10-tetrahydropyrazolo[3,4-a]carbazole-3-
10 carboxylate;
- 41 i-propyl 2,4,5,10-tetrahydropyrazolo[3,4-a]carbazole-3-
carboxylate;
- 42 butyl 2,4,5,10-tetrahydropyrazolo[3,4-a]carbazole-3-
carboxylate;
- 15 43 i-butyl 2,4,5,10-tetrahydropyrazolo[3,4-a]carbazole-3-
carboxylate;
- 44 1,4,5,10-tetrahydropyrazolo[3,4-a]carbazole-6-
carboxamide;
- 45 1,4,5,10-tetrahydropyrazolo[3,4-a]carbazole-7-
20 carboxamide;
- 46 1,4,5,10-tetrahydropyrazolo[3,4-a]carbazole-8-
carboxamide;
- 47 N-methyl-1,4,5,10-tetrahydropyrazolo[3,4-a]carbazole-6-
carboxamide;
- 25 48 N-methyl-1,4,5,10-tetrahydropyrazolo[3,4-a]carbazole-7-
carboxamide;
- 49 N-methyl-1,4,5,10-tetrahydropyrazolo[3,4-a]carbazole-8-
carboxamide;
- 50 N-ethyl-1,4,5,10-tetrahydropyrazolo[3,4-a]carbazole-6-
30 carboxamide;
- 51 N-ethyl-1,4,5,10-tetrahydropyrazolo[3,4-a]carbazole-7-
carboxamide;
- 52 N-ethyl-1,4,5,10-tetrahydropyrazolo[3,4-a]carbazole-8-
carboxamide;

- 22 -

- 53 N-propyl-1,4,5,10-tetrahydropyrazolo[3,4-a]carbazole-6-carboxamide;
- 54 N-propyl-1,4,5,10-tetrahydropyrazolo[3,4-a]carbazole-7-carboxamide;
- 5 55 N-propyl-1,4,5,10-tetrahydropyrazolo[3,4-a]carbazole-8-carboxamide;
- 56 N-isopropyl-1,4,5,10-tetrahydropyrazolo[3,4-a]carbazole-6-carboxamide;
- 57 N-isopropyl-1,4,5,10-tetrahydropyrazolo[3,4-a]carbazole-7-carboxamide;
- 10 58 N-isopropyl-1,4,5,10-tetrahydropyrazolo[3,4-a]carbazole-8-carboxamide;
- 59 N-butyl-1,4,5,10-tetrahydropyrazolo[3,4-a]carbazole-6-carboxamide;
- 15 60 N-butyl-1,4,5,10-tetrahydropyrazolo[3,4-a]carbazole-7-carboxamide;
- 61 N-butyl-1,4,5,10-tetrahydropyrazolo[3,4-a]carbazole-8-carboxamide;
- 62 N-isobutyl-1,4,5,10-tetrahydropyrazolo[3,4-a]carbazole-6-carboxamide;
- 20 63 N-isobutyl-1,4,5,10-tetrahydropyrazolo[3,4-a]carbazole-7-carboxamide;
- 64 N-isobutyl-1,4,5,10-tetrahydropyrazolo[3,4-a]carbazole-8-carboxamide;
- 25 65 N-terbutyl-1,4,5,10-tetrahydropyrazolo[3,4-a]carbazole-6-carboxamide;
- 66 N-terbutyl-1,4,5,10-tetrahydropyrazolo[3,4-a]carbazole-7-carboxamide;
- 67 N-terbutyl-1,4,5,10-tetrahydropyrazolo[3,4-a]carbazole-8-carboxamide;
- 30 68 N-phenyl-1,4,5,10-tetrahydropyrazolo[3,4-a]carbazole-6-carboxamide;
- 69 N-phenyl-1,4,5,10-tetrahydropyrazolo[3,4-a]carbazole-7-carboxamide;

- 23 -

- 70 N-phenyl-1,4,5,10-tetrahydropyrazolo[3,4-a]carbazole-8-carboxamide;
- 71 N-benzyl-1,4,5,10-tetrahydropyrazolo[3,4-a]carbazole-6-carboxamide;
- 5 72 N-benzyl-1,4,5,10-tetrahydropyrazolo[3,4-a]carbazole-7-carboxamide;
- 73 N-benzyl-1,4,5,10-tetrahydropyrazolo[3,4-a]carbazole-8-carboxamide;
- 74 N-(3-dimethylamino)propyl-1,4,5,10-tetrahydropyrazolo
- 10 [3,4-a]carbazole-6-carboxamide;
- 75 N-(3-dimethylamino)propyl-1,4,5,10-tetrahydropyrazolo
- [3,4-a]carbazole-7-carboxamide;
- 76 N-(3-dimethylamino)propyl-1,4,5,10-tetrahydropyrazolo
- [3,4-a]carbazole-8-carboxamide;
- 15 77 N-(3-dimethylamino)propyl-1,10-dihydropyrazolo[3,4-a]
- carbazole-6-carboxamide;
- 78 N-(3-dimethylamino)propyl-1,10-dihydropyrazolo[3,4-a]
- carbazole-7-carboxamide;
- 79 N-(3-dimethylamino)propyl-1,10-dihydropyrazolo[3,4-a]
- 20 carbazole-8-carboxamide;
- 80 N-(5-hydroxy-1H-pyrazol-3-yl)-1,4,5,10-
- tetrahydropyrazolo[3,4-a]carbazole-6-carboxamide;
- 81 N-(5-hydroxy-1H-pyrazol-3-yl)-1,4,5,10-
- tetrahydropyrazolo[3,4-a]carbazole-7-carboxamide;
- 25 82 N-(5-hydroxy-1H-pyrazol-3-yl)-1,4,5,10-
- tetrahydropyrazolo[3,4-a]carbazole-8-carboxamide;
- 83 N-(5-hydroxy-1H-pyrazol-3-yl)-1,10-dihydropyrazolo
- [3,4-a]carbazole-6-carboxamide;
- 84 N-(5-hydroxy-1H-pyrazol-3-yl)-1,10-dihydropyrazolo
- 30 [3,4-a]carbazole-7-carboxamide;
- 85 N-(5-hydroxy-1H-pyrazol-3-yl)-1,10-dihydropyrazolo
- [3,4-a]carbazole-8-carboxamide;
- 86 N-(3-morpholin-4-yl-propyl)-1,4,5,10-
- tetrahydropyrazolo[3,4-a]carbazole-6-carboxamide;

- 24 -

- 87 N-(3-morpholin-4-yl-propyl)-1,4,5,10-
tetrahydropyrazolo[3,4-a]carbazole-7-carboxamide;
- 88 N-(3-morpholin-4-yl-propyl)-1,4,5,10-
tetrahydropyrazolo[3,4-a]carbazole-8-carboxamide;
- 5 89 N-(3-morpholin-4-yl-propyl)-1,10-dihydropyrazolo[3,4-a]
carbazole-6-carboxamide;
- 90 N-(3-morpholin-4-yl-propyl)-1,10-dihydropyrazolo[3,4-a]
carbazole-7-carboxamide;
- 91 N-(3-morpholin-4-yl-propyl)-1,10-dihydropyrazolo[3,4-a]
10 carbazole-8-carboxamide;
- 92 N-(2-phenylamino-ethyl)-1,4,5,10-tetrahydropyrazolo
[3,4-a]carbazole-6-carboxamide;
- 93 N-(2-phenylamino-ethyl)-1,4,5,10-tetrahydropyrazolo
[3,4-a]carbazole-7-carboxamide;
- 15 94 N-(2-phenylamino-ethyl)-1,4,5,10-tetrahydropyrazolo
[3,4-a]carbazole-8-carboxamide;
- 95 N-(2-phenylamino-ethyl)-1,10-dihydropyrazolo[3,4-a]
carbazole-6-carboxamide;
- 96 N-(2-phenylamino-ethyl)-1,10-dihydropyrazolo[3,4-a]
20 carbazole-7-carboxamide;
- 97 N-(2-phenylamino-ethyl)-1,10-dihydropyrazolo[3,4-a]
carbazole-8-carboxamide;
- 98 N-[2-(1H-imidazol-4-yl)-ethyl]-1,4,5,10-
tetrahydropyrazolo[3,4-a]carbazole-6-carboxamide;
- 25 99 N-[2-(1H-imidazol-4-yl)-ethyl]-1,4,5,10-
tetrahydropyrazolo[3,4-a]carbazole-7-carboxamide;
- 100 N-[2-(1H-imidazol-4-yl)-ethyl]-1,4,5,10-
tetrahydropyrazolo[3,4-a]carbazole-8-carboxamide;
- 101 N-[2-(1H-imidazol-4-yl)-ethyl]-1,10-dihydropyrazolo
30 [3,4-a]carbazole-6-carboxamide;
- 102 N-[2-(1H-imidazol-4-yl)-ethyl]-1,10-dihydropyrazolo
[3,4-a]carbazole-7-carboxamide;
- 103 N-[2-(1H-imidazol-4-yl)-ethyl]-1,10-dihydropyrazolo
[3,4-a]carbazole-8-carboxamide;

- 25 -

- 104 N-(4-hydroxy-butyl)-1,4,5,10-tetrahydropyrazolo[3,4-a]
carbazole-6-carboxamide;
- 105 N-(4-hydroxy-butyl)-1,4,5,10-tetrahydropyrazolo[3,4-a]
carbazole-7-carboxamide;
- 5 106 N-(4-hydroxy-butyl)-1,4,5,10-tetrahydropyrazolo[3,4-a]
carbazole-8-carboxamide;
- 107 N-(4-hydroxy-butyl)-1,10-dihydropyrazolo[3,4-a]
carbazole-6-carboxamide;
- 108 N-(4-hydroxy-butyl)-1,10-dihydropyrazolo[3,4-a]
10 carbazole-7-carboxamide;
- 109 N-(4-hydroxy-butyl)-1,10-dihydropyrazolo[3,4-a]
carbazole-8-carboxamide;
- 110 N-(2-hydroxymethyl-phenyl)-1,4,5,10-tetrahydropyrazolo
[3,4-a]carbazole-6-carboxamide;
- 15 111 N-(2-hydroxymethyl-phenyl)-1,4,5,10-tetrahydropyrazolo
[3,4-a]carbazole-7-carboxamide;
- 112 N-(2-hydroxymethyl-phenyl)-1,4,5,10-tetrahydropyrazolo
[3,4-a]carbazole-8-carboxamide;
- 113 N-(2-hydroxymethyl-phenyl)-1,10-dihydropyrazolo[3,4-a]
20 carbazole-6-carboxamide;
- 114 N-(2-hydroxymethyl-phenyl)-1,10-dihydropyrazolo[3,4-a]
carbazole-7-carboxamide;
- 115 N-(2-hydroxymethyl-phenyl)-1,10-dihydropyrazolo[3,4-a]
carbazole-8-carboxamide;
- 25 116 N-(furan-2-ylmethyl)-1,4,5,10-tetrahydropyrazolo
[3,4-a]carbazole-6-carboxamide;
- 117 N-(furan-2-ylmethyl)-1,4,5,10-tetrahydropyrazolo
[3,4-a]carbazole-7-carboxamide;
- 118 N-(furan-2-ylmethyl)-1,4,5,10-tetrahydropyrazolo
30 [3,4-a]carbazole-8-carboxamide;
- 119 N-(furan-2-ylmethyl)-1,10-dihydropyrazolo[3,4-a]
carbazole-6-carboxamide;
- 120 N-(furan-2-ylmethyl)-1,10-dihydropyrazolo[3,4-a]
carbazole-7-carboxamide;

- 26 -

- 121 N-(furan-2-ylmethyl)-1,10-dihydropyrazolo[3,4-a]
carbazole-8-carboxamide;
- 122 N-(pyridin-4-ylmethyl)-1,4,5,10-tetrahydropyrazolo
[3,4-a]carbazole-6-carboxamide;
- 5 123 N-(pyridin-4-ylmethyl)-1,4,5,10-tetrahydropyrazolo
[3,4-a]carbazole-7-carboxamide;
- 124 N-(pyridin-4-ylmethyl)-1,4,5,10-tetrahydropyrazolo
[3,4-a]carbazole-8-carboxamide;
- 125 N-(pyridin-4-ylmethyl)-1,10-dihydropyrazolo[3,4-a]
10 carbazole-6-carboxamide;
- 126 N-(pyridin-4-ylmethyl)-1,10-dihydropyrazolo[3,4-a]
carbazole-7-carboxamide;
- 127 N-(pyridin-4-ylmethyl)-1,10-dihydropyrazolo[3,4-a]
carbazole-8-carboxamide;
- 15 128 N-[(methoxycarbonyl)methyl]-1,4,5,10-
tetrahydropyrazolo[3,4-a]carbazole-6-carboxamide;
- 129 N-[(methoxycarbonyl)methyl]-1,4,5,10-
tetrahydropyrazolo[3,4-a]carbazole-7-carboxamide;
- 130 N-[(methoxycarbonyl)methyl]-1,4,5,10-
20 tetrahydropyrazolo[3,4-a]carbazole-8-carboxamide;
- 131 N-[(methoxycarbonyl)methyl]-1,10-dihydropyrazolo
[3,4-a]carbazole-6-carboxamide;
- 132 N-[(methoxycarbonyl)methyl]-1,10-dihydropyrazolo
[3,4-a]carbazole-7-carboxamide;
- 25 133 N-[(methoxycarbonyl)methyl]-1,10-dihydropyrazolo
[3,4-a]carbazole-8-carboxamide;
- 134 N-(ethane-2-sulfonic acid)-1,4,5,10-tetrahydropyrazolo
[3,4-a]carbazole-6-carboxamide;
- 135 N-(ethane-2-sulfonic acid)-1,4,5,10-tetrahydropyrazolo
30 [3,4-a]carbazole-7-carboxamide;
- 136 N-(ethane-2-sulfonic acid)-1,4,5,10-tetrahydropyrazolo
[3,4-a]carbazole-8-carboxamide;
- 137 7-[(4-methylpiperazin-1-yl)carbonyl]-1,4,5,10-
tetrahydropyrazolo[3,4-a]carbazole;
- 35 138 1,4,5,10-tetrahydropyrazolo[3,4-a]carbazol-6-amine;

- 27 -

- 139 1,4,5,10-tetrahydropyrazolo[3,4-a]carbazol-7-amine;
140 1,4,5,10-tetrahydropyrazolo[3,4-a]carbazol-8-amine;
141 N-(1,4,5,10-tetrahydropyrazolo[3,4-a]carbazol-6-yl)
acetamide;
5 142 N-(1,4,5,10-tetrahydropyrazolo[3,4-a]carbazol-7-yl)
acetamide;
143 N-(1,4,5,10-tetrahydropyrazolo[3,4-a]carbazol-8-yl)
acetamide;
144 N-(1,4,5,10-tetrahydropyrazolo[3,4-a]carbazol-6-yl)
10 propanamide;
145 N-(1,4,5,10-tetrahydropyrazolo[3,4-a]carbazol-7-yl)
propanamide;
146 N-(1,4,5,10-tetrahydropyrazolo[3,4-a]carbazol-8-yl)
propanamide;
15 147 2-methyl-N-(1,4,5,10-tetrahydropyrazolo[3,4-a]
carbazol-6-yl)propanamide;
148 2-methyl-N-(1,4,5,10-tetrahydropyrazolo[3,4-a]
carbazol-7-yl)propanamide;
149 2-methyl-N-(1,4,5,10-tetrahydropyrazolo[3,4-a]
20 carbazol-8-yl)propanamide;
150 N-(1,4,5,10-tetrahydropyrazolo[3,4-a]carbazol-6-yl)
butanamide;
151 N-(1,4,5,10-tetrahydropyrazolo[3,4-a]carbazol-7-yl)
butanamide;
25 152 N-(1,4,5,10-tetrahydropyrazolo[3,4-a]carbazol-8-yl)
butanamide;
153 N-(1,4,5,10-tetrahydropyrazolo[3,4-a]carbazol-6-yl)
benzamide;
154 N-(1,4,5,10-tetrahydropyrazolo[3,4-a]carbazol-7-yl)
30 benzamide;
155 N-(1,4,5,10-tetrahydropyrazolo[3,4-a]carbazol-8-yl)
benzamide;
156 N-(1,4,5,10-tetrahydropyrazolo[3,4-a]carbazol-6-yl)
phenylacetamide;

- 28 -

- 157 N-(1,4,5,10-tetrahydropyrazolo[3,4-a]carbazol-7-yl)
phenylacetamide;
- 158 N-(1,4,5,10-tetrahydropyrazolo[3,4-a]carbazol-8-yl)
phenylacetamide;
- 5 159 3-methyl-N-(1,4,5,10-tetrahydropyrazolo[3,4-a]
carbazol-6-yl)butanamide;
- 160 3-methyl-N-(1,4,5,10-tetrahydropyrazolo[3,4-a]
carbazol-7-yl)butanamide;
- 161 3-methyl-N-(1,4,5,10-tetrahydropyrazolo[3,4-a]
10 carbazol-8-yl)butanamide;
- 162 N-(2,4,5,10-tetrahydropyrazolo[3,4-a]carbazol-7-yl)
thiophene-2-carboxamide;
- 163 N-methyl-N'-(1,4,5,10-tetrahydropyrazolo[3,4-a]
carbazol-7-yl)urea;
- 15 164 N-propyl-N'-(1,4,5,10-tetrahydropyrazolo[3,4-a]
carbazol-7-yl)urea;
- 165 N-benzyl-N'-(1,4,5,10-tetrahydropyrazolo[3,4-a]
carbazol-7-yl)urea;
- 166 N-phenyl-N'-(1,4,5,10-tetrahydropyrazolo[3,4-a]
20 carbazol-7-yl)urea;
- 167 4,9-dihydro-1H-pyrazolo[4',3':4,5]cyclopenta[1,2-b]
indole-6-carboxamide;
- 168 N-(4,9-dihydro-1H-pyrazolo[4',3':4,5]cyclopenta[1,2-b]
indol-6-yl)acetamide;
- 25 169 N-(4,9-dihydro-1H-pyrazolo[4',3':4,5]cyclopenta[1,2-b]
indol-6-yl)-3-methylbutanamide;
- 170 N-(4,9-dihydro-1H-pyrazolo[4',3':4,5]cyclopenta[1,2-b]
indol-6-yl)-2-phenylacetamide;
- 171 6-chloro-4,9-dihydro-1H-pyrazolo[4',3':4,5]
30 cyclopenta[1,2-b]indole;
- 172 N-isobutyl-4,9-dihydro-1H-pyrazolo[4',3':4,5]
cyclopenta[1,2-b]indole-6-carboxamide;
- 173 N-benzyl-4,9-dihydro-1H-pyrazolo[4',3':4,5]
cyclopenta[1,2-b]indole-6-carboxamide;


- 29 -

- 174 ethyl 4,9-dihydro-1H-pyrazolo[4',3':4,5] cyclopenta
[1,2-b] indole-3-carboxylate;
- 175 4,5,6,11-tetrahydro-1H-pyrazolo[4',3':6,7]cyclohepta
[1,2-b]indole-8-carboxamide;
- 5 176 3-methyl-N-(4,5,6,11-tetrahydro-1H-pyrazolo[4',3':6,7]
cyclohepta[1,2-b]indol-8-yl)butanamide;
- 177 8-chloro-4,5,6,11-tetrahydro-1H-pyrazolo[4',3':6,7]
cyclohepta[1,2-b]indole;
- 178 N-benzyl-4,5,6,11-tetrahydro-1H-pyrazolo[4',3':6,7]
10 cyclohepta[1,2-b]indole-8-carboxamide;
- 179 N-isobutyl-4,5,6,11-tetrahydro-1H-pyrazolo[4',3':6,7]
cyclohepta[1,2-b]indole-8-carboxamide;
- 180 ethyl 4,5,6,11-tetrahydro-1H-pyrazolo[4',3':6,7]
cyclohepta[1,2-b]indole-3-carboxylate;
- 15 181 N-(4,5,6,11-tetrahydro-1H-pyrazolo[4',3':6,7]
cyclohepta [1,2-b]indol-8-yl)acetamide;
- 182 2-phenyl-N-(4,5,6,11-tetrahydro-1H-pyrazolo
[4',3':6,7]cyclohepta[1,2-b]indol-8-yl)acetamide and
- 183 3-methylsulfanyl-1,4,5,10-tetrahydropyrazolo[3,4-a]
20 carbazole.

As set forth above, the processes for preparing the compounds of formula (I) and the pharmaceutically acceptable salts thereof are further objects of the present invention.

- 25 In a further aspect, the present invention also provides a process for preparing a compound of formula (I), which process comprises:

i) treating a compound of formula (VII)



- 30 -

wherein Y is $-(CH_2)_n-$; n, R1 and R2 are as above defined; W and Z have, respectively, one the following couple of meanings:

- a) W is a dialkylamino group, and Z is a hydrogen atom;
- 5 b) W is a hydroxy group, and Z is a hydrogen atom, a C_1-C_4 alkoxy carbonyl group or a methyl group;
- c) Z is a C_1-C_6 alkylthio or aryl C_1-C_6 alkylthio group, for instance a methylthio or a benzylthio group and W is:
- 10 -i) a methylthio group,
- ii) a substituted or disubstituted amino group, for instance an alkylamino or arylamino group;
- iii) a group of general formula $-CH(J)(X)$ where J and X are, the same or different, electron withdrawing groups,
- 15 such as, for instance, nitrile, alkoxy carbonyl, aryl including heteroaryl groups;
- iv) an alkyl or aryl group;
- v) an alkyl- or aryl-carbonyl group;
- vi) a cyano group or
- 20 d) both Z and W are substituted or disubstituted amino groups;

- with hydrazine in a suitable solvent such as methanol, ethanol, N,N-dimethyl formamide, dimethoxyethane, 1,4-dioxane and the like, to give a compound of general formula
- 25 (I) wherein Y is a $-(CH_2)_n-$ group, n, R1 and R2 are as described above, and R3 is C_1-C_6 alkylthio or aryl C_1-C_6 alkylthio group, a substituted or disubstituted amino group; a group of the formula $-CH(J)(X)$ wherein X and J are, the same or different, electron withdrawing groups,
- 30 such as, for instance, C_1-C_6 alkoxy carbonyl, aryl including heteroaryl groups; a C_1-C_6 alkyl or aryl group; a C_1-C_6 alkyl- or aryl-carbonyl group; a cyano group and
- ii) optionally converting a compound of general formula (I) into a different compound of formula (I), if necessary
- 35 separating a mixture of a compound of formula (I) wherein Y


- 31 -

is a $-\text{CH}_2-\text{CH}_2-$ group and a compound of formula (I) wherein Y is a $-\text{CH}=\text{CH}-$ group and, if desired, converting a compound of formula (I) into a pharmaceutically acceptable salt thereof or converting a salt into the free compound (I).

5 The reaction i) with hydrazine can be carried for example as described in *Pharmaceut.Chem J.* **1994**, 28, 566; at a temperature ranging from 0°C to 100°C .

In another aspect, the present invention also provides a process for preparing a compound of the formula (I) wherein
10 Y is a carbon-carbon double bond $-\text{C}=\text{C}-$, which process comprises:

i) treating with hydrazine a compound of formula (VIIa)



wherein Y is a carbon-carbon double bond $-\text{CH}=\text{CH}-$, R1 and R2
15 are as above defined, to give a compound of general formula (I) wherein Y is a carbon-carbon double bond and R1, R2 are as described above, and R3 is hydrogen atom, and

ii) optionally converting a compound of general formula (I) into a different compound of formula (I) and, if desired,
20 converting a compound of formula (I) into a pharmaceutically acceptable salt thereof or converting a salt into the free compound (I).

The treatment with hydrazine of a compound of formula (VIIa) according to step i) with can be carried out as
25 described for example in *Indian J.Chem.* 1998, 37B, 314.

It is clear to the person skilled in the art that if a compound of formula (I), prepared according to the above processes, is obtained as an admixture of isomers, their
separation into the single isomers of formula (I), carried
30 out according to conventional techniques, is still within the scope of the present invention.

- 32 -

Likewise, the salification of a compound of formula (I) or the conversion of its salt into the free compound (I), carried out according to well-known procedures in the art, are still within the scope of the invention.

- 5 The optional conversion of a compound of general formula (I) into a different compound of formula (I) may be carried out in different ways, depending on the desired transformation of the substituents. When in a compound of general formula (I) Y is $-\text{CH}_2-\text{CH}_2-$ group, the conversion
- 10 may lead to a mixture of a compound of formula (I) wherein Y is a $-\text{CH}_2-\text{CH}_2-$ group and a compound of formula (I) wherein Y is a $-\text{CH}=\text{CH}-$ group, that is, a fully aromatized compound. The two different compounds of formula (I) can be conveniently separated by known chromatographic technique.
- 15 According to a preferred aspect of the invention, for avoiding the unwanted by-products formation, a compound of formula (I) could be first supported onto a suitable solid support, such as a resin and then, after appropriate reactions for the conversion, cleaved to give a different
- 20 compound of formula (I). We describe herein below some methods for said conversion, carried out in solution or on solid support.

- A) For example, a compound of formula (I) wherein Y is a $-(\text{CH}_2)_n-$ group, n, R1 and R2 are as described above, R3 is
- 25 a straight or branched opt. substituted C_1-C_6 alkylthio, aryl C_1-C_6 alkylthio, C_1-C_6 alkylsulphinyl, C_1-C_6 alkylsulphonyl, arylthio, arylsulphinyl or arylsulphonyl group, said compound of formula (I) having optionally protected the pyrazole and cycloalkan [b]indole nitrogen atoms with
- 30 suitable N- protecting groups, may be reacted with a compound of general formula R-M where R is a suitable aliphatic or aromatic group as defined above for R3, and M represents magnesium halide, zinc halide, boronic acid or alkyl ester, to give a compound of formula (I) wherein Y is

- 33 -

a $-(CH_2)_n-$ group, n , R_1 and R_2 are as described above, and R_3 represents an aliphatic or aromatic group as defined above.

B) A compound of formula (I) wherein Y is a $-(CH_2)_n-$ group, n , R_1 and R_2 are as described above, R_3 is a C_1-C_6 alkylthio or aryl C_1-C_6 alkylthio group, said compound of formula (I) having optionally protected the pyrazole and cycloalkan [b]indole nitrogen atoms with suitable protecting groups, may be oxidised and

B') the resultant compound of formula (I) is then reacted with an appropriate nucleophile, to give a compound of general formula (I) wherein Y is a $-(CH_2)_n-$ group, n , R_1 and R_2 are as described above and R_3 represents:

- a) a different alkylthio group;
- b) an alkyloxy group;
- c) a substituted or disubstituted amino group;
- d) a group of general formula $-CH(J)(X)$ where J and X are as above defined;
- e) a cyano group.

The conversion under **A)** above is preferably carried out in the optional presence of a certain amount a transition metal-based salt or complex, such as, for instance, palladium acetate, tetrakis(triphenylphosphine) palladium, palladium chloride, bis(triphenylphosphine) nickel bromide, copper iodide, copper thiophene-2-carboxylate, in the optional presence of an organic base, such as for instance, triethylamine, or an inorganic salt, such as, for instance, caesium fluoride, caesium carbonate, potassium carbonate potassium orthophosphate and the like, in a suitable solvent such as, for instance, tetrahydrofuran, dimethoxyethane or dimethylformamide, using temperature ranging from -20° to $100^\circ C$.

The oxidation under **B)** above can be carried out for instance by means of *m*-chloroperbenzoic acid, oxone, and

- 34 -

the like, in a suitable solvent, for instance dichloromethane, tetrahydrofuran and the like, at a temperature ranging from -20°C C to the reflux temperature, for a time ranging from 5 minutes to 72 hours. The reaction
5 under **B'**) above is carried out with an appropriate nucleophile in the proper conditions according to the substituents mentioned above respectively:


- 10 a) an alkyl or aryl mercaptane in the presence of a suitable organic or inorganic base, such as, for instance, diisopropyl ethyl amine or potassium carbonate and the like;
- b) an alcohol or phenol in the presence of a suitable organic or inorganic base diisopropyl ethyl amine or potassium carbonate and the like;
- 15 c) an aliphatic or aromatic primary or secondary amine;
- d) a compound of general formula $J(CH_2)X$ where J and X are as above defined, in the presence of a suitable base, for instance sodium hydride in a inert solvent like tetrahydrofuran or dimethylformamide, at
20 temperature ranging from 0° to 100°C or
- e) an inorganic cyanide, such as, for instance, sodium cyanide or copper cyanide.

Other functionality modifications on the final tetracycle for converting a compound of formula (I) into a different
25 compound of formula (I) are reported herein below.

The esterification step of a carboxy pyrazolo[3,4-a]cycloalkan[b]indole derivative of formula (I), the reduction step of a nitro pyrazolo[3,4-a]cycloalkan[b]indole derivative of formula (I) and the
30 hydrolysis of the ester group of alkyl pyrazolo[3,4-a]cycloalkan[b]indole-3-carboxylate of formula (I) are reported in the following scheme, wherein Re is an ester residue and Y, R1, R2 and R3 are as defined above.

- 35 -

SCHEME I



5

The esterification steps can be performed by standard methods as well as the ester group hydrolysis. The transformation of nitro into amino can be performed by means of well known methods, such as, for instance, chemical reduction with iron or zinc in acids or ammonium chloride or tin (II) chloride. The reaction may occur in a suitable solvent such as, for instance, N,N-dimethylformamide, 1,4-dioxane, ethanol/water, methanol/water, 1-methyl-2-pyrrolidinone or acetonitrile, at a temperature ranging from about -10°C to reflux and for a suitable time, for instance from about 30 minutes to about 96 hours.

The said reduction may be also performed as a catalytic hydrogenation, according to conventional techniques, in the presence of a suitable catalyst such as, for instance,

20

- 36 -

copper (II) acetate, palladium on charcoal or 4-dimethylaminopyridine.

As said before, the conversion of a compound of formula (I) into a different compound of formula (I) may be preferably
5 carried out on a solid support. That conversion, which is another object of the present invention, may be carried out by reacting a compound of formula (I) as defined above with a suitable activated solid support, then making the desired functionality modifications, and cleaving the resultant
10 compound so as to eliminate the solid support obtaining the desired compound of formula (I).


Some examples of direct functionality modifications on the final tetracycle on solid phase are reported in the following schemes.

15 For example, in Scheme II the conversion into derivatives of general formula (I) containing acylamines as substituents is shown, wherein Y, R₂ and R₃ are as described above, L is CO, SO₂, NHCO, CHRa and Ra and Rb are independently hydrogen, straight or branched opt.
20 substituted C₁-C₈ alkyl group, aryl C₁-C₆ alkyl group, 5 or 6 membered saturated or unsaturated heterocyclic or heterocyclyl C₁-C₆ alkyl group or aryl; Q represents a resin of general formula Res-B wherein B represents an acid-labile linker, such as, for instance, trityl, (4-methoxyphenyl)(phenyl)-methyl, 4-hydroxyphenyl-methyl, 4-hydroxyphenyl-methyl-oxycarbonyl and the like, while Res
25 represents either a neutral core resin, such as polystyrene resin, or a hydroxyl core resin, such as, for instance, NovagelTM or TentagelTM resins.

30

- 37 -

Scheme II



5

In step one (loading) the tetracyclic derivative is supported on the solid support by reacting it with a resin, for instance, trityl resin, 4-benzyloxybenzyl bromide resin, 4-nitrophenyl carbonate resin and the like using a suitable solvent, like, for instance, dichloromethane, tetrahydrofuran, N,N-dimethylformamide and the like, in the presence of a suitable base, like, for instance, diisopropylethylamine, diazabicyclo[5.4.0]undec-7-ene and the like at temperature ranging from 0 C to about 70 C for a time varying from 15 minutes to 72 hours.

In step two (reduction) the nitro group is reduced by means of well-known methods, such as, for instance, chemical reduction with iron, zinc or tin (II) chloride treatment. The reaction may occur in a suitable solvent such as, for instance, N,N-dimethylformamide, 1,4-dioxane, 1-methyl-2-pyrrolidinone, at a temperature ranging from about -10°C to reflux and for a suitable time, for instance from about 30 minutes to about 96 hours.

- 38 -

In step three (amino derivatization) acylation of the amino group can be performed by reacting it with carboxylic acids (as formula Xa as defined below) or their derivatives, such as acyl chlorides as formula Xb as defined below) and
5 bromides, with sulphonic acid derivatives, namely sulphonylchlorides (as formula XI as defined below) and bromides, with isocyanates or isothiocyanates (as formula XII as defined below) to yield respectively carboxamido derivatives, sulphonamido derivatives, ureido or thioureido
10 derivatives.

The reaction between the solid-supported tetracyclic derivative and a carboxylic acid can be carried out in the presence of a coupling agent such as, for instance, benzotriazol-1-yloxytris(pyrrolidino)phosphonium
15 hexafluorophosphate, 1,3-dicyclohexylcarbodiimide, 1,3-diisopropylcarbodiimide, o-benzotriazol-1-yl-n,n,n',n'-tetramethyluronium tetrafluoroborate, carbonyldiimidazole, in a suitable solvent such as, for instance, dichloromethane, chloroform, tetrahydrofuran, 1,4-dioxane,
20 toluene or N,N-dimethylformamide, at a temperature ranging from about -10°C to the reflux temperature of the solvent and for a suitable time ranging from about 30 minutes to about 96 hours.

The said reaction is optionally carried out in the presence
25 of a suitable catalyst, for instance 4-dimethylaminopyridine, or in the presence of a further coupling agent such as N-hydroxybenzotriazole. The reaction can also be carried out through a mixed anhydride method, that is by using an alkyl chloroformate such as ethyl,
30 isobutyl, or isopropyl chloroformate, in the presence of a tertiary base such as triethylamine, N,N-diisopropylethylamine or pyridine, in a suitable solvent such as toluene, dichloromethane, chloroform, tetrahydrofuran, 1,4-dioxane or N,N-dimethylformamide, and

- 39 -

at a temperature ranging from about -30°C to room temperature.

The reaction between the solid-supported tetracyclic derivative and an acyl chloride or acyl bromide can be carried out in the presence of a tertiary base such as triethylamine, N,N-diisopropylethylamine or pyridine, in a suitable solvent such as toluene, dichloromethane, chloroform, tetrahydrofuran, or N,N-dimethylformamide, and at a temperature ranging from about -10°C to the reflux temperature of the solvent.

The reaction between the solid-supported tetracyclic derivative and a sulphonyl derivative, such as the chloride or the bromide, can be carried out in the presence of a tertiary base such as triethylamine, N,N-diisopropylethylamine or pyridine, in a suitable solvent such as toluene, dichloromethane, chloroform, tetrahydrofuran, or N,N-dimethylformamide, at a temperature ranging from about -10°C to the reflux temperature of the solvent.

Finally, the reaction between the solid-supported tetracyclic derivative and an isocyanate can be carried out in the presence of a tertiary base such as triethylamine, N,N-diisopropylethylamine or pyridine, in a suitable solvent such as toluene, dichloromethane, chloroform, tetrahydrofuran, or N,N-dimethylformamide, and at a temperature ranging from about -10°C to the reflux temperature of the solvent.

Alternatively the solid-supported tetracyclic derivative is reacted under reductive conditions with an aldehyde (as formula XIII as defined below) or ketone derivative of formula $RaRbCO$ so as to obtain the corresponding amine wherein Ra and Rb are as above defined.

From the above, it is clear to the skilled man that by reacting an aldehyde derivative of $RaCORb$, for instance wherein Rb is a hydrogen atom, the corresponding derivative

- 40 -


wherein L is a -CH₂- group will be obtained; likewise, by reacting a ketone derivative of formula RaCORb, a -CHRb-group will correspond to L.

This reaction, widely known as reductive alkylation of
5 amines, occurs in the presence of a reducing agent such as, for instance, sodium borohydride, sodium cyanoborohydride or sodium triacetoxyborohydride, in a suitable solvent such as N,N-dimethylformamide, N,N-dimethylacetamide, chloroform, dichloromethane, or tetrahydrofuran, optionally
10 in the presence of acetic acid, methanol or ethanol as co-solvents, at a temperature ranging from about 0°C to reflux and for a time varying from about 30 minutes to about 96 hours.

In step four (cleavage) the final compound of general
15 formula (Ie) is obtained by reacting the compound of general formula (Id) under acidic conditions, for instance, using a certain amount, typically from 1 % to 50 %, of trifluoroacetic acid in dichloromethane or chloroform at temperature ranging from 0° C to the reflux temperature of
20 the solvent, for a time ranging from 5 minutes to 10 hours. The synthetic pathway reported in Scheme III illustrates a procedure for conversion into derivatives of general formula (I) containing carboxamides as substituents, where Y, Q, R₂ and R₃ are as defined above, R_c and R_d are
25 independently hydrogen atom or a suitable organic residue, and R₅ is a C₁-C₅ alkyl group, such as, for instance methyl, ethyl and the like.

- 41 -

Scheme III



In step one the tetracyclic derivative is supported on the solid support by reacting it with a resin, for instance, trityl resin, 4-benzyloxybenzyl bromide resin, 4-nitrophenyl carbonate resin and the like using a suitable solvent, like, for instance, dichloromethane, tetrahydrofuran, N,N-dimethylformamide and the like, in the presence of a suitable base, like, for instance, diisopropylethylamine, diazabicyclo[5.4.0]undec-7-ene and the like at temperature ranging from 0 °C to about 70 °C for a time varying from 15 minutes to 72 hours.

In step two the ester is hydrolyzed by using an inorganic base, such as, for instance, lithium hydroxide or sodium hydroxide in a suitable solvent, like tetrahydrofuran, N,N-dimethylformamide, and the like, in the presence of a certain amount of water as a cosolvent, at temperature ranging from 0 °C to the reflux temperature of the solvent, for a time ranging from 1 hour to 96 hours.

- 42 -

In step three the solid-supported carboxyketocycloalkan[b] indole, is reacted with a compound of formula $RcRdNH$, wherein Rc and Rd are as defined above (as formula XIV as defined below) by means of well known methods. For instance, the reaction can be carried out in the presence of a coupling agent such as, for instance, benzotriazol-1-yloxytris(pyrrolidino)phosphonium hexafluorophosphate, 1,3-dicyclohexylcarbodiimide, 1,3-diisopropylcarbodiimide, o-benzotriazol-1-yl-n,n,n',n'-tetramethyluronium tetrafluoroborate, carbonyldiimidazole, in a suitable solvent such as, for instance, dichloromethane, chloroform, tetrahydrofuran, 1,4-dioxane, or N,N-dimethylformamide, at a temperature ranging from about $-10^{\circ}C$ to the reflux temperature of the solvent and for a suitable time ranging from about 30 minutes to about 96 hours.


The said reaction is optionally carried out in the presence of a suitable catalyst, for instance 4-dimethylamino pyridine, or in the presence of a further coupling agent such as N-hydroxybenzotriazole. The reaction can also be carried out through a mixed anhydride method, that is by using an alkyl chloroformate such as ethyl, isobutyl, or isopropyl chloroformate, in the presence of a tertiary base such as triethylamine, N,N-diisopropylethylamine or pyridine, in a suitable solvent such as toluene, dichloromethane, chloroform, tetrahydrofuran, 1,4-dioxane or N,N-dimethylformamide, and at a temperature ranging from about $-30^{\circ}C$ to room temperature.

In step four the final compound of general formula (Ie') is obtained by reacting the compound of general formula (Id') under acidic conditions, for instance, using a certain amount, typically from 1 % to 50 %, of trifluoroacetic acid in dichloromethane or chloroform at temperature ranging from $0^{\circ}C$ to reflux, for a time ranging from 5 minutes to 10 hours.

- 43 -

The synthetic pathway reported in Scheme IV illustrates an alternative procedure for the conversion into compounds of general formula (I) containing carboxamides as substituents, wherein Y, Rc, Rd, R2 and R3 are as defined above, and Qa is a resin of general formula Rs-Ka wherein Ka represents an activated type linker, such as, for instance, 4-hydroxy-2,3,5,6-tetrafluorobenzamide (as described for instance in *J. Comb. Chem.*, **2000**, 2, 691), and 4-hydroxy-3-nitrobenzamide (as described for instance in *J. Heterocycl. Chem.*, **2000**, 37, 1003) and the like, or a safety catch type linker, such as, for instance, 3-terbutoxy-4-hydroxyaniline (as described for instance in *J. Org. Chem.*, **2001**, 66, 2240) and the like. Rs represents a neutral core resin, such as polystyrene resin.

15

Scheme IV

In step one the tetracyclic scaffold, optionally protected at the indole and pyrazole nitrogen atoms with the appropriate protecting groups, is loaded on the resin by means of well known methods, for instance through the mixed anhydride method, that is by using an alkyl chloroformate such as ethyl, isobutyl, or isopropyl chloroformate, in the presence of a tertiary base such as triethylamine, N,N-diisopropylethylamine or pyridine, in a suitable solvent such as toluene, dichloromethane, chloroform, tetrahydrofuran, 1,4-dioxane or N,N-dimethylformamide, and at a temperature ranging from about -30°C to room temperature.

- 44 -

Alternatively this reaction can be carried out in the presence of a coupling agent such as, for instance, benzotriazol-1-yloxytris(pyrrolidino)phosphonium hexafluorophosphate, 1,3-dicyclohexylcarbodiimide, 1,3-diisopropylcarbodiimide, o-benzotriazol-1-yl-n,n',n'-tetramethyluronium tetrafluoroborate, carbonyldiimidazole, in a suitable solvent such as, for instance, dichloromethane, chloroform, tetrahydrofuran, 1,4-dioxane, or N,N-dimethylformamide, at a temperature ranging from about -10°C to reflux and for a suitable time ranging from about 30 minutes to about 96 hours.

The said reaction is optionally carried out in the presence of a suitable catalyst, for instance 4-dimethylaminopyridine, or in the presence of a further coupling agent such as N-hydroxybenzotriazole.

In step two the supported tetracyclic derivative, after activation of the linker when required (as described for instance in *J. Org. Chem.*, **2001**, 66, 2240), is treated with a suitable amount of an amine that cleaves the final product of general formula (Ic'') off the resin.

As stated above in general for the conversion of a compound of formula (I) into a different compound of formula (I), converting a compound of general formula (Ia), (Ia'), (Ia'') wherein Y is -CH₂-CH₂-group according to the processes depicted respectively in schemes II, III or IV, may lead to a mixture of a final compound of formula (I) wherein Y is a -CH₂-CH₂- group and a final compound of formula (I) wherein Y is a -CH=CH- group, that is, a fully aromatized compound. The two different compounds of formula (I) can be conveniently separated by known chromatographic technique. It is therefore a further object of the present invention any specific compound of formula (I) which is obtainable through the combinatorial chemistry technique described in scheme II above, by reacting each of the derivatives of

-45-

formula (X), as set forth in tables I and II, each of the derivatives of formula (XI), as set forth in table III, each of the derivatives of formula (XII), as set forth in table IV, each of the derivatives of formula (XIII), as set forth in table V with any one of the derivatives of formula (Ic), wherein R₂, R₃ and Q are as defined above, which are obtainable as above indicated.

Table I: Compounds of formula (X)

10

Ra-COOH, (Xa, acid)

1.	9-fluorenenecarboxylic acid;
2.	1-phenyl-1-cyclopropanecarboxylic acid;
3.	1-methylcyclopropane-1-carboxylic acid;
4.	Cyclobutanecarboxylic acid;
5.	cyclopentanecarboxylic acid;
6.	(-)-menthoxyacetic acid;
7.	1,2,3,4-tetrahydro-2-naphthoic acid;
8.	2-fluorobenzoic acid;
9.	2,5-dimethoxybenzoic acid;
10.	2-biphenylcarboxylic acid;
11.	2-(4-chlorobenzoyl)benzoic acid;
12.	2,6-dimethylbenzoic acid;
13.	3-cyanobenzoic acid;
14.	3-bromobenzoic acid;
15.	3,4-dimethoxybenzoic acid;
16.	3,4,5-trimethoxybenzoic acid;
17.	3,4-diethoxybenzoic acid;
18.	4-cyanobenzoic acid;
19.	4-iodobenzoic acid;
20.	4-diethylaminobenzoic acid;
21.	4-biphenylcarboxylic acid;
22.	3-methyl-2-oxovaleric acid;
23.	pyruvic acid;
24.	2-methylvaleric acid;

- 46 -

25.	tert-butylacetic acid;
26.	3-(2-methoxyphenyl)propionic acid;
27.	5-nitro-2-furoic acid;
28.	1-naphthoic acid;
29.	2-naphthoic acid;
30.	2-ketobutyric acid;
31.	pivalic acid;
32.	2,2-dimethylbutyric acid;
33.	diphenylacetic acid;
34.	N,N-dimethylglycine;
35.	2,3-dichlorophenoxyacetic acid;
36.	phenylacetic acid;
37.	2,4-dichlorophenylacetic acid;
38.	3-fluorophenylacetic acid;
39.	4-ethoxyphenylacetic acid;
40.	p-tolylacetic acid;
41.	4-pentynoic acid;
42.	mono-methyl glutarate;
43.	monomethyl adipate;
44.	6-acetamidohexanoic acid;
45.	1-pyroglutamic acid;
46.	3-furoic acid;
47.	thiophene-3-carboxylic acid;
48.	thiophene-3-acetic acid;
49.	nicotinic acid;
50.	nalidixic acid;
51.	2-nitro-4-trifluoromethylbenzoic acid;
52.	4-methyl-3-nitrobenzoic acid;
53.	3-nitrobenzoic acid;
54.	3-nitrophenylacetic acid;
55.	4-carboxybenzenesulfonamide;
56.	succinamic acid;
57.	N-(4-nitrobenzoyl)-beta-alanine;

58.	3-(phenylsulfonyl)propionic acid;
59.	2,2,3,3-tetramethylcyclopropanecarboxylic acid;
60.	2-(4-nitrophenyl)propionic acid;
61.	2,2-dimethyl-4-pentenoic acid;
62.	3-(diethylamino)propionic acid hydrochloride;
63.	4-dimethylaminobutyric acid hydrochloride;
64.	4-isopropylphenoxyacetic acid;
65.	5-benzoylpentanoic acid;
66.	4-acetamido-3-nitrobenzoic acid;
67.	d-campholic acid;
68.	2,5-dibromobenzoic acid;
69.	3-acetoxybenzoic acid;
70.	2,4,6-trimethoxyphenylacetic acid;
71.	2-benzyloxyphenylacetic acid;
72.	(3,5-dimethoxyphenyl)acetic acid;
73.	2-nitrophenoxyacetic acid;
74.	chromone-3-carboxylic acid;
75.	N-acetyl-4-fluoro-dl-phenylalanine;
76.	N-m-tolylphthalamic acid;
77.	4-acetamidobutyric acid;
78.	3-(2-thenoyl)-propionic acid;
79.	3,5-diacetamidobenzoic acid;
80.	5-acetamido-2-nitrobenzoic acid;
81.	acetic acid;
82.	5-methylhexanoic acid;
83.	N-benzoyl-b-alanine;
84.	4-bromo-3-methylbenzoic acid;
85.	4,5-dibromothiophene-2-carboxylic acid;
86.	2-acetamido-5-bromobenzoic acid;
87.	4-bromo-2-methylbenzoic acid;
88.	2-fluoro-6-iodobenzoic acid;
89.	2-furanglyoxylic acid;

- 48 -

90.	N,N-dimethylsuccinamic acid;
91.	2-(2-methoxyethoxy)acetic acid;
92.	4-chloro- α -methylphenylacetic acid;
93.	1-(p-tolyl)-1-cyclopentanecarboxylic acid;
94.	picolinic acid hydrochloride;
95.	3,5-dibromobenzoic acid;
96.	5-chlorothianaphthene-3-acetic acid;
97.	2-nitrothiophene-4-carboxylic acid;
98.	3-chloro-2-methylbenzoic acid;

99.	2-bromo-4-fluorobenzoic acid;
100.	3-(2-chloro-6-fluorophenyl)-5-methylisoxazole-4-carboxylic acid;
101.	fenbufen;
102.	indoprofen;
103.	chrysanthemum monocarboxylic acid;
104.	6-acetoxy-2-naphthoic acid;
105.	3-methylthiopropionic acid;
106.	(R)-(+)-N-(1-phenylethyl)phthalamic acid;
107.	alpha-ketovaleric acid;
108.	5-methyl-1-phenylpyrazole-4-carboxylic acid;
109.	3-methyl-1-cyclohexanecarboxylic acid;
110.	3-methoxycyclohexanecarboxylic acid;
111.	dicyclohexylacetic acid;
112.	5,6-dichloronicotinic acid;
113.	4-(dimethylamino)phenylacetic acid;
114.	(R)-(+)-N-(1-phenylethyl)succinamic acid;
115.	(S)-(-)-N-(1-phenylethyl)succinamic acid;
116.	(+)-menthyloxyacetic acid;
117.	suprofen;
118.	N,N-dimethyl-1-phenylalanine;
119.	4-iodophenylacetic acid;
120.	4-(3,4-dimethoxyphenyl)butyric acid;
121.	2-fluoro-5-nitrobenzoic acid;
122.	N,N-diethyl-3,6-difluorophthalamic acid;
123.	2-bromo-5-nitrobenzoic acid;
124.	4-bromo-2-fluorobenzoic acid;
125.	5-(2-thienyl)pentanoic acid;
126.	isoxazole-5-carboxylic acid;
127.	5-nitrothiophene-2-carboxylic acid;
128.	2-(4-pyridyl)thiazole-4-carboxylic acid;
129.	2-methyl-4,4,4-trifluorobutyric acid;
130.	1-(aminocarbonyl)-1-cyclopropanecarboxylic

- 50 -

	acid;
131.	1-cyanocyclopropanecarboxylic acid;
132.	(S)-(-)-2-acetoxypropionic acid;
133.	3-(methylsulfonyl)benzoic acid;
134.	2-chloro-4-methylsulfonylbenzoic acid;
135.	2,6-dichloropyridine-4-carboxylic acid;
136.	3-pyridinepropionic acid;
137.	5-(4-chloro-2-nitrophenyl)-2-furoic acid;
138.	7-chloro-1-ethyl-6-fluoro-4-oxohydroquinoline-3-carboxylic acid;
139.	cis-2-(2-thiophenecarbonyl)-1-cyclohexanecarboxylic acid;
140.	5-bromo-3-pyridylacetic acid;
141.	5-methylisoxazole-4-carboxylic acid;
142.	2,2-dimethylhexanoic acid;
143.	3-carboxypropanesulfonamide;
144.	6-cyanonicotinic acid;
145.	(R)-(-)-2-methoxypropionic acid;
146.	(S)-(+)-2-methoxypropionic acid;
147.	4-(tert-butoxymethyl)benzoic acid;
148.	cis-2-(benzyloxycarbonylamino)-cyclohexanecarboxylic acid;
149.	cis-2-(benzyloxycarbonylamino)-4-cyclohexene-1-carboxylic acid.

Table II: Compounds of formula (X)

Ra-COCl, (Xb, acyl chloride)

1.	3,5-bis(trifluoromethyl)benzoyl chloride
2.	benzoyl chloride
3.	2-bromobenzoyl chloride
4.	2-fluorobenzoyl chloride
5.	2,4-difluorobenzoyl chloride
6.	2,6-difluorobenzoyl chloride

- 51 -

7.	2-chlorobenzoyl chloride
8.	2,4-dichlorobenzoyl chloride
9.	2-methoxybenzoyl chloride
10.	2-(trifluoromethyl)benzoyl chloride
11.	o-toluoyl chloride
12.	3-bromobenzoyl chloride
13.	3-fluorobenzoyl chloride
14.	3-chlorobenzoyl chloride
15.	3,4-dichlorobenzoyl chloride
16.	m-anisoyl chloride
17.	3,4-dimethoxybenzoyl chloride
18.	3,4,5-trimethoxybenzoyl chloride
19.	3,5-dimethoxybenzoyl chloride
20.	3-(trifluoromethyl)benzoyl chloride
21.	m-toluoyl chloride
22.	4-bromobenzoyl chloride
23.	4-fluorobenzoyl chloride
24.	4-chlorobenzoyl chloride
25.	p-anisoyl chloride
26.	4-ethoxybenzoyl chloride
27.	4-n-butoxybenzoyl chloride
28.	4-biphenylcarbonyl chloride
29.	4-(trifluoromethyl)benzoyl chloride
30.	4-tert-butylbenzoyl chloride
31.	p-toluoyl chloride
32.	4-ethylbenzoyl chloride
33.	4-n-propylbenzoyl chloride
34.	4-n-butylbenzoyl chloride
35.	pivaloyl chloride
36.	isobutyryl chloride
37.	2-ethylhexanoyl chloride
38.	acetyl chloride
39.	phenoxyacetyl chloride

- 52 -

40.	4-chlorophenoxyacetyl chloride
41.	methoxyacetyl chloride
42.	phenylacetyl chloride
43.	tert-butylacetyl chloride
44.	isovaleryl chloride
45.	propionyl chloride
46.	hydrocinnamoyl chloride
47.	butyryl chloride
48.	pentanoyl chloride
49.	4-iodobenzoyl chloride
50.	cyclopropanecarbonyl chloride
51.	cyclobutanecarbonyl chloride
52.	cyclopentanecarbonyl chloride
53.	3-cyclopentylpropionyl chloride
54.	cyclohexanecarbonyl chloride
55.	4-cyanobenzoyl chloride
56.	2-furoyl chloride
57.	1-naphthoyl chloride
58.	2-naphthoyl chloride
59.	thiophene-2-carbonyl chloride
60.	thiophene-2-acetyl chloride
61.	(3,4-dimethoxyphenyl)acetyl chloride
62.	3,5-dichlorobenzoyl chloride
63.	2,5-difluorobenzoyl chloride
64.	3,4-difluorobenzoyl chloride
65.	9-fluorenone-4-carbonyl chloride
66.	3,5-difluorobenzoyl chloride
67.	benzyloxyacetyl chloride
68.	3-cyanobenzoyl chloride
69.	(2,5-dimethoxyphenyl)acetyl chloride
70.	3-methoxyphenylacetyl chloride
71.	nicotinoyl chloride hydrochloride
72.	isonicotinoyl chloride hydrochloride

- 53 -

73.	2,4,6-trimethylbenzoyl chloride
74.	diphenylacetyl chloride
75.	2-methylvaleryl chloride
76.	3,4-methylenedioxybenzoyl chloride
77.	2,4-dimethoxybenzoyl chloride
78.	2-phenoxypropionyl chloride
79.	2-phenylbutyryl chloride
80.	2-ethylbutyryl chloride
81.	2,3-dichlorobenzoyl chloride
82.	4-chlorophenylacetyl chloride
83.	dl-2-methylbutyryl chloride
84.	2,3-difluorobenzoyl chloride
85.	1-(4-chlorophenyl)-1-cyclopentanecarbonyl- chloride
86.	2-ethoxy-1-naphthoyl chloride
87.	benzo[b]thiophene-2-carbonyl chloride
88.	4-(trifluoromethoxy)benzoyl chloride
89.	2-(trifluoromethoxy)benzoyl chloride
90.	3-chlorobenzo[b]thiophene-2-carbonyl chloride
91.	2-fluoro-3-(trifluoromethyl)benzoyl chloride
92.	2-fluoro-4-(trifluoromethyl)benzoyl chloride
93.	2-fluoro-5-(trifluoromethyl)benzoyl chloride
94.	3-fluoro-5-(trifluoromethyl)benzoyl chloride
95.	4-fluoro-2-(trifluoromethyl)benzoyl chloride
96.	4-fluoro-3-(trifluoromethyl)benzoyl chloride
97.	2-fluoro-6-(trifluoromethyl)benzoyl chloride
98.	2,3,6-trifluorobenzoyl chloride
99.	2,4,5-trifluorobenzoyl chloride
100.	3-(trifluoromethoxy)benzoyl chloride
101.	isoxazole-5-carbonyl chloride
102.	2,4,6-trifluorobenzoyl chloride
103.	2,5-bis(trifluoromethyl)benzoyl chloride

104.	2,3,4-trifluorobenzoyl chloride
105.	2,4,6-trichlorobenzoyl chloride
106.	2,4-dichloro-5-fluorobenzoyl chloride
107.	4-methoxyphenylacetyl chloride
108.	5-fluoro-2-(trifluoromethyl)benzoyl chloride
109.	2-chloro-6-fluorobenzoyl chloride
110.	2-bromo-5-methoxybenzoyl chloride
111.	cyclopentylacetyl chloride
112.	3-chloro-4-fluorobenzoyl chloride
113.	3-fluoro-4-(trifluoromethyl)benzoyl chloride
114.	4-fluorophenylacetyl chloride
115.	4-tert-butylphenoxyacetyl chloride
116.	7-Imidazol-1-yl-5,6-dihydro-naphthalene-2-carbonyl chloride
117.	4-Imidazol-1-ylmethyl-benzoyl chloride
118.	4-bromo-3-methylbenzoyl chloride

Table III: Compounds of formula (XI)

Sulfonyl chloride of formula $Ra-SO_2Cl$ (XI)

1.	1-naphthalenesulfonyl chloride
2.	2-naphthalenesulfonyl chloride
3.	2-thiophenesulfonyl chloride
4.	8-quinolinesulfonyl chloride
5.	benzenesulfonyl chloride
6.	2,4,5-trichlorobenzenesulfonyl chloride
7.	2,5-dichlorobenzenesulfonyl chloride
8.	3,5-dichloro-2-hydroxybenzenesulfonyl chloride
9.	2-mesitylenesulfonyl chloride
10.	4-bromobenzenesulfonyl chloride
11.	4-fluorobenzenesulfonyl chloride
12.	4-chlorobenzenesulfonyl chloride
13.	pipsyl chloride
14.	4-methoxybenzenesulfonyl chloride

15.	4-tert-butylbenzenesulfonyl chloride
16.	p-toluenesulfonyl chloride
17.	isopropylsulfonyl chloride
18.	methanesulfonyl chloride
19.	alpha-toluenesulfonyl chloride
20.	ethanesulfonyl chloride
21.	1-propanesulfonyl chloride
22.	1-butanesulfonyl chloride
23.	Pentamethylbenzenesulfonyl chloride
24.	2,3,5,6-tetramethylbenzenesulfonyl chloride
25.	3-(trifluoromethyl)benzenesulphonyl chloride
26.	3,5-bis(trifluoromethyl)benzenesulfonyl chloride
27.	2,3,4-trichlorobenzenesulfonyl chloride
28.	2,5-dimethoxybenzenesulfonyl chloride
29.	4-methoxy-2,3,6-trimethylbenzenesulfonyl chloride
30.	3,4-dichlorobenzenesulfonyl chloride
31.	4,5-dibromothiophene-2-sulfonyl chloride
32.	3-chloro-4-fluorobenzenesulphonyl chloride
33.	4-ethylbenzenesulfonyl chloride
34.	4-N-propylbenzenesulfonyl chloride
35.	4-N-amybenzenesulfonyl chloride
36.	4-isopropylbenzenesulphonyl chloride
37.	4-bromo-2,5-difluorobenzenesulphonyl chloride
38.	2-fluorobenzenesulphonyl chloride
39.	3-fluorobenzenesulphonyl chloride
40.	4-(trifluoromethoxy)benzenesulphonyl chloride
41.	4-(trifluoromethyl)benzenesulfonyl chloride
42.	2,4-difluorobenzenesulphonyl chloride
43.	2,4-dichloro-5-methylbenzenesulfonyl chloride
44.	4-chloro-2,5-dimethylbenzenesulphonyl chloride
45.	2-chlorobenzenesulfonyl chloride
46.	4-bromo-2,5-dichlorothiophene-3-sulfonyl

- 56 -

	chloride
47.	2,5-dichlorothiophene-3-sulphonyl chloride
48.	5-chlorothiophene-2-sulfonyl chloride
49.	2-(trifluoromethyl)benzenesulfonyl chloride
50.	3-chlorobenzenesulfonyl chloride
51.	3,5-dichlorobenzenesulfonyl chloride
52.	m-toluenesulfonyl chloride
53.	2-chloro-6-methylbenzenesulfonyl chloride
54.	5-bromo-2-methoxybenzenesulfonyl chloride
55.	3,4-dimethoxybenzenesulfonyl chloride
56.	2,3-dichlorobenzenesulfonyl chloride
57.	2-bromobenzenesulfonyl chloride
58.	2,3-dichlorothiophene-5-sulphonyl chloride
59.	4-phenylthiophene-2,4-disulfonyl
60.	5-phenylthiophene-2,5-disulfonyl chloride
61.	3-chloro-2-methylbenzenesulfonyl chloride
62.	2-chloro-5-(trifluoromethyl)benzenesulfonyl chloride
63.	2,6-dichlorobenzenesulfonyl chloride
64.	3-bromobenzenesulfonyl chloride
65.	2-(trifluoromethoxy)benzenesulfonyl chloride
66.	4-cyanobenzenesulfonyl chloride
67.	2-cyanobenzenesulfonyl chloride
68.	4-(N-butoxy)benzenesulfonyl chloride
69.	4-acetamido-3-chlorobenzenesulfonyl chloride
70.	3,5-dimethylisoxazole-4-sulfonyl chloride
71.	2,4-dichlorobenzenesulfonyl chloride
72.	2-chloro-4-fluorobenzenesulphonyl chloride
73.	5-fluoro-2-methylbenzenesulphonyl chloride
74.	5-chloro-2-methoxybenzenesulfonyl chloride
75.	2,4,6-trichlorobenzenesulfonyl chloride
76.	4-biphenylsulfonyl chloride
77.	5-bromothiophene-2-sulfonyl chloride

78.	2,6-difluorobenzenesulfonyl chloride
79.	4-n-butylbenzenesulfonyl chloride
80.	4-methylsulfonylbenzenesulfonyl chloride
81.	2-methylsulfonylbenzenesulfonyl chloride
82.	4-acetylbenzenesulfonyl chloride
83.	3-methoxybenzenesulphonyl chloride
84.	2-methoxy-4-methylbenzenesulphonyl chloride

Table IV: Compounds of formula (XII)

Isocyanate derivatives of formula (XII, Ra-NCO, Ra-NCS)

1.	Phenyl isocyanate
2.	2-bromophenyl isocyanate
3.	2-fluorophenyl isocyanate
4.	2,4-difluorophenyl isocyanate
5.	2,6-difluorophenyl isocyanate
6.	2-chlorophenyl isocyanate
7.	2,3-dichlorophenyl isocyanate
8.	2,4-dichlorophenyl isocyanate
9.	2,5-dichlorophenyl isocyanate
10.	2,6-dichlorophenyl isocyanate
11.	2-methoxyphenyl isocyanate
12.	2,4-dimethoxyphenyl isocyanate
13.	2,5-dimethoxyphenyl isocyanate
14.	2-ethoxyphenyl isocyanate
15.	2-(trifluoromethyl)phenyl isocyanate
16.	o-tolyl isocyanate
17.	2,6-dimethylphenyl isocyanate
18.	2-ethylphenyl isocyanate
19.	3-bromophenyl isocyanate
20.	3-fluorophenyl isocyanate
21.	3-chlorophenyl isocyanate
22.	3,4-dichlorophenyl isocyanate
23.	3-methoxyphenyl isocyanate

- 58 -

24.	3-(trifluoromethyl)phenyl isocyanate
25.	m-tolyl isocyanate
26.	4-bromophenyl isocyanate
27.	4-fluorophenyl isocyanate
28.	4-chlorophenyl isocyanate
29.	4-methoxyphenyl isocyanate
30.	4-(trifluoromethyl)phenyl isocyanate
31.	p-tolyl isocyanate
32.	benzoyl isocyanate
33.	1-naphthyl isocyanate
34.	Benzyl isocyanate
35.	3,5-bis(trifluoromethyl)phenyl isocyanate
36.	2,5-difluorophenyl isocyanate
37.	2,4,5-trichlorophenyl isocyanate
38.	2,4,6-trichlorophenyl isocyanate
39.	2-isopropylphenyl isocyanate
40.	2,3-dimethylphenyl isocyanate
41.	4-methoxy-2-methylphenyl isocyanate
42.	2,4-dimethylphenyl isocyanate
43.	2,5-dimethylphenyl isocyanate
44.	2-ethyl-6-methylphenyl isocyanate
45.	3-cyanophenyl isocyanate
46.	5-chloro-2,4-dimethoxyphenyl isocyanate
47.	3-chloro-4-methylphenyl isocyanate
48.	3,5-dichlorophenyl isocyanate
49.	5-chloro-2-methoxyphenyl isocyanate
50.	3,4,5-trimethoxyphenyl isocyanate
51.	3,5-dimethoxyphenyl isocyanate
52.	3-(methylthio)phenyl isocyanate
53.	3-acetylphenyl isocyanate
54.	3,4-dimethylphenyl isocyanate
55.	3,5-dimethylphenyl isocyanate
56.	2-methoxy-5-methylphenyl isocyanate

57.	3-ethylphenyl isocyanate
58.	4-bromo-2-(trifluoromethyl)phenyl isocyanate
59.	4-chloro-2-(trifluoromethyl)phenyl isocyanate
60.	4-chloro-3-(trifluoromethyl)phenyl isocyanate
61.	4-iodophenyl isocyanate
62.	4-phenoxyphenyl isocyanate
63.	4-ethoxyphenyl isocyanate
64.	4-acetylphenyl isocyanate
65.	4-isopropylphenyl isocyanate
66.	4-ethylphenyl isocyanate
67.	4-n-butylphenyl isocyanate
68.	2,4,6-trimethylphenyl isocyanate
69.	2-isopropyl-6-methylphenyl isocyanate
70.	2,6-diethylphenyl isocyanate
71.	5-chloro-2-methylphenyl isocyanate
72.	4-chloro-2-methylphenyl isocyanate
73.	4-(trifluoromethoxy)phenyl isocyanate
74.	2-chloro-5-(trifluoromethyl)phenyl isocyanate
75.	2-chloro-6-methylphenyl isocyanate
76.	2,4,5-trimethylphenyl isocyanate
77.	3-chloro-2-methoxyphenyl isocyanate
78.	3-chloro-2-methylphenyl isocyanate
79.	3-chloro-4-fluorophenyl isocyanate
80.	4-bromo-2-methylphenyl isocyanate
81.	4-bromo-2,6-dimethylphenyl isocyanate
82.	2,6-dibromo-4-fluorophenyl isocyanate
83.	4-butoxyphenyl isocyanate
84.	3-fluoro-4-methylphenyl isocyanate
85.	5-fluoro-2-methylphenyl isocyanate
86.	2-biphenyl isocyanate
87.	4-biphenyl isocyanate
88.	2-bromo-4,6-difluorophenyl isocyanate
89.	(x)-(+) -1-phenylethyl isocyanate

- 60 -

90.	1-(1-naphthyl)ethyl isocyanate
91.	(s)-(+)-1-(1-naphthyl) ethyl isocyanate
92.	3,4-difluorophenyl isocyanate
93.	2-(trifluoromethoxy)phenyl isocyanate
94.	4-benzyloxyphenyl isocyanate
95.	4-bromo-2-chlorophenyl isocyanate
96.	4-bromo-2-fluorophenyl isocyanate
97.	2-fluoro-5-methylphenyl isocyanate
98.	2,3,4-trifluorophenyl isocyanate
99.	2-(difluoromethoxy)phenyl isocyanate
100.	4-(difluoromethoxy)phenyl isocyanate
101.	2-methylbenzyl isocyanate
102.	2-chlorobenzyl isocyanate
103.	4-fluorobenzyl isocyanate
104.	4-methoxybenzyl isocyanate
105.	2,6-difluorobenzoyl isocyanate
106.	4-fluorobenzoyl isocyanate
107.	2-fluoro-3-(trifluoromethyl)phenyl isocyanate
108.	2-fluoro-5-(trifluoromethyl)phenyl isocyanate
109.	2-fluoro-6-(trifluoromethyl)phenyl isocyanate
110.	4-fluoro-2-(trifluoromethyl)phenyl isocyanate
111.	2-(tert-butyl)phenyl isocyanate
112.	3-pyridyl isocyanate

Table V: Compounds of formula (XIII)

Aldehyde derivatives of formula (XIII) Ra-COH

1.	3,5-diiodo-4-hydroxybenzaldehyde
2.	3-iodobenzaldehyde
3.	3,5-dibromobenzaldehyde
4.	4-bromothiophene-2-carboxaldehyde
5.	2-naphthaldehyde
6.	n-ethyl-carbazole-3-aldehyde

- 61 -

7.	4-chloro-1-methylpyrazole-3-carboxaldehyde
8.	(3-formyl-1-phenyl-1h-pyrazol-5-yl)methyl acetate
9.	1-acetyl-3-indolecarboxaldehyde
10.	methyl 4-formyl-1-methylpyrrole-2-carboxylate
11.	3,5-di-tert-butyl-4-hydroxybenzaldehyde
12.	5-(methylthio)-2-thiophenecarboxaldehyde
13.	4-(methylthio)benzaldehyde
14.	3-nitro-4-(2-pyridylthio)benzaldehyde
15.	5-methyl-2-thiophenecarboxaldehyde
16.	3-acetoxybenzaldehyde
17.	3,4-dimethylbenzaldehyde
18.	4-pyridinecarboxaldehyde n-oxide
19.	4-fluoro-3-methylbenzaldehyde
20.	2,6-dichloroisonicotinaldehyde
21.	5-(2,4-difluorophenyl)-2-furaldehyde
22.	2-(4-bromobenzoyl)-1-benzofuran-5-carbaldehyde
23.	2-benzoyl-1-benzofuran-5-carbaldehyde
24.	2-butyl-4-formylimidazole
25.	5-benzyloxy-1h-pyrrolo[2,3-c]pyridine-3-carboxaldehyde
26.	6-methyl-2-pyridinecarboxaldehyde
27.	4-[4-(tert-butyl)thiazol-2-yl]benzaldehyde
28.	5-formyl-2,4-dimethoxy-pyrimidine
29.	2-[4-(4-chlorobenzyl)thio]pyrimidine-4-carbaldehyde
30.	3-fluoro-2-hydroxybenzaldehyde
31.	3-hydroxybenzaldehyde
32.	3-carboxybenzaldehyde
33.	4-vinylbenzaldehyde
34.	5-(2,5-dichlorophenyl)-2-furaldehyde
35.	2-fluoro-5-nitrobenzaldehyde
36.	5-(4-nitrophenyl)-2-furaldehyde

- 62 -

37.	4-dimethylaminobenzaldehyde
38.	4-[3-(dimethylamino)propoxy]benzaldehyde
39.	4-n-butylbenzaldehyde
40.	4-(4-benzylpiperazino)benzaldehyde
41.	2,2'-bithiophene-5-carboxaldehyde
42.	4-[4-(1-adamantyl)-1,3-thiazol-2-yl]benzaldehyde
43.	4-formyl-trans-stilbene
44.	6-chloroimidazo[2,1-b][1,3]thiazole-5-carbaldehyde
45.	4-(phenylethynyl)benzaldehyde
46.	3,3'-(4-formylphenylimino)dipropionitrile
47.	6-formyl-2-(methylthio)nicotinonitrile
48.	4-cyanobenzaldehyde
49.	3-[(4-formylphenoxy)methyl]thiophene-2-carbonitrile
50.	2-(3-formyl-1h-indol-1-yl)benzonitrile
51.	2-formyl-6-methoxyphenyl 2,6-difluorobenzoate
52.	tert-butyl 4-formyl-2-methoxyphenyl carbonate
53.	4-(difluoromethoxy)benzaldehyde
54.	2-[1-methyl-5-(trifluoromethyl)pyrazol-3-yl]thiophene-5-carboxaldehyde
55.	5-(3-trifluoromethylphenyl)furan-2-carboxaldehyde
56.	2,3-difluoro-4-methylbenzaldehyde
57.	3-chloro-5-(trifluoromethyl)pyridine-2-carboxaldehyde
58.	4-(trifluoromethoxy)benzaldehyde
59.	3-[(2,4-difluorophenyl)thio]-5-(trifluoromethyl)pyridine-2-carbaldehyde
60.	3,5-bis(trifluoromethyl)benzaldehyde
61.	2,3,5,6-tetrafluorobenzaldehyde
62.	4-(methylsulfonyl)benzaldehyde
63.	1-[(4-methylphenyl)sulfonyl]-1h-indole-3-

- 63 -

	carbaldehyde
64.	4-formyl-2-methoxyphenyl 2,4,5-trichlorobenzenesulfonate
65.	4-formylphenyl 2,3,4,5,6-pentamethylbenzenesulfonate
66.	3-(4-formylphenyl)-2-(pyridin-2-ylsulfonyl)acrylonitrile
67.	4-acetamidobenzaldehyde
68.	4-[[5-chloro-2-oxypyrimidin-1(2h)-yl]methoxy]benzaldehyde
69.	4-(5-formyl-2-furyl)benzene-1-sulfonamide
70.	3-Benzo[1,3]dioxol-5-yl-2-methyl-propionaldehyde
71.	3-(phenylthio)butyraldehyde
72.	3-chloro-4,4,4-trifluoro-2-phenylbutanal
73.	2-cyano-2-phenylacetaldehyde
74.	3-methoxyphenylacetaldehyde
75.	pyridine-3-carboxaldehyde
76.	4-chlorobenzaldehyde
77.	4-cyanobenzaldehyde
78.	3-fluorobenzaldehyde
79.	m-tolualdehyde
80.	2,4-dichlorobenzaldehyde
81.	quinoline-3-carboxaldehyde
82.	2-(trifluoromethyl)benzaldehyde
83.	methyl 4-formylbenzoate
84.	4-chloro-3-fluorobenzaldehyde
85.	4-nitrocinnamaldehyde
86.	3-thiophenecarboxaldehyde
87.	3-methoxybenzaldehyde
88.	propionaldehyde
89.	3,3-dimethylbutyraldehyde
90.	3-phenylpropionaldehyde

- 64 -

It is a further object of the present invention any specific compound of formula (I) which is obtainable through the combinatorial chemistry technique described in scheme III, by reacting each of the derivatives of formula (XIV), as set forth in tables VI, with any one of the derivatives of formula (Ic') of scheme III, wherein Y, Rc, Rd, R2, R3 and Q are as defined above, which are obtainable as above indicated.

10 Table VI: Compounds of formula (XIV)

Amine derivatives of formula (XIV) R_cR_dNH

1.	piperidine
2.	butylamine
3.	4-(2-aminoethyl)morpholine
4.	1-(3-aminopropyl)imidazole
5.	piperazine
6.	tetrahydrofurfurylamine
7.	phenethylamine
8.	3-phenylpropylamine
9.	n-propylamine
10.	isobutylamine
11.	cyclopropanemethylamine
12.	2-(2-aminoethyl)-1-methylpyrrolidine
13.	4-methylpiperidine
14.	1-methylpiperazine
15.	1-(3-aminopropyl)-2-pyrrolidinone
16.	1,3-diaminopropane
17.	ethylenediamine
18.	4-hydroxypiperidine
19.	3-amino-1-propanol
20.	2-(2-aminoethyl)pyridine
21.	1-(2-aminoethyl)piperidine
22.	pyrrolidine

- 65 -

23.	n-acetylenediamine
24.	1-acetylpiperazine
25.	3-methoxypropylamine
26.	3-methylpiperidine
27.	2-methylbutylamine
28.	1-(2-pyridyl)piperazine
29.	4-benzylpiperidine
30.	n,n-diethylnipecotamide
31.	3,5-dimethylpiperidine
32.	2-(aminomethyl)-1-ethylpyrrolidine
33.	1-(2-furoyl)piperazine
34.	thiophene-2-ethylamine
35.	1-(2-aminoethyl)-2-imidazolone
36.	thiomorpholine
37.	propargyl chloroformate
38.	4-piperidinopiperidine
39.	1-piperazinecarboxaldehyde
40.	1-benzylpiperazine
41.	3-piperidinemethanol
42.	3-ethoxypropylamine
43.	isoamylamine
44.	1-(2-fluorophenyl)piperazine
45.	1-(2-hydroxyethyl)-piperazine
46.	n,n-diethylethylenediamine
47.	1-(2-methoxyphenyl)piperazine
48.	4-(1-pyrrolidinyl)piperidine
49.	3-(dimethylamino)propylamine
50.	2-phenyl-propylamine
51.	3-hydroxypiperidine
52.	1-(3 aminopropyl) pyrrolidene
53.	1-hydroxyethylethoxypiperazine
54.	2,6-dimethylpiperazine
55.	3-isopropoxypropylamine

- 66 -

56.	1-(2,3-dimethylphenyl)-piperazine
57.	1-(3-methoxyphenyl)-piperazine
58.	n,n-diisopropylethylenediamine
59.	(x)-(-)-2-methylpiperazine
60.	1-(2,5-dimethylphenyl)piperazine
61.	2-methyl-1-(3-methylphenyl)piperazine
62.	1-cyclohexylpiperazine
63.	2-methylpiperazine
64.	1-(4-fluorophenyl)piperazine
65.	1-ethylpropylamine
66.	dl- α -methylbenzylamine
67.	3,4-dimethoxybenzylamine [veratrylamine]
68.	2-methylbenzylamine
69.	2-methoxyethylamine
70.	allylamine
71.	azetidine hydrochloride
72.	Ammonia

It is a further object of the present invention any specific compound of formula (I) which is obtainable through the combinatorial chemistry technique described in

5 scheme IV, by reacting each of the derivatives of formula (XIV), as set forth in tables VI, with any one of the derivatives of formula (Ib''), wherein Y, Rc, Rd, R2, R3 and Qa are as defined above, which are obtainable as above indicated.

10 As it will be really appreciated by the man skilled in the art, when preparing the compounds of formula (I) object of the invention, optional functional groups within both the starting materials or the intermediates thereof which could give rise to unwanted side reactions, need to be properly

15 protected according to conventional techniques. Likewise, the conversion of these latter into the free deprotected compounds may be carried out according to known procedures.


- 67 -

In addition to the above, it is also clear to the skilled man that the compounds of formula (I) of the invention can be advantageously prepared by combining the above described reactions in a combinatorial fashion, for example according to solid-phase-synthesis (SPS) techniques, so as to get a combinatorial chemical library of compounds of formula (I). It is therefore a further object of the invention a library of two or more compounds of formula (I) as defined above, which can be obtained starting from one or more compound supported onto a solid support of the formula (Ic), (Ic') or (Ib'') as defined above.

It is a further object of the present invention to provide useful intermediates of formula VII and VIIa as defined above, preferably those of formula VII wherein Y is a -CH₂-CH₂- group, with the proviso that when R₂ is a hydrogen atom, and

- i) W is dimethylamino and Z is a hydrogen atom, then R₁ is not 7-chloro, hydrogen, 7-bromo atom, 7-cyclohexyl or 7-methyl group, or
- ii) W is hydroxy and Z is a hydrogen atom, then R₁ is not hydrogen, 7-methoxy group, 7-benzyloxy, or
- iii) W is hydroxy and Z is ethyloxycarbonyl group, then R₁ is not hydrogen.


For clarity, we point out that the framework of the preferred compounds of formula (VII) of the present invention is numbered as follows:



- 68 -

The present invention also provides a process for preparing a compound of the formula (VII) or (VIIa) as above defined, which process comprises:

either i) reacting a compound of formula (VI):




wherein Y, R1 and R2 are as above defined and the indole nitrogen is optionally protected with an appropriate protecting group, with any of the following:

- a) a dialkylacetale of dimethylformamide;
- 10 b) a carboxylic ester such as alkyl formate, alkyl oxalate, alkyl acetate and the like;
- c) dimethyl trithiocarbonate and an alkyl iodide or bromide such as, for instance, methyl iodide or benzyl bromide,
- 15 to give a compound of general formula (VII) wherein Y is $-(CH_2)_n-$; n, R1 and R2 are as above defined; W and Z have, respectively, one of the following couple of meanings:
 - a) W is a dialkylamino group, and Z is a hydrogen atom;
 - 20 b) W is a hydroxy group, and Z is a hydrogen atom, a C_1-C_4 alkoxy carbonyl group or a methyl group;
 - c) Z is a C_1-C_6 alkylthio or aryl C_1-C_6 alkylthio group, and W is a methylthio group;
- and iia) optionally reacting a compound of general formula
- 25 (VII) where R1, R2 and Y are as described above and W and Z are as defined under c) with any of the following:
 - a') an aliphatic or aromatic primary or secondary amine;
 - b') a compound of general formula $W(CH_2)_nX$ where W and X
 - 30 are, the same or different, electron withdrawing

- 69 -

- groups, such as, for instance, nitrile, alkoxy carbonyl, aryl including heteroaryl groups;
- c') an organometallic compound of general formula RM, where R is either an aliphatic or aromatic group, and M represents lithium or magnesium halide;
- d') an organometallic compound of general formula of $(CH_3)_2CuLi_2B$, where B is a suitable anion species, like, for instance, a cyano group;
- e') an inorganic cyanide, such as, for instance, sodium cyanide, copper cyanide;
- to give a different compound of general formula (VII) where R1, R2 and Y are as defined above, while Z is a C₁-C₆ alkylthio or aryl C₁-C₆ alkylthio group, for instance a methylthio or a benzylthio group and W is
- i) a substituted or disubstituted amino group, such as an alkylamino or arylamino group;
- ii) a group of general formula -CH(J)(X) where J and X are, the same or different, electron withdrawing groups, such as, for instance, nitrile, alkoxy carbonyl, aryl including heteroaryl groups;
- iii) an alkyl or aryl group;
- iv) an alkyl- or aryl-carbonyl group;
- v) a cyano group or
- d) both Z and W are substituted or disubstituted amino groups,
- or ii) reacting another compound of formula (VIa):



wherein Y is $-(CH_2)_2-$, R1 and R2 are as above defined, with POCl₃ in dimethylformamide, to give a compound of general formula (VIIa) as defined above.

- 70 -

The reaction i) with the reagents under b) may be carried out in the presence of a strong base like sodium hydride or potassium hydride or sodium methoxyde in solvents like dimethylformamide, tetrahydrofuran and the like, as described for instance *Pharmaceut.Chem. J.* **1994**, 28, 566; *JCS Perkin1* **1979**, 1706; *J.Chem.Res. Synop.* **1995**, 350.


The reaction i) with the reagents under c) may be carried out in the presence of a strong base like potassium tertbutoxide, sodium hydride, lithium bis(trimethylsilyl) amide, in solvents like tetrahydrofuran, dimethylformamide and the like, using temperature ranging from -78° to 100°C. The optional reaction iia) with the reagents under b') may be carried out in the presence of a suitable base, for instance sodium hydride in a inert solvent like tetrahydrofuran or dimethylformamide, at temperature ranging from 0°C to 100°C.

The optional reaction iia) with the reagents under c') may be carried out in the optional presence of a certain amount a transition metal-based salt or complex, such as, for instance, copper (I) iodide, copper (I) bromide, copper (I) chloride, in a inert solvent like tetrahydrofuran or dimethoxyethane at temperature ranging from -20°C to 100°C. The optional reaction iia) with the reagents under d') may be carried out in the presence of an aliphatic or aromatic acyl chloride, as described for example in *Chem. Lett.* **1994**, 437.

The processes for preparing the compounds of the formula (VI) as defined above can be conveniently described as set forth below according to the following scheme:

SCHEME V

- 71 -



Scheme V describes the synthesis of the ketocycloalkan[b]indole of general formula (VI), where R1, R2 and Y are as described above, which represent key intermediates in the synthesis of the compounds object of the present invention. In route A step one, a cycloalkanone derivative is formylated with ethylformate in the presence of a base like sodium alkoxyde in an inert solvent like, for instance diethyl ether, as described in *Organic Syntheses* **1963**, vol.4, 536. In step two the aryldiazonium salt, prepared from the aniline and sodium nitrite in acids, is added to a basic hydro alcoholic solution of the cycloalkanone derivative to yield the corresponding hydrazone, as described for instance in *Chem.Pharm.Bull.* **1981**, 699.

Step three describes the Fischer indolization in acidic conditions (for instance poliphosphoric acid or acetic acid or mixtures of acetic and hydrochloric acids) applied to the hydrazone to form the ketocycloalkan[b]indole derivative as described for instance in *Heterocycles* **1986**, 711 or *Chem.Pharm.Bull.* **1981**, 699.

Route B outlines an alternative synthesis where, in step one, a classical Fischer indolization between a cycloalkanone and an aromatic hydrazine is performed under acidic conditions (for instance sulphuric acid in alcohol,

- 72 -


a Lewis acid in tetrahydrofuran or neat trifluoroacetic anhydride) in order to achieve a cycloalkan[b]indole. In the subsequent step the cycloalkan[b]indole is oxidized to the corresponding ketocycloalkan[b]indole by means of a
5 suitable oxidizing agent like, for instance, periodic acid or iodine pentoxide as described in *J. Heterocyclic Chem.* **2000**, 37, 11 or *Chem.Pharm.Bull.* **1987**, 35, 4700.

The synthetic pathways reported in the following schemes illustrate procedures that involve manipulation of
10 functional groups on the ketocycloalkan[b]indole before pyrazole ring formation, i.e. the conversion of a compound of formula VI into a different compound of formula VI.

For example in Scheme VI, wherein R₂, L, R_a and R_b are as described above, the preparation of derivatives of general
15 formula (VI) containing acylamines as substituents is shown.

- 73 -

SCHEME VI



5

In step one the starting nitroketocycloalkan[b]indole, obtained as described above, after optional protection of the indole nitrogen with a suitable protecting group, is subdued to reduction of the nitro group, by means of well known methods, such as, for instance, chemical reduction with iron, zinc or tin(II) chloride treatment. The reaction may occur in a suitable solvent such as, for instance, N,N-dimethylformamide, 1,4-dioxane, ethanol/water, methanol/water, 1-methyl-2-pyrrolidinone or acetonitrile, at a temperature ranging from about -10°C to reflux and for a suitable time, for instance from about 30 minutes to about 96 hours.

The said reduction may be also performed as a catalytic hydrogenation, according to conventional techniques, in the presence of a suitable catalyst such as, for instance, copper (II) acetate, palladium on charcoal or 4-dimethylaminopyridine.

In step two acylation of the amino group can occur reacting it with carboxylic acids or their derivatives, such as acyl chlorides and bromides, with sulphonic acid derivatives, namely sulphonyl chlorides and bromides, or with isocyanates to yield respectively carboxamido derivatives, sulphonamido derivatives or ureido derivatives.

The reaction between the aminoketocycloalkan[b]indole and a carboxylic acid can be carried out in the presence of a

30

- 74 -

coupling agent such as, for instance, benzotriazol-1-yloxytris(pyrrolidino)phosphonium hexafluorophosphate, 1,3-dicyclohexylcarbodiimide, 1,3-diisopropylcarbodiimide, o-benzotriazol-1-yl-n,n,n',n'-tetramethyluronium

5 tetrafluoroborate, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide, N-cyclohexylcarbodiimide-N'-propyloxymethyl polystyrene or N-cyclohexylcarbodiimide-N'-methyl polystyrene, in a suitable solvent such as, for instance, dichloromethane, chloroform, tetrahydrofuran,

10 diethyl ether, 1,4-dioxane, acetonitrile, toluene or N,N-dimethylformamide, at a temperature ranging from about -10°C to reflux and for a suitable time ranging from about 30 minutes to about 96 hours.

The said reaction is optionally carried out in the presence

15 of a suitable catalyst, for instance 4-dimethylaminopyridine, or in the presence of a further coupling agent such as N-hydroxybenzotriazole. The reaction can also be carried out through a mixed anhydride method, that is by using an alkyl chloroformate such as ethyl,

20 isobutyl, or isopropyl chloroformate, in the presence of a tertiary base such as triethylamine, N,N-diisopropylethylamine or pyridine, in a suitable solvent such as toluene, dichloromethane, chloroform, tetrahydrofuran, acetonitrile, diethyl ether, 1,4-dioxane

25 or N,N-dimethylformamide, and at a temperature ranging from about -30°C to room temperature.

The reaction between the aminoketocycloalkan[b]indole and an acyl chloride or bromide can be carried out in the presence of a tertiary base such as triethylamine, N,N-diisopropylethylamine or pyridine, in a suitable solvent

30 such as toluene, dichloromethane, chloroform, diethyl ether, tetrahydrofuran, acetonitrile or N,N-dimethylformamide, and at a temperature ranging from about -10°C to reflux.

- 75 -

The reaction between the aminoketocycloalkan[b]indole and a sulphonyl derivative, such as the chloride or the bromide, can be carried out in the presence of a tertiary base such as triethylamine, N,N-diisopropylethylamine or pyridine, in
5 a suitable solvent such as toluene, dichloromethane, chloroform, diethyl ether, tetrahydrofuran, acetonitrile or N,N-dimethylformamide, at a temperature ranging from about -10°C to reflux.

Finally, the reaction between the
10 aminoketocycloalkan[b]indole and an isocyanate can be carried out in the presence of a tertiary base such as triethylamine, N,N-diisopropylethylamine or pyridine, in a suitable solvent such as toluene, dichloromethane, chloroform, diethyl ether, tetrahydrofuran, acetonitrile,
15 or N,N-dimethylformamide, and at a temperature ranging from about -10°C to reflux.

Alternatively the aminoketocycloalkan[b]indole is reacted under reductive conditions with a aldehyde or ketone derivative of formula $RaRbCO$ so as to obtain the
20 corresponding amine wherein Ra and Rb are as above defined. From the above, it is clear to the skilled man that by reacting an aldehyde derivative of $RaCORb$, for instance wherein Rb is a hydrogen atom, the corresponding derivative wherein L is a $-CH_2-$ group will be obtained; likewise, by
25 reacting a ketone derivative of formula $RaCORb$, a $-CHRb-$ group will correspond to L.

This reaction, widely known as reductive alkylation of amines, occurs in the presence of a reducing agent such as, for instance, sodium borohydride, sodium cyanoborohydride
30 or sodium triacetoxyborohydride, in a suitable solvent such as N,N-dimethylformamide, N,N-dimethylacetamide, chloroform, dichloromethane, tetrahydrofuran or acetonitrile, optionally in the presence of acetic acid, methanol or ethanol as co-solvents, at a temperature
35 ranging from about -10°C to the reflux temperature of the

- 76 -

solvent and for a time varying from about 30 minutes to about 96 hours.


Finally, the ureido derivatives wherein Ra is hydrogen and L is (-NHCO-) may be prepared by reacting the
5 aminoketocycloalkan[b]indole s with a suitable acylating agent, for instance triphosgene or trichloromethyl chloroformate, in the presence of aqueous or gaseous ammonia, according to conventional techniques.

The said reaction is carried out in a suitable solvent such
10 as, for instance, dichloromethane, chloroform, toluene, tetrahydrofuran or dioxane, optionally in the presence of a tertiary base, for instance triethylamine, and of a catalyst such as 4-dimethylaminopyridine, at a temperature ranging from about -10°C to room temperature and for a time
15 varying from about 30 minutes to about 96 hours.

In Scheme VII, wherein Y is as described above and R4 is an optionally substituted phenyl group, like, for instance, 4-fluorophenyl, 4-methylphenyl and the like, the preparation of derivatives of general formula (VI) containing at one
20 time the hydroxy and carboxy groups or the carboxy group at either the position 4 or 6 of the indole ring in the cycloalkan[b]indole as substituents is shown.

SCHEME VII

- 77 -



Here in step one the aryldiazonium salt, prepared from a hydroxy and carboxy substituted aniline and sodium nitrite

5 in acids, is added to a basic hydroalcoholic solution of the cycloalkanone derivative to yield the corresponding hydrazone, as described for instance in *Chem. Pharm. Bull.* **1981**, 699. In step two the hydrazone derivative is reacted with an optionally substituted phenyl sulfonyl chloride in the presence of a suitable base, as described, for instance, in *Tetrahedron*, **1998**, 54, 45, and the resulting sulfonate (IVb) is then subjected to Fischer indole cyclization as above. The ketocycloalkan[b]indole of general formula (VIa''), can be subjected to reduction, using

10 triethylamine/Formic acid in the presence of Palladium acetate, as described, for instance in *J. Org. Chem.*, **1990**, 55, 350 to yield the ketocycloalkan[b]indole of general formula (VIc') where the carboxy group is brought at either the positions 4 or 6 of the indole ring. Alternatively the

20 ketocycloalkan[b]indole of general formula (VIa''), can be

- 78 -

subdued to hydrolysis under basic conditions, using, for instance, sodium hydroxide in hydroalcoholic solutions, to furnish the ketocycloalkan[b]indole of general formula (VIb').

- 5 The synthetic pathway reported in Scheme VIII illustrates a procedure for the preparation of derivatives of general formula (VI) containing carboxamides as substituents, wherein Rc, Rd, Y and R2 are as defined above.

Scheme VIII



10

- In scheme VIII the starting carboxyketocycloalkan[b]indole, obtained as above described, after optional protection of the indole nitrogen with a suitable protecting group, is reacted with an amine of formula RcRdNH, wherein Rc and Rd are as defined above, by means of well known methods, to give a compound of formula VI wherein R1 represents an optionally substituted group selected from C₁-C₆ alkylaminocarbonyl, C₁-C₆ dialkylaminocarbonyl, arylaminocarbonyl, hydroxyaminocarbonyl, C₁-C₆ alkyloxyaminocarbonyl, aryloxyaminocarbonyl, aminocarbonyl, and the like. For instance, the reaction can be carried out in the presence of a coupling agent such as, for instance, benzotriazol-1-yloxytris(pyrrolidino)phosphonium hexafluorophosphate, 1,3-dicyclohexylcarbodiimide, 1,3-diisopropylcarbodiimide, o-benzotriazol-1-yl-n,n,n',n'-tetramethyluronium tetrafluoroborate, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide, N-cyclohexylcarbodiimide-N'-propyloxymethyl polystyrene or N-cyclohexylcarbodiimide-N'-methyl polystyrene, in a suitable solvent such as, for instance, dichloromethane, chloroform, tetrahydrofuran, diethyl ether, 1,4-dioxane, acetonitrile,
- 15
- 20
- 25
- 30

- 79 -

toluene or N,N-dimethylformamide, at a temperature ranging from about -10°C to the reflux temperature of the solvent and for a suitable time ranging from about 30 minutes to about 96 hours.

- 5 The said reaction is optionally carried out in the presence of a suitable catalyst, for instance 4-dimethylaminopyridine, or in the presence of a further coupling agent such as N-hydroxybenzotriazole. The reaction can also be carried out through a mixed anhydride method,
10 that is by using an alkyl chloroformate such as ethyl, isobutyl, or isopropyl chloroformate, in the presence of a tertiary base such as triethylamine, N,N-diisopropylethylamine or pyridine, in a suitable solvent such as toluene, dichloromethane, chloroform,
15 tetrahydrofuran, acetonitrile, diethyl ether, 1,4-dioxane or N,N-dimethylformamide, and at a temperature ranging from about -30°C to room temperature.

- Alternatively the carboxy group can be activated by transforming it, for example, in an acyl chloride by means
20 of thionyl chloride or oxalyl chloride in a suitable solvent such as tetrahydrofuran, N,N-dimethylformamide at a temperature ranging from about -10°C to the reflux temperature of the solvent and for a suitable time ranging from about 30 minutes to about 96 hours.

- 25 The reaction between the ketocycloalkan[b]indole carbonyl chloride or bromide and a primary (Rc=H) or secondary amine can be carried out in the presence of a tertiary base such as triethylamine, N,N-diisopropylethylamine or pyridine, in a suitable solvent such as toluene, dichloromethane,
30 chloroform, diethyl ether, tetrahydrofuran, acetonitrile or N,N-dimethylformamide, and at a temperature ranging from about -10°C to the reflux temperature of the solvent. The starting compounds of the formula (II), (III), (X), (XI), (XII), (XIII) and (XIV) are known or can be prepared
35 starting from known compounds using known methods of

- 80 -

preparation.

PHARMACOLOGY

The compounds of formula (I) are active as protein kinase inhibitors and may be therefore useful, for instance, to restrict the unregulated proliferation of tumour cells.

- 5 In therapy, they may be used in the treatment of various tumours, such as those formerly reported, as well as in the treatment of other cell proliferative disorders such as psoriasis, vascular smooth cell proliferation associated with atherosclerosis and post-surgical stenosis and restenosis and in the treatment of Alzheimer's disease.

- 10 The inhibiting activity of putative cdk/cyclin inhibitors and the potency of selected compounds is determined through a method of assay based on the use of the SPA technology (Amersham Pharmacia Biotech).

- The assay consists of the transfer of radioactivity labelled phosphate moiety by the kinase to a biotinylated substrate. The resulting ³³P-labelled biotinylated product is allowed to bind to streptavidin-coated SPA beads (biotin capacity 130 pmol/mg), and
15 light emitted was measured in a scintillation counter.

Inhibition assay of cdk2/Cyclin A activity

- Kinase reaction:** 4 µM in house biotinylated histone H1 (Sigma # H-5505) substrate, 10 µM ATP (0.1 microCi P³³γ-ATP), 1.1 nM Cyclin A/CDK2 complex, inhibitor in a final volume of 30 µl buffer (TRIS HCl 10 mM pH 7.5, MgCl₂ 10 mM, DTT 7.5 mM +
20 0.2 mg/ml BSA) were added to each well of a 96 U bottom. After incubation for 60 min at room temperature, the reaction was stopped by addition of 100 µl PBS buffer containing 32 mM EDTA, 500 µM cold ATP, 0.1% Triton X100 and 10mg/ml streptavidin coated SPA beads. After 20 min incubation, 110 µL of suspension were withdrawn and transferred into 96-well OPTIPLATES containing 100 µl of 5M CsCl.
25 After 4 hours, the plates were read for 2 min in a Packard TOP-Count radioactivity reader.

IC₅₀ determination: inhibitors were tested at different concentrations ranging from 0.0015 to 10 µM. Experimental data were analyzed by the computer program GraphPad Prism using the four parameter logistic equation:

- 30 $y = \text{bottom} + (\text{top} - \text{bottom}) / (1 + 10^{((\log \text{IC}_{50} - x) * \text{slope})})$

- 81 -

where x is the logarithm of the inhibitor concentration, y is the response; y starts at bottom and goes to top with a sigmoid shape.

Ki calculation:

Experimental method: Reaction was carried out in buffer (10 mM Tris, pH 7.5, 10 mM MgCl₂, 0.2 mg/ml BSA, 7.5 mM DTT) containing 3.7 nM enzyme, histone and ATP (constant ratio of cold/labeled ATP 1/3000). Reaction was stopped with EDTA and the substrate captured on phosphomembrane (Multiscreen 96 well plates from Millipore). After extensive washing, the multiscreen plates were read on a top counter. Control (time zero) for each ATP and histone concentrations was measured.

Experimental design: Reaction velocities are measured at four ATP, substrate (histone) and inhibitor concentrations. An 80-point concentration matrix was designed around the respective ATP and substrate K_m values, and the inhibitor IC₅₀ values (0.3, 1, 3, 9 fold the K_m or IC₅₀ values). A preliminary time course experiment in the absence of inhibitor and at the different ATP and substrate concentrations allows the selection of a single endpoint time (10 min) in the linear range of the reaction for the K_i determination experiment.

Kinetic parameter estimates: Kinetic parameters were estimated by simultaneous nonlinear least-square regression using [Eq.1] (competitive inhibitor respect to ATP, random mechanism) using the complete data set (80 points):

20

$$v = \frac{V_m \cdot A \cdot B}{\alpha \cdot K_a \cdot K_b + \alpha \cdot K_a \cdot B + \alpha \cdot K_b \cdot A + A \cdot B + \alpha \cdot \frac{K_a}{K_i} \cdot I \cdot (K_b + \frac{B}{\beta})} \quad [\text{Eq.1}]$$

where A=[ATP], B=[Substrate], I=[inhibitor], V_m= maximum velocity, K_a, K_b, K_i the dissociation constants of ATP, substrate and inhibitor respectively. α and β the cooperativity factor between substrate and ATP binding and substrate and inhibitor binding respectively.

In addition the selected compounds are characterized on a panel of ser/thr kinases strictly related to cell cycle (cdk2/cyclin E, cdk1/cyclin B1, cdk5/p25, cdk4/cyclin D1), and also for specificity on MAPK, PKA, EGFR, IGF1-R, Aurora-2 and Cdc 7.

Inhibition assay of cdk2/Cyclin E activity

- 82 -

Kinase reaction: 10 μ M in house biotinylated histone H1 (Sigma # H-5505) substrate, 30 μ M ATP (0.3 microCi $P^{33}\gamma$ -ATP), 4 ng GST-Cyclin E/CDK2 complex, inhibitor in a final volume of 30 μ l buffer (TRIS HCl 10 mM pH 7.5, $MgCl_2$ 10 mM, DTT 7.5 mM + 0.2 mg/ml BSA) were added to each well of a 96 U bottom. After incubation for 60 min at room temperature, the reaction was stopped by addition of 100 μ l PBS buffer containing 32 mM EDTA, 500 μ M cold ATP, 0.1% Triton X100 and 10mg/ml streptavidin coated SPA beads. After 20 min incubation, 110 μ L of suspension were withdrawn and transferred into 96-well OPTIPLATES containing 100 μ l of 5M CsCl. After 4 hours, the plates were read for 2 min in a Packard TOP-Count radioactivity reader.

IC50 determination: see above

Inhibition assay of cdk1/Cyclin B1 activity

Kinase reaction: 4 μ M in house biotinylated histone H1 (Sigma # H-5505) substrate, 20 μ M ATP (0.2 microCi $P^{33}\gamma$ -ATP), 3 ng Cyclin B/CDK1 complex, inhibitor in a final volume of 30 μ l buffer (TRIS HCl 10 mM pH 7.5, $MgCl_2$ 10 mM, DTT 7.5 mM + 0.2 mg/ml BSA) were added to each well of a 96 U bottom. After 20 min at r.t. incubation, reaction was stopped by 100 μ l PBS + 32 mM EDTA + 0.1% Triton X-100 + 500 μ M ATP, containing 1 mg SPA beads. Then a volume of 110 μ l is transferred to Optiplate. After 20 min. incubation for substrate capture, 100 μ l 5M CsCl were added to allow statification of beads to the top of the Optiplate and let stand 4 hours before radioactivity counting in the Top-Count instrument.

IC50 determination: see above

Inhibition assay of cdk5/p25 activity

The inhibition assay of cdk5/p25 activity is performed according to the following protocol.

Kinase reaction: 10 μ M biotinylated histone H1 (Sigma # H-5505) substrate, 30 μ M ATP (0.3 microCi $P^{33}\gamma$ -ATP), 15 ng CDK5/p25 complex, inhibitor in a final volume of 30 μ l buffer (TRIS HCl 10 mM pH 7.5, $MgCl_2$ 10 mM, DTT 7.5 mM + 0.2 mg/ml BSA) were added to each well of a 96 U bottom. After incubation for 35 min at room temperature, the reaction was stopped by addition of 100 μ l PBS buffer containing 32 mM EDTA, 500 μ M cold ATP, 0.1% Triton X100 and 10 mg/ml streptavidin coated

- 83 -

SPA beads. After 20 min incubation, 110 μ L of suspension were withdrawn and transferred into 96-well OPTIPLATEs containing 100 μ l of 5M CsCl. After 4 hours, the plates were read for 2 min in a Packard TOP-Count radioactivity reader.

IC50 determination: see above

5 **Inhibition assay of cdk4/Cyclin D1 activity**

Kinase reaction: 0.4 μ M mouse GST-Rb (769-921) (# sc-4112 from Santa Cruz) substrate, 10 μ M ATP (0.5 μ Ci $P^{33}\gamma$ -ATP), 100 ng of baculovirus expressed GST-cdk4/GST-Cyclin D1, suitable concentrations of inhibitor in a final volume of 50 μ l buffer (TRIS HCl 10 mM pH 7.5, $MgCl_2$ 10 mM, 7.5 mM DTT+ 0.2mg/ml BSA) were added to each well of a 96 U bottom well plate. After 40 min at 37 °C incubation, reaction was stopped by 20 μ l EDTA 120 mM.

Capture: 60 μ l were transferred from each well to MultiScreen plate, to allow substrate binding to phosphocellulose filter. Plates were then washed 3 times with 150 μ l/well PBS Ca^{++}/Mg^{++} free and filtered by MultiScreen filtration system.

15 **Detection:** filters were allowed to dry at 37°C, then 100 μ l/well scintillant were added and ^{33}P labeled Rb fragment was detected by radioactivity counting in the Top-Count instrument.

IC50 determination: see above

Inhibition assay of MAPK activity

20 **Kinase reaction:** 10 μ M in house biotinylated MBP (Sigma # M-1891) substrate, 15 μ M ATP (0.15 microCi $P^{33}\gamma$ -ATP), 30 ng GST-MAPK (Upstate Biotechnology # 14-173), inhibitor in a final volume of 30 μ l buffer (TRIS HCl 10 mM pH 7.5, $MgCl_2$ 10 mM, DTT 7.5 mM + 0.2 mg/ml BSA) were added to each well of a 96 U bottom. After incubation for 35 min at room temperature, the reaction was stopped by addition of 100 μ l PBS buffer containing 32 mM EDTA, 500 μ M cold ATP, 0.1% Triton X100 and 10mg/ml streptavidin coated SPA beads. After 20 min incubation, 110 μ L of suspension were withdrawn and transferred into 96-well OPTIPLATEs containing 100 μ l of 5M CsCl. After 4 hours, the plates were read for 2 min in a Packard TOP-Count radioactivity reader.

30 **IC50 determination:** see above

Inhibition assay of PKA activity

- 84 -

Kinase reaction: 10 μ M in house biotinylated histone H1 (Sigma # H-5505) substrate, 10 μ M ATP (0.2 microM $P^{33}\gamma$ -ATP), 0.45 U PKA (Sigma # 2645), inhibitor in a final volume of 30 μ l buffer (TRIS HCl 10 mM pH 7.5, $MgCl_2$ 10 mM, DTT 7.5 mM + 0.2 mg/ml BSA) were added to each well of a 96 U bottom. After incubation for 90 min at room temperature, the reaction was stopped by addition of 100 μ l PBS buffer containing 32 mM EDTA, 500 μ M cold ATP, 0.1% Triton X100 and 10mg/ml streptavidin coated SPA beads. After 20 min incubation, 110 μ L of suspension were withdrawn and transferred into 96-well OPTIPLATES containing 100 μ l of 5M CsCl. After 4 hours, the plates were read for 2 min in a Packard TOP-Count radioactivity reader.

5
10 **IC50 determination:** see above

Inhibition assay of EGFR activity

Kinase reaction: 10 μ M in house biotinylated MBP (Sigma # M-1891) substrate, 2 μ M ATP (0.04 microCi $P^{33}\gamma$ -ATP), 36 ng insect cell expressed GST-EGFR, inhibitor in a final volume of 30 μ l buffer (Hepes 50 mM pH 7.5, $MgCl_2$ 3 mM, $MnCl_2$ 3 mM, DTT 1 mM, $NaVO_3$ 3 μ M, + 0.2 mg/ml BSA) were added to each well of a 96 U bottom. After incubation for 20 min at room temperature, the reaction was stopped by addition of 100 μ l PBS buffer containing 32 mM EDTA, 500 μ M cold ATP, 0.1% Triton X100 and 10mg/ml streptavidin coated SPA beads. After 20 min incubation, 110 μ L of suspension were withdrawn and transferred into 96-well OPTIPLATES containing 100 μ l of 5M CsCl. After 4 hours, the plates were read for 2 min in a Packard TOP-Count radioactivity reader.

15
20 **IC50 determination:** see above

Inhibition assay of IGF1-R activity

The inhibition assay of IGF1-R activity is performed according to the following protocol.

25 **Enzyme activation:** IGF1-R must be activated by auto-phosphorylation before starting the experiment. Just prior to the assay, a concentrated enzyme solution (694 nM) is incubated for half a hour at 28°C in the presence of 100 μ M ATP and then brought to the working dilution in the indicated buffer.

30 **Kinase reaction:** 10 μ M biotinylated IRS1 peptide (PRIMM) substrate, 0-20 μ M inhibitor, 6 μ M ATP, 1 microCi ^{33}P -ATP, and 6 nM GST-IGF1-R (pre-incubated for 30 min at room temperature with cold 60 μ M cold ATP) in a final volume of 30 μ l buffer

- 85 -

(50 mM HEPES pH 7.9, 3 mM MnCl₂, 1 mM DTT, 3 μM NaVO₃) were added to each well of a 96 U bottom well plate. After incubation for 35 min at room temperature, the reaction was stopped by addition of 100 μl PBS buffer containing 32 mM EDTA, 500 μM cold ATP, 0.1% Triton X100 and 10mg/ml streptavidin coated SPA beads. After 20 min incubation, 110 μL of suspension were withdrawn and transferred into 96-well OPTIPLATES containing 100 μl of 5M CsCl. After 4 hours, the plates were read for 2 min in a Packard TOP-Count radioactivity reader.

Inhibition assay of Aurora-2 activity

Kinase reaction: 8 μM biotinylated peptide (4 repeats of LRRWSLG), 10 μM ATP (0.5 uCi P³³_γ-ATP), 7.5 ng Aurora 2, inhibitor in a final volume of 30 μl buffer (HEPES 50 mM pH 7.0, MgCl₂ 10 mM, 1 mM DTT, 0.2 mg/ml BSA, 3 μM orthovanadate) were added to each well of a 96 U bottom well plate. After 60 minutes at room temperature incubation, reaction was stopped and biotinylated peptide captured by adding 100 μl of bead suspension.

Stratification: 100 μl of CsCl 5 M were added to each well and let stand 4 hour before radioactivity was counted in the Top-Count instrument.

IC50 determination: see above

Inhibition assay of Cdc7/dbf4 activity

The inhibition assay of Cdc7/dbf4 activity is performed according to the following protocol.

The Biotin-MCM2 substrate is trans-phosphorylated by the Cdc7/Dbf4 complex in the presence of ATP traced with γ³³-ATP. The phosphorylated Biotin-MCM2 substrate is then captured by Streptavidin-coated SPA beads and the extent of phosphorylation evaluated by β counting.

The inhibition assay of Cdc7/dbf4 activity was performed in 96 wells plate according to the following protocol.

To each well of the plate were added:

- 10 μl substrate (biotinylated MCM2, 6 μM final concentration)
- 10 μl enzyme (Cdc7/Dbf4, 17.9 nM final concentration)
- 10 μl test compound (12 increasing concentrations in the nM to μM range to generate a dose-response curve)

- 86 -

- 10 μ l of a mixture of cold ATP (2 μ M final concentration) and radioactive ATP (1/5000 molar ratio with cold ATP) was then used to start the reaction which was allowed to take place at 37°C.

Substrate, enzyme and ATP were diluted in 50 mM HEPES pH 7.9 containing 15 mM
5 MgCl_2 , 2 mM DTT, 3 μ M NaVO_3 , 2mM glycerophosphate and 0.2mg/ml BSA. The solvent for test compounds also contained 10% DMSO.

After incubation for 60 minutes, the reaction was stopped by adding to each well 100 μ l of PBS pH 7.4 containing 50 mM EDTA, 1 mM cold ATP, 0.1% Triton X100 and 10 mg/ml streptavidin coated SPA beads.

- 10 After 20 min incubation, 110 μ L of suspension were withdrawn and transferred into 96-well OPTIPLATES containing 100 μ l of 5M CsCl. After 4 hours, the plates were read for 2 min in a Packard TOP-Count radioactivity reader.

IC50 determination: see above.

- 87 -

The compounds of formula (I) of the present invention, suitable for administration to a mammal, e.g. to humans, can be administered by the usual routes and the dosage level depends upon the age, weight, conditions of the patient and the administration route.

For example, a suitable dosage adopted for oral administration of a compound of formula (I) may range from about 10 to about 500 mg pro dose, from 1 to 5 times daily. The compounds of the invention can be administered in a variety of dosage forms, e.g. orally, in the form of tablets, capsules, sugar or film coated tablets, liquid solutions or suspensions; rectally in the form of suppositories; parenterally, e.g. intramuscularly, or by intravenous and/or intrathecal and/or intraspinal injection or infusion.

In addition, the compounds of the invention can be administered either as single agents or, alternatively, in combination with known anticancer treatments such as radiation therapy or chemotherapy regimen in combination with cytostatic or cytotoxic agents, antibiotic-type agents, alkylating agents, antimetabolite agents, hormonal agents, immunological agents, interferon-type agents, cyclooxygenase inhibitors (e.g. COX-2 inhibitors), metalloproteinase inhibitors, telomerase inhibitors, tyrosine kinase inhibitors, anti-growth factor receptor agents, anti-HER agents, anti-EGFR agents, anti-angiogenesis agents, farnesyl transferase inhibitors, ras-raf signal transduction pathway inhibitors, cell cycle inhibitors, other cdks inhibitors, tubulin binding agents, topoisomerase I inhibitors, topoisomerase II inhibitors and the like, optionally within liposomal formulations thereof. If formulated as a fixed dose, such combination products employ the compounds of this invention within the dosage range described above and the other pharmaceutically active agent within the approved dosage range.

- 88 -

Compounds of formula (I) may be used sequentially with known anticancer agents when a combination formulation is inappropriate.

The present invention also includes pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof in association with a pharmaceutically acceptable excipient (which can be a carrier or a diluent).

The pharmaceutical compositions containing the compounds of the invention are usually prepared following conventional methods and are administered in a pharmaceutically suitable form.

For example, the solid oral forms may contain, together with the active compound, diluents, e.g. lactose, dextrose, saccharose, sucrose, cellulose, corn starch or potato starch; lubricants, e.g. silica, talc, stearic, magnesium or calcium stearate, and/or polyethylene glycols; binding agents, e.g. starches, arabic gum, gelatin, methylcellulose, carboxymethylcellulose or polyvinyl pyrrolidone; disaggregating agents, e.g. a starch, alginic, alginates or sodium starch glycolate; effervescing mixtures; dyestuffs; sweeteners; wetting agents such as lecithin, polysorbates, laurylsulfates; and, in general, non-toxic and pharmacologically inactive substances used in pharmaceutical formulations. Said pharmaceutical preparations may be manufactured in known manner, for example, by means of mixing, granulating, tableting, sugar-coating, or film-coating processes.

The liquid dispersions for oral administration may be e.g. syrups, emulsions and suspensions.

The syrups may contain as carrier, for example, saccharose or saccharose with glycerin and/or mannitol and/or sorbitol.

The suspensions and the emulsions may contain as carrier, for example, a natural gum, agar, sodium alginate, pectin,

- 89 -

methylcellulose, carboxymethylcellulose, or polyvinyl alcohol.

The suspension or solutions for intramuscular injections may contain, together with the active compound, a pharmaceutically acceptable carrier, e.g. sterile water, olive oil, ethyl oleate, glycols, e.g. propylene glycol, and, if desired, a suitable amount of lidocaine hydrochloride. The solutions for intravenous injections or infusions may contain as carrier, for example, sterile water or preferably they may be in the form of sterile, aqueous, isotonic saline solutions or they may contain as a carrier propylene glycol.

The suppositories may contain together with the active compound a pharmaceutically acceptable carrier, e.g. cocoa butter, polyethylene glycol, a polyoxyethylene sorbitan fatty ester surfactant or lecithin.

Experimental Part

General Methods

Flash chromatography was performed on silica gel (Merck grade 9385, 60Å). HPLC/MS was performed on a Waters X Terra RP 18 (4.6 x 50 mm, 3.5 µm) column using a Waters 2790 HPLC system equipped with a 996 Waters PDA detector and a Micromass mod. ZQ single quadrupole mass spectrometer, equipped with an electrospray (ESI) ion source. Mobile phase A was ammonium acetate 5 mM buffer (pH 5.5 with acetic acid / acetonitrile 95:5), and Mobile phase B was H₂O / acetonitrile (5:95). Gradient from 10 to 90% B in 8 minutes, hold 90% B 2 min. UV detection at 220 nm and 254 nm. Flow rate 1 ml/min. Injection volume 10 µl. Full scan, mass range from 100 to 800 amu. Capillary voltage was 2.5 KV; Source temp. was 120°C; Cone was 10 V. Retention Times (HPLC Rt) are given in minutes at 220 nm or 254 nm. Mass are given as m/z ratio.

- 90 -

When necessary compounds have been purified by Preparative HPLC on a Waters Symmetry C18 (19 x 50 mm, 5um) column using a Waters preparative HPLC 600 equipped with a 996 Waters PDA detector and a Micromass mod. ZMD single quadrupole mass spectrometer, electrospray ionisation, positive mode. Mobile phase A was water 0.01% TFA, and Mobile phase B was acetonitrile. Gradient from 10 to 90%B in 8 min, hold 90%B 2 min. Flow rate 20 ml/m.

¹H-NMR spectroscopy was performed on a Mercury VX 400 operating at 400.45 MHz equipped with a 5mm double resonance probe (1H {15N-31P} ID_PFG Varian).

EXAMPLES

The following examples are herewith intended to better illustrate the present invention without posing any limitation to it.

Preparation of Compounds of general formula IV

Preparation a

Cyclohexane-1,2-dione (4-nitrophenyl)hydrazone (IVa)

To a stirred solution of 4-nitroaniline (4 g, 29 mmol) in 37% aqueous HCl (9 mL), cooled between -5 and 0°C, a cooled solution of sodium nitrite (4.4 g, 63.8 mmol) in 18 mL of water was slowly dropped, maintaining the temperature between -5 and 0°C. After addition the cooled solution was stirred for 30' and slowly added to a cold (-5°C) solution of 2-hydroxymethylenecyclohexanone (4 g, 31.7 mmol) and sodium acetate (6.4 g), in a mixture of methanol (35 mL) and water (160 mL).

During addition a bright yellow precipitate formed. After stirring 30' at 0°C the precipitate was filtered and washed thoroughly with water. After drying, the desired hydrazone was obtained as a yellow solid (6.8 g, 27 mmol, 92% yield).

¹H-NMR (DMSO-d₆), diagnostic signals (ppm): 10.4 (s, 1H), 8.2 (d, 2H), 7.4 (d, 2H), 2.7 (m, 2H), 2.5 (m, 2H), 1.8 (m, 4H).

- 91 -

 $[M+H]^+ = 248$ **Preparation b****4-[2-(2-Oxocyclohexylidene)hydrazino]benzoic acid (IVb)**

The compound was prepared as described above for
5 cyclohexane-1,2-dione (4-nitrophenyl)hydrazone, by using
the appropriate aniline derivative. Yellow solid in 70%
yield.

$^1\text{H-NMR}$ (DMSO-d_6), diagnostic signals (ppm): 10.1 (s, 1H),
7.9 (d, 2H), 7.3 (d, 2H), 2.6 (m, 2H), 2.4 (m, 2H), 1.8 (m,
10 4H).

 $[M+H]^+ = 247$ **Preparation c****3-[2-(2-Oxocyclohexylidene)hydrazino]benzoic acid (IVc)**

The compound was prepared as described above for
15 cyclohexane-1,2-dione (4-nitrophenyl)hydrazone, by using
the appropriate aniline derivative. Yellow solid (88%
yield).

$^1\text{H-NMR}$ (DMSO-d_6), diagnostic signals (ppm): 10.0 (s, 1H),
7.9 (s, 1H), 7.5-7.35 (m, 3H), 2.6 (t, 2H), 2.4 (t, 2H),
20 1.8 (m, 4H).

 $[M+H]^+ = 247$ **Preparation d****4-hydroxy-3-[2-(2-oxocyclohexylidene)hydrazino]benzoic acid (IVd)**

25 A solution of diazonium salt was prepared from 1 gram
(6.5mmoles) of 3-amino-4-hydroxybenzoic acid and 0.46 grams
(6.6mmoles) of sodium nitrite in 5 mL of water. With
constant stirring at room temperature, 2.1 grams of conc.
HCl was added to the above. This diazonium salt solution
30 was added dropwise to a solution of 0.8 grams (6.6 mmoles)
of 2-hydroxymethylenecyclohexanone and 0.4 grams
(6.8mmoles) of 50% KOH aq. (KOH : H_2O = 0.4 grams : 0.4
mL) in 10 mL of EtOH stirred at 0°C.

- 92 -

Upon complete diazonium salt addition, the system was stirred an additional 30 minutes at room temperature at which time the thick, red-colored product was poured into 30 mL of water. The dark red precipitates were collected by
5 filtration, washed once with 10 mL of water and dried under vacuum. 1.53 grams of product was so isolated (89%). [M+H]⁺ = 263

Preparation e

4-toluenesulfonyloxy-3-[2-(2-oxocyclohexylidene)hydrazino]

10 benzoic acid (IVe)

0.10 grams (0.38mmoles) of [9-hydroxy-3,4,-
dihydrocarbazole-1(2H)-one-5-carboxy late] was dissolved in
2 mL of pyridine to which 1.3 equivalents, (0.09 grams,
0.49 mmoles) of p-toluenesulfonyl chloride was added. The
15 mixture was stirred at room temperature for 16 hours after
which time the solvent volume was reduced under vacuum. The
crude, red oil was re-dissolved in 10 mL of DCM and washed
twice with 10 mL of saturated brine solution. Upon
evaporation of the organic solvent, 0.11 grams (76%) of
20 red, crystalline crude product was obtained.
[M+H]⁺ = 417

Preparation f

4-fluorobenzenesulfonyloxy-3-[(2Z)-2-(2-oxocyclohexylidene) hydrazino] benzoic acid (IVf)

25 Prepared using the protocol described for 4-
toluenesulfonyloxy-3-[2-(2-
oxocyclohexylidene)hydrazino]benzoic acid. Here, 0.20 grams
(0.76 mmoles) of [9-hydroxy-3,4,-dihydrocarbazole-1(2H)-
one-5-carboxy late] and 1.3 equivalents, (0.19 grams, 1.0
30 mmoles) of 4-fluorobenzenesulfonyl chloride in 4 mL of
pyridine were used.

After extraction and solvent evaporation, 0.25 grams (74%)
of red, crystalline crude product was obtained.

- 93 -

 $[M+H]^+ = 421$ **Compounds of general formula VI****Preparation g****6-Nitro-2,3,4,9-tetrahydro-1H-carbazol-1-one (VIa)**

- 5 Cyclohexane-1,2-dione (4-nitrophenyl)hydrazone (Iva) (5 g, 20.4 mmol) was added to freshly prepared polyphosphoric acid, obtained mixing under vigorous magnetic stirring P_2O_5 (10 g) and H_3PO_4 (40 mL), and the thick mixture was stirred at 120-125°C for 45'. Heating was removed and the mixture
10 was let to cool to room temperature before pouring it into 200 mL of stirred water. After 30' stirring the brown precipitate was filtered. The filtrate was extracted (x 4) with ethyl acetate, the organic phase dried over sodium sulphate and concentrated under reduced pressure. The
15 combined raw solids (3.5 g) were purified by silica gel chromatography, eluting with dichloromethane/methanol 25:1. Obtained an orange solid (2.2 g, 9.6 mmol, 47% yield).
 ^1H -NMR ($DMSO-d_6$), diagnostic signals (ppm): 12.3 (s, m 1H), 8.7 (s, 1H), 8.1 (d, 1H), 7.5 (d, 1H), 3.0 (t, 2H), 2.6 (t, 2H), 2.15 (m, 2H).
20 $[M+H]^+ = 231$

Preparation h**1-Oxo-2,3,4,9-tetrahydro-1H-carbazole-6-carboxylic acid (VIc)**

- 25 The compound was prepared as described above for 6-nitro-2,3,4,9-tetrahydro-1H-carbazol-1-one, without need for silica gel chromatography. Obtained a brownish solid (94% yield).
 ^1H -NMR ($DMSO-d_6$), diagnostic signals (ppm): 8.35 (s, 1H),
30 7.9 (dd, 2H), 7.4 (d, 1H), 3.0 (t, 2H), 2.6 (t, 2H), 2.2 (t, 2H).
 $[M+H]^+ = 230$

Preparation i

- 94 -

1-Oxo-2,3,4,9-tetrahydro-1H-carbazole-5-carboxylic acid (VIId) + 1-oxo-2,3,4,9-tetrahydro-1H-carbazole-7-carboxylic acid (VIe)

5 The compound was prepared as described above for 6-nitro-2,3,4,9-tetrahydro-1H-carbazol-1-one, purifying the crude by silica gel chromatography, eluting with dichloromethane/methanol 15:1. Obtained a whitish solid, mixture of the two regioisomeric acids (34% yield).

¹H-NMR (DMSOd₆), diagnostic signals (ppm): 11.9 (s, 2H),
10 8.05 (s, 2H), 7.75 (d, 2H), 7.7-7.3 (m, 4H), 7.5-7.35 (m, 3H), 3.15 (m, 2H), 2.95 (t, 2H), 2.5 (m, 4H), 2.1 (m, 4H).
[M+H]⁺ = 230

Preparation j

6-Amino-2,3,4,9-tetrahydro-1H-carbazol-1-one (VIIf)

15 A suspension of 6-nitro-2,3,4,9-tetrahydro-1H-carbazol-1-one (VIa, 0.12 g, 0.5 mmol) in methanol (3 mL), water (1 mL), powdered iron (0.08 g) and ammonium chloride (0.12 g) was refluxed for 2 hrs under vigorous stirring. The reaction mixture was cooled, filtered through dicalite,
20 concentrated and dissolved in a mixture of dichloromethane/water. The organic phase was washed with water, dried over sodium sulphate and concentrated under reduced pressure to give a yellow solid (0.07 g, 0.35 mmol, 70% yield).
25 [M+H]⁺ = 201

Preparation k

N-(1-oxo-2,3,4,9-tetrahydro-1H-carbazol-6-yl)acetamide (VIg)

To a solution of 6-amino-2,3,4,9-tetrahydro-1H-carbazol-1-one (VIIf, 0.1 g, 0.5 mmol) in dry tetrahydrofuran (2 mL)
30 and DIPEA (0.2 mL) acetyl-chloride (0.07 mL, 1 mmol) was added at room temperature under stirring. After 1 hr at room temperature the mixture was concentrated and dissolved in ethyl acetate. The organic phase was washed with water,

-95-

dried over sodium sulphate and concentrated under reduced pressure to give, after precipitation in ether, a whitish solid (0.11 g, 0.45 mmol, 90% yield).

¹H-NMR (DMSO-d₆), diagnostic signals (ppm): 11.4 (s, 1H),
5 9.8 (s, 1H), 7.95 (s, 1H), 7.3 (m, 2H), 2.8 (t, 2H), 2.5
(t, 2H), 2.15 (m, 2H), 2.0 (s, 3H).
[M+H]⁺ = 243

Preparation 1

3-Methyl-N-(1-oxo-2,3,4,9-tetrahydro-1H-carbazol-6-yl)butanamide (VIh)

The compound was prepared as described for N-(1-oxo-2,3,4,9-tetrahydro-1H-carbazol-6-yl)acetamide as a brownish solid in 78% yield after precipitation from ether.

¹H-NMR (DMSO-d₆), diagnostic signals (ppm): 11.45 (s, 1H),
15 9.7 (s, 1H), 8.0 (s, 1H), 7.3 (dd, 2H), 2.9 (t, 2H), 2.55
(t, 2H), 2.2-2.0 (m, 5H), 0.9 (d, 6H).
[M+H]⁺ = 285

Preparation m

N-isobutyl-1-oxo-2,3,4,9-tetrahydro-1H-carbazole-6-carboxamide (VII)

To a solution of 1-oxo-2,3,4,9-tetrahydro-1H-carbazole-6-carboxylic acid (see example 2, 0.46 g, 2 mmol) in dry tetrahydrofuran (20 mL) and dimethylformamide (2 drops), cooled at 0°C under argon atmosphere, oxalyl chloride (1
25 mL, 11.8 mmol) was added dropwise. After addition the reaction mixture was let to warm to room temperature and stirred for 1 hr. The reaction mixture was concentrated to dryness under reduced pressure and dissolved in dichloromethane (20 mL) and DMAP (0.2 mL, 1.2 mmol). To
30 this solution at room temperature isobutylamine (0.5 mL, 5 mmol) was slowly added. The reaction mixture was stirred at room temperature for 2 hr, and then it was concentrated. The crude material was purified by flash chromatography

-96-

(eluant: CH₂Cl₂/MeOH 30:1) to give a yellow solid (0.14 g, 0.46 mmol, 23% two step yield).

¹H-NMR (DMSO-d₆), diagnostic signals (ppm): 11.8 (s, 1H), 8.35 (t, 1H), 8.24 (s, 1H), 7.8 (d, 1H), 7.4 (d, 1H), 3.1 (t, 2H), 3.0 (t, 2H), 2.6 (t, 2H), 2.15 (m, 2H), 1.85 (m, 1H), 0.9 (d, 6H).
[M+H]⁺ = 285

Preparation n

10 N-(1-oxo-2,3,4,9-tetrahydro-1H-carbazol-7-yl)thiophene-2-carboxamide (VIj)

The compound was prepared as described for N-(1-oxo-2,3,4,9-tetrahydro-1H-carbazol-6-yl)acetamide, as a brownish solid in 74% yield after precipitation from ether.

¹H-NMR (DMSO-d₆), diagnostic signals (ppm): 11.5 (s, 1H), 10.2 (s, 1H), 8.0 (m, 2H), 7.8 (d, 1H), 7.45 (dd, 1H), 7.35 (d, 1H), 7.2 (m, 1H), 2.9 (t, 2H), 2.55 (t, 2H), 2.15 (m, 2H). [M+H]⁺ = 311

Preparation o

20 6-[(4-Methylpiperazin-1-yl)carbonyl]-2,3,4,9-tetrahydro-1H-carbazol-1-one (VII)

The product was obtained as described for N-isobutyl-1-oxo-2,3,4,9-tetrahydro-1H-carbazole-6-carboxamide, after flash chromatography (eluant: CH₂Cl₂/MeOH 20:1), as a yellowish solid in 45% yield.

¹H-NMR (DMSO-d₆), diagnostic signals (ppm): 11.75 (s, 1H), 7.7 (s, 1H), 7.4 (d, 1H), 7.3 (d, 1H), 3.5 (bs, 4H), 2.95 (t, 2H), 2.55 (t, 2H), 2.3 (bs, 4H), 2.2 (s, 3H), 2.15 (m, 2H). [M+H]⁺ = 312

Preparation p

30 8-Oxo-1-(toluene-4-sulfinyloxy)-6,7,8,9-tetrahydro-5H-carbazole-4-carboxylic acid (VIIm)

4-toluenesulfonyloxy-3-[2-(2-oxocyclohexylidene)hydrazino]benzoic acid, (0.10 grams, 0.24mmoles) was mixed with 1 mL of polyphosphoric acid

- 97 -

(PPA). The mixture was heated to 80°C with stirring for 1 hour. The black colored reaction mixture was diluted with water to 2 mL and stirred at 80°C for an additional 30 minutes. The mixture was allowed to cool to room temperature and diluted again with 2 mL of water. Following extraction three times, each with 3mL of ethyl acetate, the combined organic fractions were dried over sodium sulfate and the solvent removed under vacuum. After extraction and solvent evaporation, 0.073 grams (76%) of dark brown oil was obtained.

[M+H]⁺ ≈ 400

Preparation q

8-Oxo-1-(fluorobenzene-4-sulfinyloxy)-6,7,8,9-tetrahydro-5H-carbazole-4-carboxylic acid (VIIn)

Prepared using the protocol indicated for 8-oxo-1-(toluene-4-sulfinyloxy)-6,7,8,9-tetrahydro-5H-carbazole-4-carboxylic acid.

After extraction and solvent evaporation, 0.18 grams (89%) of dark brown to black oil was obtained.

This product was purified by column chromatography over 5 grams of silica gel with hexane-ethyl acetate. A single fraction, containing predominantly desired product was isolated. Here, 0.062 grams (30%) of yellow to brown crystalline product was isolated with the correct structural identity.

[M+H]⁺ ≈ 404

Preparation r

9-(Tetrahydro-pyran-2-yl)-2,3,4,9-tetrahydro-carbazol-1-one (VIo)

To 15 ml of a solution of 2,3,4,9-tetrahydro-carbazol-1-one (1 g, 5.4 mmol) in dichloromethane 3,4-dihydro-2H-pyran (0.681 g, 8.1 mmol) was added. After the addition of 50 mg (0.25 mmol) of p-toluenesulphonic acid the solution was stirred at room temperature for six hours. After

- 98 -

evaporation of the solvent the crude was purified by silica gel chromatography eluting with hexane- ethyl acetate 8 - 2, yielding 645 mg (50% yield) of product as a colourless solid.

5 [M+H]⁺ =270

Preparation s

Methyl 1-oxo-2,3,4,9-tetrahydro-1H-carbazole-6-carboxylate (Vip)

A suspension of methyl 1-oxo-2,3,4,9-tetrahydro-1H-carbazole-6-carboxylic acid (8 g, 34.9 mmol) in methanol (800 mL) and sulfuric acid (2 ml) was refluxed for 16 hours under vigorous stirring. The reaction mixture was cooled, and a solution of NaHCO₃ 10% in water (100 ml) was added, methanol was removed under reduced pressure and the aqueous phase was extracted with ethyl acetate (3x100ml). The organic phase was dried over sodium sulphate and concentrated under reduced pressure to give a brown solid (7.7 g, 31 mmol, 90% yield).

[M+H]⁺ =244

20 ¹H-NMR (DMSO-d₆), diagnostic signals (ppm): 2.00 (s, 3H), 2.15 (m, 2H), 2.50 (t, 2H), 2.80 (t, 2H), 7.3 (m, 2H), 7.95 (s, 1H), 9.80 (s, 1H), 11.40 (s, 1H).

Preparation t

1-Oxo-1,2,3,4-tetrahydro-9H-carbazole-5-carboxylic acid (Vid)

0.060 grams (0.15 mmoles) of [8-fluorobenzenesulfonyloxy-1,2,3,4,-tetrahydro-9H-carbazole-5-carboxylic acid] were dissolved in 1 mL of degassed dimethylformamide. Under an argon atmosphere at room temperature were sequentially added Et₃N (0.075g, 0.75mmoles), formic acid (0.034g, 0.075 mmoles), 1,3-bis(diphenylphosphino)propane (DPPP) (0.18g, 0.0075mmoles) and Pd(AcO)₂ (0.0017g, 0.0075mmoles). The reaction temperature was raised to 90°C for 1 hour. After 1 hour, the reaction mixture was cooled to room temperature

- 99 -

where 5 mL of DCM was added. The system was washed two times with 10 mL of 5% aqueous hydrochloric acid followed by one wash with water. The organic layer was passed through a 2 gram silica plug and washed with an additional 5 mL portion of DCM. Elution of the desired product from the column was accomplished with 20 mL of ethyl acetate. Upon solvent removal, 0.043g of a light brown solid was isolated.

$[M+H]^+ = 230$

10 Compounds of general formula VII

Preparation u

2-[(Dimethylamino)methylene]-6-nitro-2,3,4,9-tetrahydro-1H-carbazol-1-one (VIIa)

6-Nitro-2,3,4,9-tetrahydro-1H-carbazol-1-one (VIa, 1 g, 4.34 mmol) and N,N-dimethylformamide diethylacetal (30 mL, 180 mmol) were stirred at 110-115°C, distilling off the ethanol formed. After 90' the temperature was raised to reflux for 1hr. After cooling the precipitate was filtered and washed with diethyl ether. Obtained an orange solid (0.9 g, 3.15 mmol, 72% yield).

$^1\text{H-NMR}$ (DMSO-d_6), diagnostic signals (ppm): 12.1 (s, 1H), 8.6 (s, 1H), 8.05 (d, 1H), 7.5 (d, 2H), 3.12 (s, 6H), 3.05 (t, 2H), 2.85 (t, 2H).

$[M+H]^+ = 286$

25 Preparation v

2-(Hydroxymethylene)-1-oxo-2,3,4,9-tetrahydro-1H-carbazole-6-carboxylic acid (VIIf)

To 1-oxo-2,3,4,9-tetrahydro-1H-carbazole-6-carboxylic acid (VIc, 0.23 g, 1 mmol), dissolved in anhydrous dimethylformamide (5 mL), 95% NaH (0.24 g, 10 mmol) was added and the reaction mixture stirred at room temperature for 15'. Ethyl formate (1 mL, 12.4 mmol) was added dropwise and slowly and the reaction mixture stirred at room temperature for 1 hr. The reaction mixture was poured onto

- 100 -

ice-cooled 2N hydrochloric acid (7 mL) under stirring. The dark precipitate was filtered, washed with water, dried and used in the subsequent step.

$[M+H]^+ \approx 258$

5

Preparation w

2-(Hydroxymethylene)-1-oxo-2,3,4,9-tetrahydro-1H-carbazole-5-carboxylic acid (VIIc) and

2-(hydroxymethylene)-1-oxo-2,3,4,9-tetrahydro-1H-carbazole-7-carboxylic acid (VIId).

- 10 The compounds were prepared as described above for 2-(hydroxymethylene)-1-oxo-2,3,4,9-tetrahydro-1H-carbazole-6-carboxylic acid. The precipitate was extracted (three times) with ethyl acetate, washed with water, dried over sodium sulphate and concentrated to yield a yellow solid,
- 15 mixture of the two regioisomeric acids, that was used in the subsequent step without further purification.

$[M+H]^+ \approx 258$

Preparation y

- Ethyl 2-hydroxy(1-oxo-1,3,4,9-tetrahydro-2H-carbazol-2-ylidene)ethanoate (VIIe)**
- 20

- The compound was prepared as described above for 2-(hydroxymethylene)-1-oxo-2,3,4,9-tetrahydro-1H-carbazole-6-carboxylic acid, reacting diethyloxalate in place of ethylformate with commercially available 2,3,4,9-tetrahydro-1H-carbazol-1-one. Obtained a yellow solid in
- 25 77% yield.

$^1\text{H-NMR}$ (DMSO-d_6), diagnostic signals (ppm): 7.7 (d, 1H), 7.4 (m, 2H), 7.2 (m, 1H), 4.4 (q, 2H), 3.25 (t, 2H), 3.05 (t, 2H), 1.4 (t, 3H).

- 30 $[M+H]^+ \approx 286$

Preparation x

N-{2-[(dimethylamino)methylene]-1-oxo-2,3,4,9-tetrahydro-1H-carbazol-6-yl}acetamide (VIIIf)

- 101 -

The compound was prepared as described for 2-[(dimethylamino)methylene]-6-nitro-2,3,4,9-tetrahydro-1H-carbazol-1-one, obtaining a yellow solid in 60% yield.

$[M+H]^+ = 298$

5

Preparation z

N-{2-[(Dimethylamino)methylene]-1-oxo-2,3,4,9-tetrahydro-1H-carbazol-6-yl}-3-methylbutanamide (VIIg)

The compound was prepared as described for 2-[(dimethylamino)methylene]-6-nitro-2,3,4,9-tetrahydro-1H-carbazol-1-one, obtaining a brownish solid in 60% yield.

10

$[M+H]^+ = 340$

Preparation aa

N-{2-[(dimethylamino)methylene]-1-oxo-2,3,4,9-tetrahydro-1H-carbazol-6-yl}thiophene-2-carboxamide (VIIh)

The compound was prepared as described for 2-[(dimethylamino)methylene]-6-nitro-2,3,4,9-tetrahydro-1H-carbazol-1-one, obtaining a brownish solid that was used as such in the subsequent reaction.

15

$[M+H]^+ = 366$

20

Preparation ab

2-[(dimethylamino)methylene]-N-isobutyl-1-oxo-2,3,4,9-tetrahydro-1H-carbazole-6-carboxamide (VIIi)

The compound was prepared as described for 2-[(dimethylamino)methylene]-6-nitro-2,3,4,9-tetrahydro-1H-carbazol-1-one, obtaining a brownish solid that was used as such in the subsequent reaction.

25

$[M+H]^+ = 340$

Preparation ac

2-[(Dimethylamino)methylene]-6-[(4-methylpiperazin-1-yl)carbonyl]-2,3,4,9-tetrahydro-1H-carbazol-1-one (VIIj)

30

The compound was prepared as described for 2-[(dimethylamino)methylene]-6-nitro-2,3,4,9-tetrahydro-1H-carbazol-1-one, obtaining a brownish solid that was used as such in the subsequent reaction.

- 102 -

 $[M+H]^+ = 367$ **Preparation ad****2-(Hydroxymethylene)-1-oxo-2,3,4,9-tetrahydro-1H-carbazole-6-carboxylic acid methyl ester (VIIf)**

5 To methyl 1-oxo-2,3,4,9-tetrahydro-1H-carbazole-6-carboxylate (1.345 g, 1 mmol), dissolved in anhydrous tetrahydrofuran (50 mL), 60% NaH (1.771 g, 8 mmol) was added and the reaction mixture stirred at room temperature for 15 minutes. Methyl formate (1 mL, 16.6 mmol) was slowly
10 added dropwise and the reaction mixture stirred at room temperature for 1 hr. The reaction mixture was poured onto ice-cooled 2N hydrochloric acid (50 mL) under stirring. The organic solvent was removed under reduced pressure and the dark yellow precipitate was filtered, washed with water,
15 dried and used in the subsequent step.

 $[M+H]^+ = 272$.**Preparation ae****2-(Bis-methylsulfanyl-methylene)-9-(tetrahydro-pyran-2-yl)-2,3,4,9-tetrahydro-carbazol-1-one (VIIm)**

20 A mixture of 9-(tetrahydropyran-2-yl)-2,3,4,9-tetrahydro-carbazol-1-one (554 mg, 1.86 mmol) and potassium tertbutoxide (414 mg, 3.70 mmol) was dissolved in anhydrous tetrahydrofuran (15 ml). Dimethyltrithiocarbonate (510 mg, 3.70 mmol) and methyl iodide (340 μ l, 775 mg, 5.46 mmol)
25 were then added. After stirring for one hour at room temperature, the mixture was poured into iced water (15 ml) and extracted with ethyl acetate (3 X 10 ml). The combined organic layer was dried over sodium sulphate and evaporated under vacuum. The oil material so obtained was taken up
30 with petroleum ether to yield a yellow crystalline material.

$^1\text{H-NMR}$ (DMSO-d_6), diagnostic signals (ppm): 7.80 (d, 1H), 7.65 (d, 1H), 7.32 (dd, 1H), 7.12 (dd, 1H), 6.69 (m, 1H),

- 103 -

4.10 (m, 1H), 3.62 (m, 1H), 2.90-3.40 (m, 4H), 2.39 (s, 3H), 2.37 (s, 3H), 1.49-2.25 (m, 6H)
[M+H]⁺ = 374

Compounds of general formula (I)

5

Example 1

7-Nitro-2,4,5,10-tetrahydropyrazolo[3,4-a]carbazole (Ia)

To 2-[(dimethylamino)methylene]-6-nitro-2,3,4,9-tetrahydro-1H-carbazol-1-one (0.4 g, 1.4 mmol) in dimethylformamide (2 mL) and absolute ethanol (7 mL) was added 98% hydrazine hydrate (2 mL) and the mixture was warmed to 90-95°C under stirring for 1hr. The reaction mixture was cooled, the precipitate filtered and washed with ethanol. Obtained an orange solid (0.3 g, 1.18 mmol, 84% yield).
Melting Point (M.p.): >260°C.

¹H-NMR (DMSO-d₆), diagnostic signals (ppm): 8.5 (m, 1H), 8.0 (dd, 1H), 7.6 (s, 1H), 7.45 (d, 1H), 3.0 (t, 2H), 2.9 (t, 2H). [M+H]⁺ = 255

Example 2

2,4,5,10-Tetrahydropyrazolo[3,4-a]carbazole-7-carboxylic acid (Ib)

The compound was prepared as described above for 7-nitro-2,4,5,10-tetrahydropyrazolo[3,4-a]carbazole. After flash chromatography (eluant: CH₂Cl₂/MeOH 20:1, then CH₂Cl₂/MeOH 10:1) obtained a yellow solid in 25% yield two steps. M.p.: >260°C.

¹H-NMR (DMSO-d₆), diagnostic signals (ppm): 11.7 (s, 1H), 8.1 (s, 1H), 7.65 (d, 1H), 7.55 (s, 1H), 7.36 (d, 1H), 2.9 (t, 2H), 2.6 (t, 2H).
[M+H]⁺ = 254

30

Example 3

2,4,5,10-Tetrahydropyrazolo[3,4-a]carbazole-6-carboxylic acid (Ic)

The compound was prepared as described above for 7-nitro-2,4,5,10-tetrahydropyrazolo[3,4-a]carbazole. After flash

- 104 -

chromatography (eluant: CH₂Cl₂/MeOH 10:1) obtained a yellow solid in 20% yield two steps.

M.p.: >260°C.

¹H-NMR (DMSOd₆), diagnostic signals (ppm): 11.7 (s, 1H),
5 8.1 (s, 1H), 7.65 (d, 1H), 7.55 (s, 1H), 7.36 (d, 1H),
2.9 (t, 2H), 2.6 (t, 2H).
[M+H]⁺ = 254

Example 4

2,4,5,10-Tetrahydropyrazolo[3,4-a]carbazole-8-carboxylic acid (Id)

10 The compound was prepared as described above for 2,4,5,10-Tetrahydropyrazolo[3,4-a]carbazole-6-carboxylic acid. After flash chromatography (eluant: CH₂Cl₂/MeOH 10:1) obtained a yellow solid in 35% two step yield.

15 M.p.: >260°C.

¹H-NMR (DMSOd₆), diagnostic signals (ppm): 11.75 (s, 1H),
7.5 (m, 3H), 7.05 (t, 1H), 3.15 (t, 2H), 2.75 (t, 2H).
[M+H]⁺ = 254

Example 5

20 Ethyl 2,4,5,10-tetrahydropyrazolo[3,4-a]carbazole-3-carboxylate (Ie)

The compound was prepared as described above for 7-nitro-2,4,5,10-tetrahydropyrazolo[3,4-a]carbazole. After flash chromatography (eluant: CH₂Cl₂/MeOH 30:1) obtained a
25 whitish solid in 35% yield.

M.p. 224-226°C

¹H-NMR (DMSOd₆), diagnostic signals (ppm): 13.5 (s, 1H),
11.5 (s, 1H), 7.45 (d, 1H), 7.3 (d, 1H), 7.0 (2m, 2H), 4.3 (q, 2H),
3.05 (t, 2H), 2.95 (t, 2H), 1.35 (t, 3H).
30 [M+H]⁺ = 282

Example 6

N-(1,4,5,10-tetrahydropyrazolo[3,4-a]carbazol-7-yl)acetamide (If)

- 105 -

The compound was prepared as described above for 7-nitro-2,4,5,10-tetrahydropyrazolo[3,4-a]carbazole with no need for chromatography. It was obtained as an orange solid, 25% yield, M.p. 187-193°C.

- 5 ¹H-NMR (DMSO-d₆), diagnostic signals (ppm): 12.4 (s, 1H), 11.25 (s, 1H), 9.65 (s, 1H), 7.7 (s, 1H), 7.5 (s, 1H), 7.15 (q, 2H), 2.8 (m, 4H), 2.0 (s, 3H).
[M+H]⁺ = 267

Example 7

- 10 **3-Methyl-N-(1,4,5,10-tetrahydropyrazolo[3,4-a]carbazol-7-yl)butanamide (Ig)**

The compound was prepared as described above for 7-nitro-2,4,5,10-tetrahydropyrazolo[3,4-a]carbazole. After flash chromatography (eluant: CH₂Cl₂/MeOH 15:1) obtained an orange solid in 17% yield.

M.p. 182-185°C

¹H-NMR (DMSO-d₆), diagnostic signals (ppm): 9.6 (s, 1H), 7.7 (s, 1H), 7.5 (s, 1H), 7.3-7.1 (q, 2H), 2.8 (t, 2H), 2.5 (t, 2H), 2.2-2.0 (m, 3H), 0.95 (d, 6H).

- 20 [M+H]⁺ = 309

Example 8

N-(1,4,5,10-tetrahydropyrazolo[3,4-a]carbazol-7-yl)thiophene-2-carboxamide (Ii)

The compound was prepared as described above for 7-nitro-2,4,5,10-tetrahydropyrazolo[3,4-a]carbazole. After flash chromatography (eluant: CH₂Cl₂/MeOH 20:1) obtained a yellow solid in 20% two step yield.

M.p. 176-180°C

¹H-NMR (DMSO-d₆), diagnostic signals (ppm): 12.5 (s, 1H), 11.3 (s, 1H), 10.0 (s, 1H), 8.0 (m, 1H), 7.8 (m, 2H), 7.5 (s, 1H), 7.3 (m, 2H), 7.2 (m, 1H), 2.85 (m, 4H).

- 30

- 106 -

 $[M+H]^+ = 335$ **Example 9****N-isobutyl-1,4,5,10-tetrahydropyrazolo[3,4-a]carbazole-7-carboxamide (Ij)**

5 The compound was prepared as described above for 7-nitro-2,4,5,10-tetrahydropyrazolo[3,4-a]carbazole. The crude product was precipitated in ether, and obtained as yellow solid (0.015 g, 0.05 mmol, 23% two step yield).

M.p.: 186-190°C

10 $^1\text{H-NMR}$ (DMSO-d_6), diagnostic signals (ppm): 12.5 (s, 1H), 11.6 (s, 1H), 8.25 (t, 1H), 8.05 (s, 1H), 7.6 (m, 2H), 7.3 (d, 1H), 3.1 (t, 2H), 2.9 (t, 2H), 2.85 (t, 2H), 1.85 (m, 1H), 0.9 (d, 6H).

 $[M+H]^+ = 309$

15

Example 10**7-[(4-Methylpiperazin-1-yl)carbonyl]-1,4,5,10-tetrahydropyrazolo[3,4-a]carbazole (Ik)**

The compound was prepared as described above for 7-nitro-2,4,5,10-tetrahydropyrazolo[3,4-a]carbazole. The crude
20 product was purified by flash chromatography (eluant: $\text{CH}_2\text{Cl}_2/\text{MeOH}$ 15:1). A whitish solid was obtained in 36% yield.

M.p. 198-205°C

$^1\text{H-NMR}$ (DMSO-d_6), diagnostic signals (ppm): 12.5 (s, 1H),
25 11.6 (s, 1H), 7.5 (d, 2H), 7.3 (d, 1H), 7.05 (dd, 1H), 3.5 (bs, 4H), 2.9 (m, 2H), 2.8 (m, 2H), 2.3 (bs, 4H), 2.2 (s, 3H).

 $[M+H]^+ = 336$

30

Example 11**Ethyl 1,4,5,10-tetrahydropyrazolo[3,4-a]carbazole-7-carboxylate (Il)**

A solution of 1,4,5,10-tetrahydropyrazolo[3,4-a]carbazole-7-carboxylic acid (0.28 g, 1 mmol) in absolute ethanol

- 107 -

(30mL) and two drops of sulphuric acid was refluxed for 10 hrs. After cooling the reaction mixture was cautiously poured into stirred 5% aqueous sodium hydrogencarbonate solution. The precipitate was collected by filtration, washed thoroughly with water and dried. After flash chromatography (eluant: CH₂Cl₂/MeOH 10:1), the title compound was obtained as a yellowish solid (0.23 g, 0.82 mmol, 82% yield).

M.p. 214-216°C

¹H-NMR (DMSO-d₆), diagnostic signals (ppm): 12.5 (s, 1H), 11.7 (s, 1H), 8.3 (s, 1H), 7.7-7.3 (m, 3H), 4.6 (q, 2H), 2.8 (t, 2H), 2.7 (t, 2H), 1.3 (t, 3H).
[M+H]⁺ = 282

Example 12

Methyl 1,4,5,10-tetrahydropyrazolo[3,4-a]carbazole-8-carboxylate (Im)

The product was prepared analogously to ethyl 2,4,5,10-tetrahydropyrazolo[3,4-a]carbazole-7-carboxylate. Obtained a yellowish solid in 75% yield.

M.p.: 240-243°C

¹H-NMR (DMSO-d₆), diagnostic signals (ppm): 12.65 (s, 1H), 11.85 (s, 1H), 8.0 (s, 1H), 7.7-7.5 (m, 3H), 3.8 (s, 3H), 2.9 (t, 2H), 2.8 (t, 2H).
[M+H]⁺ = 268

Example 13

1,4,5,10-Tetrahydropyrazolo[3,4-a]carbazol-7-amine hydrochloride (In)

A mixture of 7-nitro-2,4,5,10-tetrahydropyrazolo[3,4-a]carbazole (see example 1, 0.1 g, 0.39 mmol), powdered iron (0.07 g, 1.2 mmol) and ammonium chloride (0-11 g, 2 mmol) in methanol (3 mL) and water (1 mL) was refluxed under stirring. After 11 hrs the hot mixture was filtered through a pad of dicalite, the filtrate concentrated and charged on flash silica gel (eluant: CH₂Cl₂/MeOH 10:1). The

- 108 -

fractions containing the desired compound were pooled, acidified with HCl in methanol (Congo red) and precipitated in ether. Obtained a tan solid (0.06 g, 0.24 mmol, 60% yield).

5 M.p. 237-241°C

¹H-NMR (DMSO-d₆), diagnostic signals (ppm): 11.7 (s, 1H), 9.9 (s, 2H), 7.55 (s, 1H), 7.4 (d, 2H), 7.0 (d, 1H), 2.9-2.5 (2t, 4H).

[M+H]⁺ = 225

10

Example 14

1,4,5,10-Tetrahydropyrazolo[3,4-a]carbazole-3-carboxylic acid hydrochloride (Ic)

A solution of ethyl 2,4,5,10-tetrahydropyrazolo[3,4-a]carbazole-3-carboxylate (see example 5, 0.2 g, 0.71 mmol) in tetrahydrofuran (7 mL), ethanol (2 mL) and 2N NaOH (1 mL) was stirred at 75-80°C for 3 hrs. After cooling the reaction mixture was concentrated, 2N NaOH solution was added and the basic aqueous phase was extracted with dichloromethane. After cooling to 0°C it was acidified with 2N HCl and extracted with ethyl acetate. After drying over sodium sulphate and concentration under reduced pressure, a pale yellow solid was obtained (0.11 g, 0.44 mmol, 63% yield).

20 M.p. >260°C

25 ¹H-NMR (DMSO-d₆), diagnostic signals (ppm): 11.4 (s, 1H), 7.5-6.9 (m, 4H), 3.05 (m, 2H), 2.9 (m, 2H).

[M+H]⁺ = 254

Example 15

3-methylsulfonyl-1,4,5,10-Tetrahydropyrazolo[3,4-a]carbazole

30 2-(bis-methylsulfonyl-methylene)-9-(tetrahydro-pyran-2-yl)-2,3,4,9-tetrahydro-carbazol-1-one (50 mg, 0.134 mmol) was dissolved in 1,4-dioxane (1.5 mL). To this solution hydrazine hydrate (50 µL, excess) was added, and the

- 109 -

mixture was refluxed overnight. The solvent was evaporated and the crude dissolved in 2 ml dichloromethane. To this solution, trifluoroacetic acid (0.5 ml) was added, and stirring at room temperature was continued for 15 minutes.

5 The solvent was then evaporated to dryness, and the crude purified by silica gel chromatography, eluting with hexane-ethyl acetate 85-15. The solid material obtained was taken up with ethyl ether and the solution filtered off. 20 mg (58 % yield) of colorless solid was so isolated.

10 ¹H-NMR (DMSO-d₆), diagnostic signals (ppm): 2.45 (s, 3H), 2.75-3.02 (m, 4H), 6.99 (dt, 1H), 7.06 (dt, 1H), 7.34 (d, 1H), 7.46 (d, 1H), 11.36 (s, 1H), 12.58 (br. S, 1H).

[M+H]⁺ = 256

Solid phase syntheses

15 **1-resin-trityl-1,4,5,10-tetrahydropyrazolo[3,4-a]carbazole-7-carboxylate methyl ester.**

To commercially available chlorotrityl resin (1 eq., declared loading 1.35 mmol/g), a solution of methyl 2,4,5,10-tetrahydropyrazolo[3,4-a]carbazole-7-carboxylate
20 (54 mg, 1.5 eq, 0.2 mmol) and diisopropylethyl amine (0.07 ml, 3 eq, 0.41 mmol) in DCM/dimethylformamide 10:1 (3 ml) was added. The final suspension was shaken for 3 hours and then the resin was filtered, washed with N,N-dimethylformamide, dichloromethane, methanol,
25 dichloromethane (3 times) and dried under positive pressure of nitrogen. The loading was verified by micro cleavage of a resin sample.

1-resin-trityl-1,4,5,10-tetrahydropyrazolo[3,4-a]carbazole-7-carboxylic acid.
30

A solution of LiOH·H₂O (42 mg, 5 eq, 1.0 mmol) in tetrahydrofuran/MeOH/H₂O 8:1:1 (3 ml) was added to 1-resin-trityl-2,4,5,10-tetrahydropyrazolo[3,4-a]carbazole-7-

- 110 -

carboxylate methyl ester (1 eq, 0.2 mmol), and the suspension was shaken for 48 hours at 60°C. The resin was filtered, washed with N,N-dimethylformamide, dichloromethane, methanol, dichloromethane (3 times) and
5 dried under positive pressure of nitrogen. Hydrolysis was verified by means of a micro cleavage of a resin sample showing that the ester was no longer present.

1-resin-trityl-N-(furan-2-ylmethyl)-1,4,5,10-tetrahydropyrazolo[3,4-a]carbazole-7-carboxamide

A solution of PyBOP (520 mg, 5 eq, 1.0 mmol) and diisopropylethyl amine (0.171 ml, 5 eq, 1.0 mmol) in dimethylformamide (3 ml) was added to 1-resin-trityl-1,4,5,10-tetrahydropyrazolo[3,4-a]carbazole-7-carboxylic
15 acid (0.2 mmol, 1 eq), and the resulting suspension was shaken. After 30 minutes furan-2-yl-methylamine was added (5 eq, 1.0 mmol), and shaking continued for 24 hours. The resin was washed and a second cycle with the same amount of reagents was performed. The resin was filtered, washed with
20 N,N-dimethylformamide, dichloromethane, methanol, dichloromethane (three times).

Example 16

N-(furan-2-ylmethyl)-1,4,5,10-tetrahydropyrazolo[3,4-a]carbazole-7-carboxamide

1'-resin-trityl-N-(furan-2-ylmethyl)-1,4,5,10-tetrahydropyrazolo[3,4-a]carbazole-7-carboxamide was treated with a solution of TFA 5% in DCM the resulting
25 suspension was gently stirred or shaken at 22°C for 20 minutes. The solution was collected, and the resin washed with dichloromethane, methanol, dichloromethane. The collected organic solution was dried under vacuum to give a crude solid, the, as highlighted by MS-HPLC analysis

- 111 -

contained the titled compound and the corresponding dehydro-derivative N-(furan-2-ylmethyl)-1,10-dihydropyrazolo[3,4-a]carbazole-7-carboxamide, in a 1 to 1 ratio. The two were separated by preparative HPLC.

5

N-(furan-2-ylmethyl)-1,4,5,10-tetrahydropyrazolo[3,4-a]carbazole-7-carboxamide. HPLC Rt = 4.6 min; [M+H]⁺ = 333.
¹H-NMR (DMSO-d₆), diagnostic signals (ppm): 2,87 (t, 2H), 2,96 (t, 2H), 4,5 (d, 2H), 6,29 (m, 1H), 6,42 (m, 1H), 7,37 (d, 1H), 7,57 (s, 1H), 7,58 (d, 1H), 7,62 (d, 1H), 8,1 (s, 1H), 8,77 (t, 1H).

10

N-(furan-2-ylmethyl)-1,10-dihydropyrazolo[3,4-a]carbazole-7-carboxamide HPLC Rt = 4.8 min; [M+H]⁺ = 331.

15

Repeating the last two steps with the appropriate amine all the following compounds have been prepared

20

N-(3-dimethylamino)propyl-1,4,5,10-tetrahydropyrazolo[3,4-a]carbazole-7-carboxamide HPLC Rt = 2.6 min; [M+H]⁺ = 338.
N-[3-(dimethylamino)propyl]-1,10-dihydropyrazolo[3,4-a]carbazole-7-carboxamide HPLC Rt = 2.8 min; [M+H]⁺ = 336.

25

N-(5-hydroxy-1H-pyrazol-3-yl)-1,4,5,10-tetrahydropyrazolo[3,4-a]carbazole-7-carboxamide HPLC Rt = 3.4 min; [M+H]⁺ = 335.
N-(5-hydroxy-1H-pyrazol-3-yl)-1,10-dihydropyrazolo[3,4-a]carbazole-7-carboxamide HPLC Rt = 3.5 min; [M+H]⁺ = 333.

30

N-(3-morpholin-4-yl-propyl)-1,4,5,10-tetrahydropyrazolo[3,4-a]carbazole-7-carboxamide HPLC Rt = 2.9 min; [M+H]⁺ = 380.
¹H-NMR (DMSO-d₆), diagnostic signals (ppm): 1,7 (bm, 2H), 2,52 (dt, 6H), 2,85 (t, 2H), 2,95 (t, 2H), 3,62 (m, 4H),

- 112 -

7,35 (d, 1H), 7,57 (s, 1H), 7,6 (d, 1H), 8,06 (s, 1H), 8,36 (bs, 1H).

N-(3-morpholin-4-yl-propyl)-1,10-dihydropyrazolo[3,4-a]carbazole-7-carboxamide HPLC Rt = 3.1 min; [M+H]⁺ = 378.

N-(2-phenylamino-ethyl)-1,4,5,10-tetrahydropyrazolo[3,4-a]carbazole-7-carboxamide HPLC Rt = 5.2 min; [M+H]⁺ = 372.

N-(2-phenylamino-ethyl)-1,10-dihydropyrazolo[3,4-a]carbazole-7-carboxamide HPLC Rt = 5.4 min; [M+H]⁺ = 370.

N-[2-(1H-imidazol-4-yl)-ethyl]-1,4,5,10-tetrahydropyrazolo[3,4-a]carbazole-7-carboxamide
HPLC Rt = 2.8 min; [M+H]⁺ = 347.

¹H-NMR (DMSO-d₆), diagnostic signals (ppm): 2,8 (t, 2H), 2,88 (t, 2H), 2,98 (t, 2H), 3,51 (m, 2H), 6,86 (s, 1H), 7,57 (s, 1H), 7,6 (m, 2H), 8,04 (s, 1H), 8,4 (t, 1H).

N-[2-(1H-imidazol-4-yl)-ethyl]-1,10-dihydropyrazolo[3,4-a]carbazole-7-carboxamide HPLC Rt = 3. min; [M+H]⁺ = 345.

N-(4-hydroxy-butyl)-1,4,5,10-tetrahydropyrazolo[3,4-a]carbazole-7-carboxamide HPLC Rt = 3.1 min; [M+H]⁺ = 325.

¹H-NMR (DMSO-d₆), diagnostic signals (ppm): 1,37-1,7 (bm, 4H), 2,77-3 (m, 4H), 3.17-3.5 (m, 4H), 7,3 (m, 1H), 7,53 (s, 1H), 7,56 (dd, 1H), 8 (bs, 1H), 8,25 (bt, 1H).

N-(4-hydroxy-butyl)-1,10-dihydropyrazolo[3,4-a]carbazole-7-carboxamide HPLC Rt = 3.3 min; [M+H]⁺ = 323.

¹H-NMR (DMSO-d₆), diagnostic signals (ppm): 1,45-1,65 (bm, 4H), 3.23-3.51 (m, 4H), 7,3 (m, 1H), 7,66 (bs, 1H), 7,84 (m, 1H), 8.2 (bs, 1H), 8,35 (bt, 1H).

- 113 -

N-(2-hydroxymethyl-phenyl)-1,4,5,10-tetrahydropyrazolo[3,4-a]carbazole-7-carboxamide HPLC Rt = 4.0 min; [M+H]⁺ = 307.

5 N-(2-hydroxymethyl-phenyl)-1,10-dihydropyrazolo[3,4-a]carbazole-7-carboxamide HPLC Rt = 4.1 min; [M+H]⁺ = 305.

N-(pyridin-4-ylmethyl)-1,4,5,10-tetrahydropyrazolo[3,4-a]carbazole-7-carboxamide HPLC Rt = 3.6 min; [M+H]⁺ = 344.
1H-NMR (DMSO-d₆), diagnostic signals (ppm): 2,9 (m, 4H),
10 4,54 (d, 2H), 7,33 (d, 2H), 7,38 (d, 1H), 7,57 (s, 1H),
7,66 (d, 1H), 8,13 (bs, 1H), 8,50 (d, 2H), 8,95 (bt, 1H).

N-(pyridin-4-ylmethyl)-1,10-dihydropyrazolo[3,4-a]carbazole-7-carboxamide HPLC Rt = 3.8 min; [M+H]⁺ = 342.
15

N-[(methoxycarbonyl)methyl]-1,4,5,10-tetrahydropyrazolo[3,4-a]carbazole-7-carboxamide HPLC Rt =
3.6 min; [M+H]⁺ = 325.

20 N-[(methoxycarbonyl)methyl]-1,10-dihydropyrazolo[3,4-a]carbazole-7-carboxamide HPLC Rt = 3.8 min; [M+H]⁺ = 323.

[4-(2-ethoxyphenyl)piperazin-1-yl]-1,4,5,10-tetrahydropyrazolo[3,4-a]carbazole-7-carboxamide HPLC Rt =
25 5.6 min; [M+H]⁺ = 442.

1H-NMR (DMSO-d₆), diagnostic signals (ppm): 1,36 (t, 3H),
2,8 (t, 2H), 2,9 (t, 2H), 3 (m, 4H), 3,7 (m, 4H), 4,05 (m,
2H), 6,95 (m, 4H), 7,15 (d, 1H), 7,37 (d, 1H), 7,57 (m,
2H).

30 [4-(2-ethoxyphenyl)piperazin-1-yl]-1,10-dihydropyrazolo[3,4-a]carbazole-7-carboxamide HPLC Rt = 5.8
min; [M+H]⁺ = 440.

- 114 -

(4-benzylpiperazin-1-yl)-1,4,5,10-tetrahydropyrazolo[3,4-a]carbazole-7-carboxamide HPLC Rt = 4.8 min; [M+H]⁺ = 412.

¹H-NMR (DMSO-d₆), diagnostic signals (ppm): 2.4 (m, 4H), 2.8 (t, 2H), 2.9 (t, 2H), 3.7 (m, 6H), 7.09 (d, 1H), 7.35 (m, 6H), 7.57 (m, 2H).

(4-benzylpiperazin-1-yl)-1,10-dihydropyrazolo[3,4-a]carbazole-7-carboxamide HPLC Rt = 4.9 min; [M+H]⁺ = 410.

10 [4-phenyl-1-piperidin-4-yl]ethanone-1,4,5,10-tetrahydropyrazolo[3,4-a]carbazole-7-carboxamide HPLC Rt = 5.3 min; [M+H]⁺ = 439.

¹H-NMR (DMSO-d₆), diagnostic signals (ppm): 1.94 (s, 3H), 2.2 (m, 2H), 2.4 (m, 2H), 2.8 (t, 2H), 2.9 (t, 2H), 3.8 (m, 4H), 7.11 (d, 1H), 7.39 (m, 6H), 7.54 (m, 2H).

[4-phenyl-1-piperidin-4-yl]ethanone-1,10-tetrahydropyrazolo[3,4-a]carbazole-7-carboxamide HPLC Rt = 5.4 min; [M+H]⁺ = 437

20 N-methyl-N-(1-naphthylmethyl)-1,4,5,10-tetrahydropyrazolo[3,4-a]carbazole-7-carboxamide HPLC Rt = 5.9 min; [M+H]⁺ = 407

¹H-NMR (DMSO-d₆), diagnostic signals (ppm): 2.7 (m, 3H), 2.8 (t, 2H), 2.9 (t, 2H), 5.16 (s, 2H), 7.16 (d, 1H), 7.33 (d, 1H), 7.46-7.66 (m, 6H), 7.91 (m, 2H), 8 (m, 2H).

N-methyl-N-(1-naphthylmethyl)-1,10-tetrahydropyrazolo[3,4-a]carbazole-7-carboxamide HPLC Rt = 6.0 min; [M+H]⁺ = 405

30 N-ethyl-1,4,5,10-tetrahydropyrazolo[3,4-a]carbazole-7-carboxamide HPLC Rt = 4.2 min; [M+H]⁺ = 281

- 115 -

¹H-NMR (DMSO-d₆), diagnostic signals (ppm): 1,16 (t, 3H), 2,87 (t, 2H), 2,97 (t, 2H), 3,3 (m, 2H), 7,35 (d, 1H), 7,57 (s, 1H), 7,58 (d, 2H), 8,04 (s, 1H), 8,28 (t, 1H).

N-ethyl-1,4,5,10-tetrahydropyrazolo[3,4-a]carbazole-7-carboxamide HPLC Rt = 4.4 min; [M+H]⁺ = 479

N-(1-ethylpiperidin-3-yl)-1,4,5,10-tetrahydropyrazolo[3,4-a]carbazole-7-carboxamide HPLC Rt = 5.5 min; [M+H]⁺ = 364

¹H-NMR (DMSO-d₆), diagnostic signals (ppm): 1,26 (t, 3H), 2 (m, 4H), 2,7-3,7 (m, 10H), 7,39 (d, 1H), 7,58 (s, 1H), 7,60 (d, 1H), 8,06 (s, 1H), 8,39 (d, 1H).

N-(1-ethylpiperidin-3-yl)-1,4,5,10-tetrahydropyrazolo[3,4-a]carbazole-7-carboxamide HPLC Rt = 5.7 min; [M+H]⁺ = 362

N-neopentyl-1,4,5,10-tetrahydropyrazolo[3,4-a]carbazole-7-carboxamide HPLC Rt = 5.0 min; [M+H]⁺ = 323

¹H-NMR (DMSO-d₆), diagnostic signals (ppm): 0,93 (s, 9H), 2,87 (m, 2H), 2,98 (m, 2H), 3,15 (d, 2H), 7,36 (d, 1H), 7,57 (s, 1H), 7,60 (d, 1H), 8,06 (s, 1H), 8,15 (t, 1H).

N-neopentyl-1,10-dihydropyrazolo[3,4-a]carbazole-7-carboxamide HPLC Rt = 5.2 min; [M+H]⁺ = 321

N-(4-methoxy-2-methylphenyl)-1,4,5,10-tetrahydropyrazolo[3,4-a]carbazole-7-carboxamide HPLC Rt = 5.0 min; [M+H]⁺ = 373

¹H-NMR (DMSO-d₆), diagnostic signals (ppm): 2,23 (s, 3H), 2,88 (m, 2H), 2,9 (m, 2H), 3,77 (s, 3H), 6,81 (m, 1H), 6,86 (d, 1H), 7,25 (d, 1H), 7,42 (d, 1H), 7,58 (s, 1H), 7,70 (d, 1H), 8,20 (s, 1H), 9,61 (s, 1H).

N-(4-methoxy-2-methylphenyl)-1,10-dihydropyrazolo[3,4-a]carbazole-7-carboxamide HPLC Rt = 5.2 min; [M+H]⁺ = 371

- 116 -

N-[3-(dimethylamino)propyl]-1,4,5,10-tetrahydropyrazolo[3,4-a]carbazole-7-carboxamide HPLC Rt = 2.2 min; [M+H]⁺ = 338

5 ¹H-NMR (DMSO-d₆), diagnostic signals (ppm): 1,91 (m, 2H), 2,8-3,5 (m, 14H), 7,38 (d, 1H), 7,58 (s, 1H), 7,59 (d, 1H), 8,05 (s, 1H), 8,48 (t, 1H).

N-[3-(dimethylamino)propyl]-1,10-dihydropyrazolo[3,4-a]carbazole-7-carboxamide HPLC Rt = 2.3 min; [M+H]⁺ = 336

10

N-(2,5-difluorobenzyl)-1,4,5,10-tetrahydropyrazolo[3,4-a]carbazole-7-carboxamide HPLC Rt = 5.3 min; [M+H]⁺ = 379

¹H-NMR (DMSO-d₆), diagnostic signals (ppm): 2,23 (s, 3H), 2,88 (m, 2H), 2,9 (m, 2H), 3,77 (s, 3H), 6,81 (m, 1H), 6,86
15 (d, 1H), 7,25 (d, 1H), 7,42 (d, 1H), 7,58 (s, 1H), 7,70 (d, 1H), 8,20 (s, 1H), 9,61 (s, 1H).

N-(2,5-difluorobenzyl)-1,10-dihydropyrazolo[3,4-a]carbazole-7-carboxamide HPLC Rt = 5.4 min; [M+H]⁺ = 377

20

N-(2-fluorobenzyl)-1,4,5,10-tetrahydropyrazolo[3,4-a]carbazole-7-carboxamide HPLC Rt = 5.0 min; [M+H]⁺ = 361

¹H-NMR (DMSO-d₆), diagnostic signals (ppm): 2,88 (m, 2H), 2,9 (m, 2H), 4,55 (m, 2H), 7,15-7,35 (m, 5H), 7,58 (s, 1H),
25 7,64 (d, 1H), 8,5 (t, 1H).

N-(2-fluorobenzyl)-1,10-dihydropyrazolo[3,4-a]carbazole-7-carboxamide HPLC Rt = 5.2 min; [M+H]⁺ = 359

30

N-cyclopentyl-1,4,5,10-tetrahydropyrazolo[3,4-a]carbazole-7-carboxamide HPLC Rt = 4.75 min; [M+H]⁺ = 321

- 117 -

¹H-NMR (DMSO-d₆), diagnostic signals (ppm): 1,5-2,0 (m, 8H), 2,87 (m, 2H), 2,98 (m, 2H), 4,26 (m, 1H), 7,35 (d, 1H), 7,57 (s, 1H), 7,58 (d, 1H), 8,04 (s, 1H), 8,08 (d, 1H).

5

N-cyclopentyl-1,10-dihydropyrazolo[3,4-a]carbazole-7-carboxamide HPLC Rt = 4.96 min; [M+H]⁺ = 319

10 **N-(2-methoxyethyl)-1,4,5,10-tetrahydropyrazolo[3,4-a]carbazole-7-carboxamide** HPLC Rt = 4.5 min; [M+H]⁺ = 311

¹H-NMR (DMSO-d₆), diagnostic signals (ppm): 2,87 (m, 2H), 2,98 (m, 2H), 3,30 (s, 3H), 3.4-3.5 (m, 4H), 7,35 (d, 1H), 7,57 (s, 1H), 7,58 (d, 1H), 8,04 (s, 1H), 8,32 (t, 1H).

15

N-(2-methoxyethyl)-1,10-dihydropyrazolo[3,4-a]carbazole-7-carboxamide HPLC Rt = 4.7 min; [M+H]⁺ = 309

20 **N-(4-fluorobenzyl)-1,4,5,10-tetrahydropyrazolo[3,4-a]carbazole-7-carboxamide** HPLC Rt = 5.1 min; [M+H]⁺ = 361

¹H-NMR (DMSO-d₆), diagnostic signals (ppm): 2,87 (m, 2H), 2,98 (m, 2H), 4,48 (d, 2H), 7,16 (t, 2H), 7,38 (m, 3H), 7,57 (s, 1H), 7,63 (d, 1H), 8,11 (s, 1H), 8,88 (t, 1H).

25 **N-(4-fluorobenzyl)-1,10-dihydropyrazolo[3,4-a]carbazole-7-carboxamide** HPLC Rt = 5.2 min; [M+H]⁺ = 360

30 **N-benzyl-1,4,5,10-tetrahydropyrazolo[3,4-a]carbazole-7-carboxamide** HPLC Rt = 5.0 min; [M+H]⁺ = 343

¹H-NMR (DMSO-d₆), diagnostic signals (ppm): 2,87 (m, 2H), 2,98 (m, 2H), 4,52 (d, 2H), 7,20-7,40 (m, 6H), 7,57 (s, 1H), 7,67 (d, 1H), 8,12 (s, 1H), 8,87 (t, 1H).

- 118 -

N-benzyl-1, 10-dihydropyrazolo[3,4-a]carbazole-7-carboxamide HPLC Rt = 5.2 min; [M+H]⁺ = 341

5

N-(1,2,3,4-tetrahydronaphthalen-1-yl)-1,4,5,10-tetrahydropyrazolo[3,4-a]carbazole-7-carboxamide HPLC Rt = 5.8 min; [M+H]⁺ = 383

¹H-NMR (DMSO-d₆), diagnostic signals (ppm): 1,6-2,15 (m, 4H), 2,87 (m, 2H), 2,98 (m, 2H), 5,30 (m, 1H), 7,1-7,27 (m, 4H), 7,37 (d, 1H), 7,57 (s, 1H), 7,68 (d, 1H), 8,16 (s, 1H), 8,56 (m, 1H).

N-(1,2,3,4-tetrahydronaphthalen-1-yl)-1,10-dihydropyrazolo[3,4-a]carbazole-7-carboxamide HPLC Rt = 5.9 min; [M+H]⁺ = 381

N-(3-methoxypropyl)-1,4,5,10-tetrahydropyrazolo[3,4-a]carbazole-7-carboxamide HPLC Rt = 3.57 min; [M+H]⁺ = 325

¹H-NMR (DMSO-d₆), diagnostic signals (ppm): 1,79 (m, 2H), 2,87 (m, 2H), 2,98 (m, 2H), 3,28 (s, 3H); 3,3-3,5 (m, 4H), 7,36 (d, 1H), 7,57 (s, 1H), 7,60 (d, 1H), 8,04 (s, 1H), 8,28 (t, 1H).

N-(3-methoxypropyl)-1,10-dihydropyrazolo[3,4-a]carbazole-7-carboxamide HPLC Rt = 3.7 min; [M+H]⁺ = 323

N-[3-(benzyloxy)phenyl]-1,4,5,10-tetrahydropyrazolo[3,4-a]carbazole-7-carboxamide HPLC Rt = 6.6 min; [M+H]⁺ = 435

¹H-NMR (DMSO-d₆), diagnostic signals (ppm): 2,98 (m, 2H), 3,01 (m, 2H), 5,12 (s, 2H); 6,77 (m, 1H), 7,24 (t, 1H); 7,37 (m, 1H), 7,40-7,52 (m, 6H), 7,58 (d, 1H), 7,63 (m, 1H); 7,71 (d, 1H); 8,18 (s, 1H), 10,08 (s, 1H).

- 119 -

N-[3-(benzyloxy)phenyl]-1,4,5,10-tetrahydropyrazolo[3,4-a]carbazole-7-carboxamide HPLC Rt = 6.8 min; [M+H]⁺ = 433

5 **N-cycloheptyl-1,4,5,10-tetrahydropyrazolo[3,4-a]carbazole-7-carboxamide** HPLC Rt = 5.49 min; [M+H]⁺ = 349
¹H-NMR (DMSO-d₆), diagnostic signals (ppm): 1,3-2,0 (m, 12H); 2,85 (m, 2H), 3,0 (m, 2H), 4,0 (m, 1H); 7,37 (m, 1H), 7,58 (d, 1H), 7,63 (m, 1H); 8,05 (m, 2H).

10 **N-cycloheptyl-1,10-dihydropyrazolo[3,4-a]carbazole-7-carboxamide** HPLC Rt = 5.75 min; [M+H]⁺ = 347

N-prop-2-ynyl-1,4,5,10-tetrahydropyrazolo[3,4-a]carbazole-7-carboxamide HPLC Rt = 3.77 min; [M+H]⁺ = 291
15 ¹H-NMR (DMSO-d₆), diagnostic signals (ppm): 2,85 (m, 2H), 2,95 (m, 2H), 3,09 (m, 1H); 4,08 (m, 2H); 7,37 (m, 1H), 7,58 (d, 1H), 7,62 (m, 1H); 8,08 (s, 1H).

N-prop-2-ynyl-1,10-dihydropyrazolo[3,4-a]carbazole-7-carboxamide HPLC Rt = 3.95 min; [M+H]⁺ = 289
20

Solid phase syntheses

1-resin-trityl-7-nitro-1,4,5,10-tetrahydropyrazolo[3,4-a]carbazole.

25 To commercially available chlorotriptyl resin (1 eq, declared loading 1.35 mmol/g), a solution of 7-nitro-2,4,5,10-tetrahydropyrazolo[3,4-a]carbazole (54 mg, 1.5 eq, 0.2 mmol) and diisopropylethyl amine (0.07 ml, 3 eq, 0.41 mmol) in dimethylformamide (3 ml) was added. The final
30 suspension was shaken for 3 hours and then the resin was filtered, washed with N,N-dimethylformamide, dichloromethane, methanol, dichloromethane (3 times) and dried under positive pressure of nitrogen. The loading was verified by micro cleavage of a resin sample.

- 120 -

1-resin-trityl-7-nitro-1,4,5,10-tetrahydropyrazolo[3,4-a]carbazole.

5 A solution of $\text{SnCl}_2 \cdot 2\text{H}_2\text{O}$ 3 ml 2M in dimethylformamide was added to 1-resin-trityl-7-nitro-2,4,5,10-tetrahydropyrazolo[3,4-a]carbazole (1 eq, 0.2 mmol), and the suspension was shaken for 48 hours at room temperature. The resin was filtered, washed with N,N-dimethylformamide,
10 dichloromethane, methanol, dichloromethane (3 times) and dried under positive pressure of nitrogen. Hydrolysis was verified by means of a micro cleavage of a resin sample showing that the nitro group was no longer present.

15 **1-resin-trityl-3,4-dimethoxy-N-(1,4,5,10-tetrahydropyrazolo[3,4-a]carbazol-7-yl)benzamide**

A solution of PyBOP (223 mg, 3 eq, 0.43 mmol) and diisopropylethyl amine (0.074 ml, 3 eq, 0.43 mmol) in
20 dimethylformamide (3 ml) was added to 3,4-dimethoxybenzoic acid (78 mg, 0.43 mmol, 3 eq), and the resulting suspension was shaken. After 30 minutes 1-resin-trityl-2,4,5,10-tetrahydropyrazolo[3,4-a]carbazol-7-amine was added (1 eq, 0.15 mmol), and shaking continued for 24 hours. The resin
25 was filtered, washed with N,N-dimethylformamide, dichloromethane, methanol, dichloromethane (three times).

Example 17

30 3,4-dimethoxy-N-(1,4,5,10-tetrahydropyrazolo[3,4-a]carbazol-7-yl)benzamide was treated with a solution of TFA 5% in DCM the resulting suspension was gently stirred or shaken at 22°C for 20 minutes. The solution was collected, and the resin washed with dichloromethane,

- 121 -

methanol, dichloromethane. The collected organic solution was dried under vacuum to give a crude solid, the, as highlighted by MS-HPLC analysis contained the titled compound and the corresponding dehydro-derivative 3,4-dimethoxy-N-(1,10-dihydropyrazolo[3,4-a]carbazol-7-yl)benzamide, in a 2 to 1 ratio. The two were separated by preparative HPLC.

3,4-dimethoxy-N-(1,4,5,10-tetrahydropyrazolo[3,4-a]carbazol-7-yl)benzamide Rt = 4.63 min; [M+H]⁺ = 389

¹H-NMR (DMSO-d₆), diagnostic signals (ppm): 2,89 (m, 4H); 3,87 (s, 6H); 7,10 (d, 1H); 7,31 (m, 1H); 7,34 (m, 1H), 7,55 (bs, 1H); 7,60 (s, 1H); 7,65 (m, 1H); 7,86 (bs, 1H); 9.91 (s, 1H); 11,35 (s, 1H); 12,50 (s, 1H).

3,4-dimethoxy-N-(1,10-dihydropyrazolo[3,4-a]carbazol-7-yl)benzamide Rt = 4.74 min; [M+H]⁺ = 387

Repeating the last two steps with the appropriate amine all the following compounds have been prepared

3-(2-methoxyphenyl)-N-(1,4,5,10-tetrahydropyrazolo[3,4-a]carbazol-7-yl)propanamide Rt = 5.3 min; [M+H]⁺ = 387

¹H-NMR (DMSO-d₆), diagnostic signals (ppm): 2,55 (m, 2H); 2,8-3,0 (m, 6H); 3,82 (s, 3H); 7,10-7,28 (m, 5H); 7,55 (bs, 1H); 7,60 (s, 1H); 7,77 (m, 1H); 9.95 (s, 1H); 11,28 (s, 1H); 12,50 (s, 1H).

3-(2-methoxyphenyl)-N-(1,10-dihydropyrazolo[3,4-a]carbazol-7-yl)propanamide Rt = 5.5 min; [M+H]⁺ = 385

- 122 -

4-(4-methylphenyl)-4-oxo-N-(1,4,5,10-tetrahydropyrazolo[3,4-a]carbazol-7-yl)butanamide Rt = 5.31 min; [M+H]⁺ = 399
¹H-NMR (DMSO-d₆), diagnostic signals (ppm): 2,40 (s, 3H);
5 2,71 (t, 2H); 2,84 (m, 4H); 3,33 (m, 2H); 7,17 (d, 1H);
7,23 (m, 1H); 7,37 (d, 2H); 7,53 (bs, 1H); 7,78 (m, 1H);
7,91 (d, 2H); 9,79 (s, 1H); 11,26 (s, 1H); 12,48 (s, 1H).

4-(4-methylphenyl)-4-oxo-N-(1,10-dihydropyrazolo[3,4-a]carbazol-7-yl)butanamide Rt = 5.45 min; [M+H]⁺ = 397

N-2-[(benzylamino)carbonyl]-N~1~-(1,4,5,10-tetrahydropyrazolo[3,4-a]carbazol-7-yl)glycinamide Rt = 5.6 min; [M+H]⁺ = 415
15 ¹H-NMR (DMSO-d₆), diagnostic signals (ppm): 2,86 (m, 4H);
3,88 (d, 2H); 3,88 (d, 2H); 4,25 (d, 1H); 6,72 (bt, 2H);
7,17 (m, 1H); 7,2-7,37 (m, 6H); 7,54 (bs, 1H); 7,75 (s, 1H);
9,71 (s, 1H); 11,32 (s, 1H); 12,48 (s, 1H).

N-2-[(benzylamino)carbonyl]-N~1~-(1,10-dihydropyrazolo[3,4-a]carbazol-7-yl)glycinamide Rt = 5.8 min; [M+H]⁺ = 413

(2E)-3-(1H-imidazol-4-yl)-N-(1,4,5,10-tetrahydropyrazolo[3,4-a]carbazol-7-yl)prop-2-enamide Rt =
25 3.14 min; [M+H]⁺ = 345
¹H-NMR (DMSO-d₆), diagnostic signals (ppm): 2,88 (m, 4H);
6,6 (m, 1H); 6,9 (s, 1H); 7,10 (s, 1H); 7,25 (s, 1H); 7,55
(bs, 1H); 7,60 (s, 1H); 7,77 (m, 1H); 9,95 (s, 1H); 11,28
(s, 1H); 12,50 (s, 1H).

30

(2E)-3-(1H-imidazol-4-yl)-N-(1,10-dihydropyrazolo[3,4-a]carbazol-7-yl)prop-2-enamide Rt = 3.4 min; [M+H]⁺ = 343

- 123 -

2-methyl-N-(1,4,5,10-tetrahydropyrazolo[3,4-a]carbazol-7-yl)nicotinamide Rt = 3.5 min; [M+H]⁺ = 344

¹H-NMR (DMSO-d₆), diagnostic signals (ppm): 2,60 (s, 3H);
2,86 (m, 4H); 7,30 (s, 2H); 7,35 (m, 1H); 7,55 (s, 1H);
5 7,86 (d, 1H); 7,93 (s, 1H); 8,85 (m, 1H); 10,22 (s, 1H);
11,38 (s, 1H); 12,50 (s, 1H).

2-methyl-N-(1,10-dihydropyrazolo[3,4-a]carbazol-7-yl)nicotinamide Rt = 3.81 min; [M+H]⁺ = 342

10

N-(1,4,5,10-tetrahydropyrazolo[3,4-a]carbazol-7-yl)-2-thien-3-ylacetamide Rt = 4.79 min; [M+H]⁺ = 349

¹H-NMR (DMSO-d₆), diagnostic signals (ppm): 2,86 (m, 4H);
3,65 (s, 2H); 7,14 (m, 1H); 7,18 (m, 1H); 7,34 (m, 1H);
15 7,51 (m, 1H); 7,54 (s, 1H); 7,78 (s, 1H); 9,90 (s, 1H);
11,31 (s, 1H); 12,50 (s, 1H).

N-(1,10-dihydropyrazolo[3,4-a]carbazol-7-yl)-2-thien-3-ylacetamide Rt = 5.0 min; [M+H]⁺ = 347

20

3-methyl-N-(1,4,5,10-tetrahydropyrazolo[3,4-a]carbazol-7-yl)but-2-enamide Rt = 4.7 min; [M+H]⁺ = 307

¹H-NMR (DMSO-d₆), diagnostic signals (ppm): 2,18 (s, 6H);
2,84 (m, 4H); 5,89 (s, 1H); 7,18 (d, 1H); 7,22 (m, 1H);
25 7,54 (s, 1H); 7,85 (s, 1H); 9,60 (s, 1H); 11,28 (s, 1H);
12,48 (s, 1H).

3-methyl-N-(1,10-dihydropyrazolo[3,4-a]carbazol-7-yl)but-2-enamide Rt = 4.9 min; [M+H]⁺ = 305

30

5-oxo-N-(1,4,5,10-tetrahydropyrazolo[3,4-a]carbazol-7-yl)hexanamide Rt = 3.5 min; [M+H]⁺ = 337

- 124 -

¹H-NMR (DMSO-d₆), diagnostic signals (ppm): 1,80 (m, 2H); 2,29 (m, 4H); 2,84 (m, 4H); 7,16 (d, 1H); 7,22 (m, 1H); 7,54 (s, 1H); 7,77 (s, 1H); 9,65 (s, 1H); 11,28 (s, 1H); 12,48 (s, 1H).

5

5-oxo-N-(1,10-dihydropyrazolo[3,4-a]carbazol-7-yl)hexanamide Rt = 3.7 min; [M+H]⁺ = 335

2,5-dimethyl-N-(1,4,5,10-tetrahydropyrazolo[3,4-a]carbazol-7-yl)-3-furamide Rt = 5.2 min; [M+H]⁺ = 347


¹H-NMR (DMSO-d₆), diagnostic signals (ppm): 2,55 (s, 6H); 2,88 (m, 4H); 6,69 (s, 1H); 7,28 (m, 2H); 7,54 (s, 1H); 7,82 (s, 1H); 9,42 (s, 1H); 11,33 (s, 1H); 12,49 (s, 1H).

2,5-dimethyl-N-(1,10-dihydropyrazolo[3,4-a]carbazol-7-yl)-3-furamide Rt = 5.5 min; [M+H]⁺ = 345

- 125 -

CLAIMS

1. A method for treating a disease caused by and/or associated with an altered protein kinase activity which comprises administering to a mammal in need thereof an effective amount of a tetracyclic pyrazole derivative represented by formula (I):



(I)

wherein

- R1 and R2, being the same or different, are independently hydrogen or halogen atom, nitro, cyano, hydroxy, carboxy, hydroxyaminocarbonyl group, or an optionally substituted group selected from aminocarbonyl, amino or sulfonamido group, a straight or branched C₁-C₈ alkyl group, a perfluorinated C₁-C₈ alkyl, a straight or branched C₁-C₈ alkoxy C₁-C₆ alkyl group, a saturated or unsaturated C₃-C₇ cycloalkyl, a saturated or unsaturated C₃-C₇ cycloalkyl C₁-C₆ alkyl, a straight or branched C₂-C₈ alkenyl group, a straight or branched C₁-C₈ alkyloxy group, a saturated or unsaturated C₃-C₆ cycloalkyloxy, a straight or branched C₁-C₈ alkyloxy C₁-C₆ alkyloxy group, C₁-C₆ alkyloxycarbonyl, aryloxycarbonyl, aryl C₁-C₆ alkyloxycarbonyl, heteroaryloxycarbonyl, heteroaryl C₁-C₆ alkyloxycarbonyl, C₁-C₆ alkylaminocarbonyl, C₁-C₆ dialkylaminocarbonyl, arylaminocarbonyl, heteroarylaminocarbonyl, C₁-C₆ alkyloxyaminocarbonyl, aryloxyaminocarbonyl, C₁-C₆ alkylcarbonyloxy, arylcarbonyloxy, C₁-C₆ alkylcarbonyl, arylcarbonyl, heterocyclylcarbonyl, aryl, aryl C₁-C₆ alkyl group, aryl C₁-C₆ alkyloxy group, aryloxy, heteroaryl, heteroaryl C₁-C₆ alkyl group, a straight or branched C₁-C₆ alkylthio, C₁-C₆ alkylsulphinyl, C₁-C₆ alkylsulphonyl,

- 126 -

arylthio, arylsulphiny, arylsulphonyl, C₁-C₆ alkylamino, di
 C₁-C₆ alkylamino, arylamino, aryl C₁-C₆ alkylamino,
 heteroaryl amino, heteroaryl C₁-C₆ alkylamino, C₁-C₆
 alkylcarbonylamino, arylcarbonylamino, C₁-C₆
 5 alkyloxy carbonylamino, aryl C₁-C₆ alkyloxy carbonylamino,
 aryloxy carbonylamino, ureido, thioureido group, C₁-C₆
 alkylaminocarbonylamino, C₁-C₆ dialkylaminocarbonylamino,
 arylaminocarbonylamino, C₁-C₆ alkylaminothiocabonylamino,
 C₁-C₆ dialkylaminothiocabonylamino, arylaminothiocabonyl-
 10 amino, C₁-C₆ alkylsulfonylamino, arylsulfonylamino, C₁-C₆
 alkylaminosulfonyl and arylaminosulfonyl group;
 Y is a -(CH₂)_n- group wherein n is 1, 2 or 3, or a
 carbon-carbon double bond (-CH₂=CH₂-);
 R₃ is hydrogen atom, cyano, carboxy, hydroxyaminocarbonyl
 15 group, or an optionally substituted group selected from
 aminocarbonyl, amino or sulfonamido group, a straight or
 branched C₁-C₈ alkyl group, a perfluorinated C₁-C₈ alkyl, a
 straight or branched C₁-C₈ alkoxy C₁-C₆ alkyl group, a
 saturated or unsaturated C₃-C₇ cycloalkyl, a saturated or
 20 unsaturated C₃-C₇ cycloalkyl C₁-C₆ alkyl, a straight or
 branched C₂-C₈ alkenyl group, an aryl, an aryl C₁-C₆ alkyl
 group, a straight or branched C₁-C₈ alkyloxy group, a
 saturated or unsaturated C₃-C₆ cycloalkyloxy, a straight or
 branched C₁-C₈ alkyloxy C₁-C₆ alkyloxy group, C₁-C₆
 25 alkyloxy carbonyl, aryloxy carbonyl, aryl C₁-C₆
 alkyloxy carbonyl, heteroaryloxy carbonyl, heteroaryl C₁-C₆
 alkyloxy carbonyl, C₁-C₆ alkylaminocarbonyl, C₁-C₆
 dialkylaminocarbonyl, arylaminocarbonyl, C₁-C₆
 alkyloxyaminocarbonyl, aryloxyaminocarbonyl, C₁-C₆
 30 alkylcarbonyloxy, arylcarbonyloxy, C₁-C₆ alkylcarbonyl,
 arylcarbonyl, heterocyclylcarbonyl, aryl C₁-C₆ alkyloxy
 group, aryloxy, a straight or branched C₁-C₆ alkylthio,
 aryl C₁-C₆ alkylthio, C₁-C₆ alkylsulphiny group, C₁-C₆
 alkylsulphonyl, arylthio, arylsulphiny, arylsulphonyl, C₁-
 35 C₆ alkylamino, di C₁-C₆ alkylamino, arylamino, aryl C₁-C₆

- 127 -

alkylamino, heteroarylamino, heteroaryl C₁-C₆ alkylamino, C₁-C₆ alkylcarbonylamino, arylcarbonylamino, C₁-C₆ alkyloxycarbonylamino, aryl C₁-C₆ alkyloxycarbonylamino, aryloxycarbonylamino, an ureido, thioureido group, C₁-C₆ alkylaminocarbonylamino, C₁-C₆ dialkylaminocarbonylamino, arylaminocarbonylamino, C₁-C₆ alkylaminothiocarbonylamino, C₁-C₆ dialkylaminothiocarbonylamino, arylaminothiocarbonylamino, C₁-C₆ alkylsulfonylamino, arylsulfonylamino, C₁-C₆ alkylaminosulfonyl, and arylaminosulfonyl group, or a pharmaceutically acceptable salt thereof.

2. The method of claim 1 wherein the disease caused by and/or associated with an altered protein kinase activity is selected from the group consisting of cancer, cell proliferative disorders, Alzheimer's disease, viral infections, auto-immune diseases and neurodegenerative disorders.

3. The method of claim 2 wherein the cancer is selected from carcinoma, squamous cell carcinoma, hematopoietic tumors of myeloid or lymphoid lineage, tumors of mesenchymal origin, tumors of the central and peripheral nervous system, melanoma, seminoma, teratocarcinoma, osteosarcoma, xeroderma pigmentosum, keratoxanthoma, thyroid follicular cancer and Kaposi's sarcoma.

4. The method of claim 2 wherein the cell proliferative disorder is selected from the group consisting of benign prostate hyperplasia, familial adenomatosis polyposis, neuro-fibromatosis, psoriasis, vascular smooth cell proliferation associated with atherosclerosis, pulmonary fibrosis, arthritis glomerulonephritis and post-surgical stenosis and restenosis.

5. The method of claim 1 which provides tumor angiogenesis and metastasis inhibition.

6. The method of claim 1 further comprising subjecting the mammal in need thereof to a radiation therapy or


- 128 -

chemotherapy regimen in combination with at least one cytostatic or cytotoxic agent.

7. The method of claim 1 wherein the mammal in need thereof is a human.

8. A method for inhibiting protein kinase activity which comprises contacting the said kinase with an effective amount of a compound of formula (I) of claim 1.

9. A tetracyclic pyrazole derivative represented by formula (I):



(I)

wherein

R1 and R2, being the same or different, are independently hydrogen or halogen atom, nitro, cyano, hydroxy, carboxy, hydroxyaminocarbonyl group, or an optionally substituted group selected from aminocarbonyl, amino or sulfonamido group, a straight or branched C₁-C₈ alkyl group, a perfluorinated C₁-C₈ alkyl, a straight or branched C₁-C₈ alkoxy C₁-C₆ alkyl group, a saturated or unsaturated C₃-C₇ cycloalkyl, a saturated or unsaturated C₃-C₇ cycloalkyl C₁-C₆ alkyl, a straight or branched C₂-C₈ alkenyl group, a straight or branched C₁-C₈ alkyloxy group, a saturated or unsaturated C₃-C₆ cycloalkyloxy, a straight or branched C₁-C₈ alkyloxy C₁-C₆ alkyloxy group, C₁-C₆ alkyloxycarbonyl, aryloxycarbonyl, aryl C₁-C₆ alkyloxycarbonyl, heteroaryloxycarbonyl, heteroaryl C₁-C₆ alkyloxycarbonyl, C₁-C₆ alkylaminocarbonyl, C₁-C₆ dialkylaminocarbonyl, arylaminocarbonyl, heteroarylaminocarbonyl, C₁-C₆ alkyloxyaminocarbonyl, aryloxyaminocarbonyl, C₁-C₆ alkylcarbonyloxy, arylcarbonyloxy, C₁-C₆ alkylcarbonyl,


- 129 -

arylcarbonyl, heterocyclylcarbonyl, aryl, aryl C₁-C₆ alkyl
 group, aryl C₁-C₆ alkyloxy group, aryloxy, heteroaryl,
 heteroaryl C₁-C₆ alkyl group, a straight or branched C₁-C₆
 alkylthio, C₁-C₆ alkylsulphanyl, C₁-C₆ alkylsulphonyl,
 5 arylthio, arylsulphanyl, arylsulphonyl, C₁-C₆ alkylamino, di
 C₁-C₆ alkylamino, arylamino, aryl C₁-C₆ alkylamino,
 heteroarylamino, heteroaryl C₁-C₆ alkylamino, C₁-C₆
 alkylcarbonylamino, arylcarbonylamino, C₁-C₆
 alkyloxy carbonylamino, aryl C₁-C₆ alkyloxy carbonylamino,
 10 aryloxy carbonylamino, ureido, thioureido group, C₁-C₆
 alkylaminocarbonylamino, C₁-C₆ dialkylaminocarbonylamino,
 arylaminocarbonylamino, C₁-C₆ alkylaminothiocarbonylamino,
 C₁-C₆ dialkylaminothiocarbonylamino, arylaminothiocarbonyl-
 amino, C₁-C₆ alkylsulfonylamino, arylsulfonylamino, C₁-C₆
 15 alkylaminosulfonyl and arylaminosulfonyl group;
 Y is a -(CH₂)_n- group wherein n is 1, 2 or 3, or a
 carbon-carbon double bond (-CH₂=CH₂-);
 R₃ is hydrogen atom, cyano, carboxy, hydroxyaminocarbonyl
 group, or an optionally substituted group selected from
 20 aminocarbonyl, amino or sulfonamido group, a straight or
 branched C₁-C₈ alkyl group, a perfluorinated C₁-C₈ alkyl, a
 straight or branched C₁-C₈ alkoxy C₁-C₆ alkyl group, a
 saturated or unsaturated C₃-C₇ cycloalkyl, a saturated or
 unsaturated C₃-C₇ cycloalkyl C₁-C₆ alkyl, a straight or
 25 branched C₂-C₈ alkenyl group, an aryl, an aryl C₁-C₆ alkyl
 group, a straight or branched C₁-C₈ alkyloxy group, a
 saturated or unsaturated C₃-C₆ cycloalkyloxy, a straight or
 branched C₁-C₈ alkyloxy C₁-C₆ alkyloxy group, C₁-C₆
 alkyloxy carbonyl, aryloxy carbonyl, aryl C₁-C₆
 30 alkyloxy carbonyl, heteroaryloxy carbonyl, heteroaryl C₁-C₆
 alkyloxy carbonyl, C₁-C₆ alkylaminocarbonyl, C₁-C₆
 dialkylaminocarbonyl, arylaminocarbonyl, C₁-C₆
 alkyloxyaminocarbonyl, aryloxyaminocarbonyl, C₁-C₆
 alkylcarbonyloxy, arylcarbonyloxy, C₁-C₆ alkylcarbonyl,
 35 arylcarbonyl, heterocyclylcarbonyl, aryl C₁-C₆ alkyloxy

- 130 -

group, aryloxy, a straight or branched C₁-C₆ alkylthio, arylC₁-C₆ alkylthio, C₁-C₆ alkylsulphinyl group, C₁-C₆ alkylsulphonyl, arylthio, arylsulphinyl, arylsulphonyl, C₁-C₆ alkylamino, di C₁-C₆ alkylamino, arylamino, aryl C₁-C₆ alkylamino, heteroaryl amino, heteroaryl C₁-C₆ alkylamino, C₁-C₆ alkylcarbonylamino, arylcarbonylamino, C₁-C₆ alkyloxycarbonylamino, aryl C₁-C₆ alkyloxycarbonylamino, aryloxycarbonylamino, an ureido, thioureido group, C₁-C₆ alkylaminocarbonylamino, C₁-C₆ dialkylaminocarbonylamino, arylaminocarbonylamino, C₁-C₆ alkylaminothiocarbonylamino, C₁-C₆ dialkylaminothiocarbonylamino, arylaminothiocarbonylamino, C₁-C₆ alkylsulfonylamino, arylsulfonylamino, C₁-C₆ alkylaminosulfonyl, and arylaminosulfonyl group, with the proviso that when R₂ and R₃ are both hydrogen atoms and Y is a -CH₂-CH₂- group, then R₁ is not hydrogen or 7-chloro, 7-bromo atom, 7-cyclohexyl or 7-methyl group, or a pharmaceutically acceptable salt thereof.

10. A 1,4,5,10-tetrahydropyrazolo [3,4-a] carbazole derivative according to claim 9 represented by formula (IA):



(IA)

wherein R₁ is halogen atom, cyano, nitro, hydroxy, carboxy, aminocarbonyl, hydroxyaminocarbonyl, amino or sulfonamido group, or an optionally substituted group selected from a straight or branched C₁-C₈ alkyl group, a perfluorinated C₁-C₈ alkyl, a saturated or unsaturated C₃-C₇ cycloalkyl, a straight or branched C₁-C₈ alkoxy group, alkyloxycarbonyl, aryloxycarbonyl, heteroaryloxycarbonyl, heteroaryl C₁-C₆ alkyloxycarbonyl, C₁-C₆ alkylaminocarbonyl, C₁-C₆ dialkylaminocarbonyl, arylaminocarbonyl, C₁-C₆

- 131 -

alkoxyaminocarbonyl, aryloxyaminocarbonyl, C₁-C₆
 alkylcarbonyloxy, arylcarbonyloxy, an C₁-C₆ alkylamino,
 arylamino, aryl C₁-C₆ alkylamino, C₁-C₆ alkylcarbonylamino,
 arylcarbonylamino, aryloxycarbonylamino, C₁-C₆
 5 alkylaminocarbonylamino, C₁-C₆ dialkylaminocarbonylamino,
 aryl C₁-C₆ alkylaminocarbonylamino, arylaminocarbonylamino,
 C₁-C₆ alkylsulfonylamino, arylsulfonylamino, C₁-C₆
 alkylaminosulfonyl and arylaminosulfonyl;

R₃ is hydrogen atom, a carboxy group or an optionally
 10 substituted group selected from C₁-C₆ straight or branched
 alkyl, C₁-C₆ alkyloxy carbonyl, aryl C₁-C₆ alkyloxy carbonyl,
 C₁-C₆ alkylaminocarbonyl, C₁-C₆ dialkylaminocarbonyl,
 arylaminocarbonyl and aryl C₁-C₆ alkylaminocarbonyl, with
 the proviso that when R₃ is hydrogen atom, then R₁ is not
 15 hydrogen or 7-chloro, 7-bromo atom, 7-cyclohexyl or 7-
 methyl group, or a pharmaceutically acceptable salt
 thereof.

11. A compound of formula (I), optionally in the form of a
 pharmaceutically acceptable salt, selected from the group
 20 consisting of:

6-fluoro-2,4,5,10-tetrahydropyrazolo[3,4-a]carbazole;
 7-fluoro-2,4,5,10-tetrahydropyrazolo[3,4-a]carbazole;
 8-fluoro-2,4,5,10-tetrahydropyrazolo[3,4-a]carbazole;
 6-chloro-2,4,5,10-tetrahydropyrazolo[3,4-a]carbazole;
 25 8-chloro-2,4,5,10-tetrahydropyrazolo[3,4-a]carbazole;
 6-bromo-2,4,5,10-tetrahydropyrazolo[3,4-a]carbazole;
 8-bromo-2,4,5,10-tetrahydropyrazolo[3,4-a]carbazole;
 6-cyano-2,4,5,10-tetrahydropyrazolo[3,4-a]carbazole;
 7-cyano-2,4,5,10-tetrahydropyrazolo[3,4-a]carbazole;
 30 8-cyano-2,4,5,10-tetrahydropyrazolo[3,4-a]carbazole;
 6-nitro-2,4,5,10-tetrahydropyrazolo[3,4-a]carbazole;
 7-nitro-2,4,5,10-tetrahydropyrazolo[3,4-a]carbazole;
 8-nitro-2,4,5,10-tetrahydropyrazolo[3,4-a]carbazole;
 6-methyl-2,4,5,10-tetrahydropyrazolo[3,4-a]carbazole;
 35 8-methyl-2,4,5,10-tetrahydropyrazolo[3,4-a]carbazole;

- 132 -

- 6-trifluoromethyl-2,4,5,10-tetrahydropyrazolo[3,4-a]
carbazole;
7-trifluoromethyl-2,4,5,10-tetrahydropyrazolo[3,4-a]
carbazole;
5 8-trifluoromethyl-2,4,5,10-tetrahydropyrazolo[3,4-a]
carbazole;
6-methoxy-2,4,5,10-tetrahydropyrazolo[3,4-a] carbazole;
7-methoxy-2,4,5,10-tetrahydropyrazolo[3,4-a] carbazole;
8-methoxy-2,4,5,10-tetrahydropyrazolo[3,4-a] carbazole;
10 6-hydroxy-2,4,5,10-tetrahydropyrazolo[3,4-a] carbazole;
7-hydroxy-2,4,5,10-tetrahydropyrazolo[3,4-a] carbazole;
8-hydroxy-2,4,5,10-tetrahydropyrazolo[3,4-a] carbazole;
2,4,5,10-tetrahydropyrazolo[3,4-a]carbazole-6-carboxylic
acid;
15 2,4,5,10-tetrahydropyrazolo[3,4-a]carbazole-7-carboxylic
acid;
2,4,5,10-tetrahydropyrazolo[3,4-a]carbazole-8-carboxylic
acid;
methyl2,4,5,10-tetrahydropyrazolo[3,4-a]carbazole-6-
20 carboxylate;
methyl2,4,5,10-tetrahydropyrazolo[3,4-a]carbazole-7-
carboxylate;
methyl2,4,5,10-tetrahydropyrazolo[3,4-a]carbazole-8-
carboxylate;
25 ethyl2,4,5,10-tetrahydropyrazolo[3,4-a]carbazole-6-
carboxylate;
ethyl2,4,5,10-tetrahydropyrazolo[3,4-a]carbazole-7-
carboxylate;
ethyl2,4,5,10-tetrahydropyrazolo[3,4-a]carbazole-8-
30 carboxylate;
i-butyl2,4,5,10-tetrahydropyrazolo[3,4-a]carbazole-6-
carboxylate;
i-butyl2,4,5,10-tetrahydropyrazolo[3,4-a]carbazole-7-
carboxylate;

- 133 -

- i-butyl2,4,5,10-tetrahydropyrazolo[3,4-a]carbazole-8-carboxylate;
1,4,5,10-tetrahydropyrazolo[3,4-a]carbazole-3-carboxylic acid;
- 5 methyl2,4,5,10-tetrahydropyrazolo[3,4-a]carbazole-3-carboxylate;
ethyl2,4,5,10-tetrahydropyrazolo[3,4-a]carbazole-3-carboxylate;
propyl2,4,5,10-tetrahydropyrazolo[3,4-a]carbazole-3-
- 10 carboxylate;
i-propyl2,4,5,10-tetrahydropyrazolo[3,4-a]carbazole-3-carboxylate;
butyl2,4,5,10-tetrahydropyrazolo[3,4-a]carbazole-3-carboxylate;
- 15 i-butyl2,4,5,10-tetrahydropyrazolo[3,4-a]carbazole-3-carboxylate;
1,4,5,10-tetrahydropyrazolo[3,4-a]carbazole-6-carboxamide;
1,4,5,10-tetrahydropyrazolo[3,4-a]carbazole-7-carboxamide;
1,4,5,10-tetrahydropyrazolo[3,4-a]carbazole-8-carboxamide;
- 20 N-methyl-1,4,5,10-tetrahydropyrazolo[3,4-a]carbazole-6-carboxamide;
N-methyl-1,4,5,10-tetrahydropyrazolo[3,4-a]carbazole-7-carboxamide;
N-methyl-1,4,5,10-tetrahydropyrazolo[3,4-a]carbazole-8-
- 25 carboxamide;
N-ethyl-1,4,5,10-tetrahydropyrazolo[3,4-a]carbazole-6-carboxamide;
N-ethyl-1,4,5,10-tetrahydropyrazolo[3,4-a]carbazole-7-carboxamide;
- 30 N-ethyl-1,4,5,10-tetrahydropyrazolo[3,4-a]carbazole-8-carboxamide;
N-propyl-1,4,5,10-tetrahydropyrazolo[3,4-a]carbazole-6-carboxamide;
N-propyl-1,4,5,10-tetrahydropyrazolo[3,4-a]carbazole-7-
- 35 carboxamide;

- 134 -

- N-propyl-1,4,5,10-tetrahydropyrazolo[3,4-a]carbazole-8-carboxamide;
- N-isopropyl-1,4,5,10-tetrahydropyrazolo[3,4-a]carbazole-6-carboxamide;
- 5 N-isopropyl-1,4,5,10-tetrahydropyrazolo[3,4-a]carbazole-7-carboxamide;
- N-isopropyl-1,4,5,10-tetrahydropyrazolo[3,4-a]carbazole-8-carboxamide;
- N-butyl-1,4,5,10-tetrahydropyrazolo[3,4-a]carbazole-6-
- 10 carboxamide;
- N-butyl-1,4,5,10-tetrahydropyrazolo[3,4-a]carbazole-7-carboxamide;
- N-butyl-1,4,5,10-tetrahydropyrazolo[3,4-a]carbazole-8-carboxamide;
- 15 N-isobutyl-1,4,5,10-tetrahydropyrazolo[3,4-a]carbazole-6-carboxamide;
- N-isobutyl-1,4,5,10-tetrahydropyrazolo[3,4-a]carbazole-7-carboxamide;
- N-isobutyl-1,4,5,10-tetrahydropyrazolo[3,4-a]carbazole-8-
- 20 carboxamide;
- N-terbutyl-1,4,5,10-tetrahydropyrazolo[3,4-a]carbazole-6-carboxamide;
- N-terbutyl-1,4,5,10-tetrahydropyrazolo[3,4-a]carbazole-7-carboxamide;
- 25 N-terbutyl-1,4,5,10-tetrahydropyrazolo[3,4-a]carbazole-8-carboxamide;
- N-phenyl-1,4,5,10-tetrahydropyrazolo[3,4-a]carbazole-6-carboxamide;
- N-phenyl-1,4,5,10-tetrahydropyrazolo[3,4-a]carbazole-7-
- 30 carboxamide;
- N-phenyl-1,4,5,10-tetrahydropyrazolo[3,4-a]carbazole-8-carboxamide;
- N-benzyl-1,4,5,10-tetrahydropyrazolo[3,4-a]carbazole-6-carboxamide;

- 135 -

- N-benzyl-1,4,5,10-tetrahydropyrazolo[3,4-a]carbazole-7-carboxamide;
N-benzyl-1,4,5,10-tetrahydropyrazolo[3,4-a]carbazole-8-carboxamide;
- 5 N-(3-dimethylamino)propyl-1,4,5,10-tetrahydropyrazolo[3,4-a]carbazole-6-carboxamide;
N-(3-dimethylamino)propyl-1,4,5,10-tetrahydropyrazolo[3,4-a]carbazole-7-carboxamide;
N-(3-dimethylamino)propyl-1,4,5,10-tetrahydropyrazolo[3,4-a]carbazole-8-carboxamide;
- 10 N-(3-dimethylamino)propyl-1,10-dihydropyrazolo[3,4-a]carbazole-6-carboxamide;
N-(3-dimethylamino)propyl-1,10-dihydropyrazolo[3,4-a]carbazole-7-carboxamide;
N-(3-dimethylamino)propyl-1,10-dihydropyrazolo[3,4-a]carbazole-8-carboxamide;
- 15 N-(5-hydroxy-1H-pyrazol-3-yl)-1,4,5,10-tetrahydropyrazolo[3,4-a]carbazole-6-carboxamide;
N-(5-hydroxy-1H-pyrazol-3-yl)-1,4,5,10-tetrahydropyrazolo[3,4-a]carbazole-7-carboxamide;
- 20 N-(5-hydroxy-1H-pyrazol-3-yl)-1,4,5,10-tetrahydropyrazolo[3,4-a]carbazole-8-carboxamide;
N-(5-hydroxy-1H-pyrazol-3-yl)-1,10-dihydropyrazolo[3,4-a]carbazole-6-carboxamide;
N-(5-hydroxy-1H-pyrazol-3-yl)-1,10-dihydropyrazolo[3,4-a]carbazole-7-carboxamide;
- 25 N-(5-hydroxy-1H-pyrazol-3-yl)-1,10-dihydropyrazolo[3,4-a]carbazole-8-carboxamide;
- N-(3-morpholin-4-yl-propyl)-1,4,5,10-tetrahydropyrazolo[3,4-a]carbazole-6-carboxamide;
- 30 N-(3-morpholin-4-yl-propyl)-1,4,5,10-tetrahydropyrazolo[3,4-a]carbazole-7-carboxamide;
N-(3-morpholin-4-yl-propyl)-1,4,5,10-tetrahydropyrazolo[3,4-a]carbazole-8-carboxamide;

- 136 -

- N-(3-morpholin-4-yl-propyl)-1,10-dihydropyrazolo[3,4-a]
carbazole-6-carboxamide;
- N-(3-morpholin-4-yl-propyl)-1,10-dihydropyrazolo[3,4-a]
carbazole-7-carboxamide;
- 5 N-(3-morpholin-4-yl-propyl)-1,10-dihydropyrazolo[3,4-a]
carbazole-8-carboxamide;
- N-(2-phenylamino-ethyl)-1,4,5,10-tetrahydropyrazolo[3,4-a]
carbazole-6-carboxamide;
- N-(2-phenylamino-ethyl)-1,4,5,10-tetrahydropyrazolo[3,4-a]
10 carbazole-7-carboxamide;
- N-(2-phenylamino-ethyl)-1,4,5,10-tetrahydropyrazolo[3,4-a]
carbazole-8-carboxamide;
- N-(2-phenylamino-ethyl)-1,10-dihydropyrazolo[3,4-a]
carbazole-6-carboxamide;
- 15 N-(2-phenylamino-ethyl)-1,10-dihydropyrazolo[3,4-a]
carbazole-7-carboxamide;
- N-(2-phenylamino-ethyl)-1,10-dihydropyrazolo[3,4-a]
carbazole-8-carboxamide;
- N-[2-(1H-imidazol-4-yl)-ethyl]-1,4,5,10-
20 tetrahydropyrazolo[3,4-a]carbazole-6-carboxamide;
- N-[2-(1H-imidazol-4-yl)-ethyl]-1,4,5,10-
tetrahydropyrazolo[3,4-a]carbazole-7-carboxamide;
- N-[2-(1H-imidazol-4-yl)-ethyl]-1,4,5,10-
tetrahydropyrazolo[3,4-a]carbazole-8-carboxamide;
- 25 N-[2-(1H-imidazol-4-yl)-ethyl]-1,10-dihydropyrazolo[3,4-a]
carbazole-6-carboxamide;
- N-[2-(1H-imidazol-4-yl)-ethyl]-1,10-dihydropyrazolo[3,4-a]
carbazole-7-carboxamide;
- N-[2-(1H-imidazol-4-yl)-ethyl]-1,10-dihydropyrazolo[3,4-a]
30 carbazole-8-carboxamide;
- N-(4-hydroxy-butyl)-1,4,5,10-tetrahydropyrazolo[3,4-a]
carbazole-6-carboxamide;
- N-(4-hydroxy-butyl)-1,4,5,10-tetrahydropyrazolo[3,4-a]
carbazole-7-carboxamide;

- 137 -

- N-(4-hydroxy-butyl)-1,4,5,10-tetrahydropyrazolo[3,4-a]
carbazole-8-carboxamide;
- N-(4-hydroxy-butyl)-1,10-dihydropyrazolo[3,4-a]carbazole-6-
carboxamide;
- 5 N-(4-hydroxy-butyl)-1,10-dihydropyrazolo[3,4-a]carbazole-7-
carboxamide;
- N-(4-hydroxy-butyl)-1,10-dihydropyrazolo[3,4-a]carbazole-8-
carboxamide;
- N-(2-hydroxymethyl-phenyl)-1,4,5,10-tetrahydropyrazolo
10 [3,4-a]carbazole-6-carboxamide;
- N-(2-hydroxymethyl-phenyl)-1,4,5,10-tetrahydropyrazolo
[3,4-a]carbazole-7-carboxamide;
- N-(2-hydroxymethyl-phenyl)-1,4,5,10-tetrahydropyrazolo
[3,4-a]carbazole-8-carboxamide;
- 15 N-(2-hydroxymethyl-phenyl)-1,10-dihydropyrazolo[3,4-a]
carbazole-6-carboxamide;
- N-(2-hydroxymethyl-phenyl)-1,10-dihydropyrazolo[3,4-a]
carbazole-7-carboxamide;
- N-(2-hydroxymethyl-phenyl)-1,10-dihydropyrazolo[3,4-a]
20 carbazole-8-carboxamide;
- N-(furan-2-ylmethyl)-1,4,5,10-tetrahydropyrazolo[3,4-a]
carbazole-6-carboxamide;
- N-(furan-2-ylmethyl)-1,4,5,10-tetrahydropyrazolo[3,4-a]
carbazole-7-carboxamide;
- 25 N-(furan-2-ylmethyl)-1,4,5,10-tetrahydropyrazolo[3,4-a]
carbazole-8-carboxamide;
- N-(furan-2-ylmethyl)-1,10-dihydropyrazolo[3,4-a]carbazole-
6-carboxamide;
- N-(furan-2-ylmethyl)-1,10-dihydropyrazolo[3,4-a]carbazole-
30 7-carboxamide;
- N-(furan-2-ylmethyl)-1,10-dihydropyrazolo[3,4-a]carbazole-
8-carboxamide;
- N-(pyridin-4-ylmethyl)-1,4,5,10-tetrahydropyrazolo[3,4-a]
carbazole-6-carboxamide;

- 138 -

- N-(pyridin-4-ylmethyl)-1,4,5,10-tetrahydropyrazolo[3,4-a]
carbazole-7-carboxamide;
N-(pyridin-4-ylmethyl)-1,4,5,10-tetrahydropyrazolo[3,4-a]
carbazole-8-carboxamide;
- 5 N-(pyridin-4-ylmethyl)-1,10-dihydropyrazolo[3,4-a]
carbazole-6-carboxamide;
N-(pyridin-4-ylmethyl)-1,10-dihydropyrazolo[3,4-a]
carbazole-7-carboxamide;
N-(pyridin-4-ylmethyl)-1,10-dihydropyrazolo[3,4-a]
10 carbazole-8-carboxamide;
N-[(methoxycarbonyl)methyl]-1,4,5,10-tetrahydropyrazolo
[3,4-a]carbazole-6-carboxamide;
N-[(methoxycarbonyl)methyl]-1,4,5,10-tetrahydropyrazolo
[3,4-a]carbazole-7-carboxamide;
- 15 N-[(methoxycarbonyl)methyl]-1,4,5,10-tetrahydropyrazolo
[3,4-a]carbazole-8-carboxamide;
N-[(methoxycarbonyl)methyl]-1,10-dihydropyrazolo[3,4-a]
carbazole-6-carboxamide;
N-[(methoxycarbonyl)methyl]-1,10-dihydropyrazolo[3,4-a]
20 carbazole-7-carboxamide;
N-[(methoxycarbonyl)methyl]-1,10-dihydropyrazolo[3,4-a]
carbazole-8-carboxamide;
N-(ethane-2-sulfonic acid)-1,4,5,10-tetrahydropyrazolo
[3,4-a]carbazole-6-carboxamide;
- 25 N-(ethane-2-sulfonic acid)-1,4,5,10-tetrahydropyrazolo
[3,4-a]carbazole-7-carboxamide;
N-(ethane-2-sulfonic acid)-1,4,5,10-tetrahydropyrazolo
[3,4-a]carbazole-8-carboxamide;
7-[(4-methylpiperazin-1-yl)carbonyl]-1,4,5,10-
30 tetrahydropyrazolo[3,4-a]carbazole;
1,4,5,10-tetrahydropyrazolo[3,4-a]carbazol-6-amine;
1,4,5,10-tetrahydropyrazolo[3,4-a]carbazol-7-amine;
1,4,5,10-tetrahydropyrazolo[3,4-a]carbazol-8-amine;
N-(1,4,5,10-tetrahydropyrazolo[3,4-a]carbazol-6-yl)
35 acetamide;

- 139 -


- N-(1,4,5,10-tetrahydropyrazolo[3,4-a]carbazol-7-yl)
acetamide;
N-(1,4,5,10-tetrahydropyrazolo[3,4-a]carbazol-8-yl)
acetamide;
5 N-(1,4,5,10-tetrahydropyrazolo[3,4-a]carbazol-6-yl)
propanamide;
N-(1,4,5,10-tetrahydropyrazolo[3,4-a]carbazol-7-yl)
propanamide;
N-(1,4,5,10-tetrahydropyrazolo[3,4-a]carbazol-8-yl)
10 propanamide;
2-methyl-N-(1,4,5,10-tetrahydropyrazolo[3,4-a]carbazol-6-
yl) propanamide;
2-methyl-N-(1,4,5,10-tetrahydropyrazolo[3,4-a]carbazol-7-
yl)propanamide;
15 2-methyl-N-(1,4,5,10-tetrahydropyrazolo[3,4-a]carbazol-8-
yl)propanamide;
N-(1,4,5,10-tetrahydropyrazolo[3,4-a]carbazol-6-yl)
butanamide;
N-(1,4,5,10-tetrahydropyrazolo[3,4-a]carbazol-7-yl)
20 butanamide;
N-(1,4,5,10-tetrahydropyrazolo[3,4-a]carbazol-8-yl)
butanamide;
N-(1,4,5,10-tetrahydropyrazolo[3,4-a]carbazol-6-yl)
benzamide;
25 N-(1,4,5,10-tetrahydropyrazolo[3,4-a]carbazol-7-yl)
benzamide;
N-(1,4,5,10-tetrahydropyrazolo[3,4-a]carbazol-8-yl)
benzamide;
N-(1,4,5,10-tetrahydropyrazolo[3,4-a]carbazol-6-yl)
30 phenylacetamide;
N-(1,4,5,10-tetrahydropyrazolo[3,4-a]carbazol-7-yl)
phenylacetamide;
N-(1,4,5,10-tetrahydropyrazolo[3,4-a]carbazol-8-yl)
phenylacetamide;

- 140 -

- 3-methyl-N-(1,4,5,10-tetrahydropyrazolo[3,4-a]carbazol-6-yl)butanamide;
3-methyl-N-(1,4,5,10-tetrahydropyrazolo[3,4-a]carbazol-7-yl)butanamide;
5 3-methyl-N-(1,4,5,10-tetrahydropyrazolo[3,4-a]carbazol-8-yl)butanamide;
N-(2,4,5,10-tetrahydropyrazolo[3,4-a]carbazol-7-yl)thiophene-2-carboxamide;
N-methyl-N'-(1,4,5,10-tetrahydropyrazolo[3,4-a]carbazol-7-yl)urea;
10 N-propyl-N'-(1,4,5,10-tetrahydropyrazolo[3,4-a]carbazol-7-yl)urea;
N-benzyl-N'-(1,4,5,10-tetrahydropyrazolo[3,4-a]carbazol-7-yl)urea;
15 N-phenyl-N'-(1,4,5,10-tetrahydropyrazolo[3,4-a]carbazol-7-yl)urea;
4,9-dihydro-1H-pyrazolo[4',3':4,5]cyclopenta[1,2-b]indole-6-carboxamide;
N-(4,9-dihydro-1H-pyrazolo[4',3':4,5]cyclopenta[1,2-b]indol-6-yl)acetamide;
20 N-(4,9-dihydro-1H-pyrazolo[4',3':4,5]cyclopenta[1,2-b]indol-6-yl)-3-methylbutanamide;
N-(4,9-dihydro-1H-pyrazolo[4',3':4,5]cyclopenta[1,2-b]indol-6-yl)-2-phenylacetamide;
25 6-chloro-4,9-dihydro-1H-pyrazolo[4',3':4,5]cyclopenta[1,2-b]indole;
N-isobutyl-4,9-dihydro-1H-pyrazolo[4',3':4,5]cyclopenta[1,2-b]indole-6-carboxamide;
N-benzyl-4,9-dihydro-1H-pyrazolo[4',3':4,5]cyclopenta[1,2-b]indole-6-carboxamide;
30 ethyl 4,9-dihydro-1H-pyrazolo[4',3':4,5]cyclopenta[1,2-b]indole-3-carboxylate;
4,5,6,11-tetrahydro-1H-pyrazolo[4',3':6,7]cyclohepta[1,2-b]indole-8-carboxamide;

- 141 -

- 3-methyl-N-(4,5,6,11-tetrahydro-1H-pyrazolo[4',3':6,7]
cyclohepta[1,2-b]indol-8-yl)butanamide;
8-chloro-4,5,6,11-tetrahydro-1H-pyrazolo[4',3':6,7]
cyclohepta[1,2-b]indole;
- 5 N-benzyl-4,5,6,11-tetrahydro-1H-pyrazolo[4',3':6,7]
cyclohepta[1,2-b]indole-8-carboxamide;
N-isobutyl-4,5,6,11-tetrahydro-1H-pyrazolo[4',3':6,7]
cyclohepta[1,2-b]indole-8-carboxamide;
ethyl-4,5,6,11-tetrahydro-1H-pyrazolo[4',3':6,7]
10 cyclohepta[1,2-b]indole-3-carboxylate;
N-(4,5,6,11-tetrahydro-1H-pyrazolo[4',3':6,7] cyclohepta
[1,2-b]indol-8-yl)acetamide;
2-phenyl-N-(4,5,6,11-tetrahydro-1H-pyrazolo
[4',3':6,7]cyclohepta[1,2-b]indol-8-yl)acetamide and
15 3-methylsulfonyl-1,4,5,10-tetrahydropyrazolo[3,4-a]
carbazole.
12. A process for preparing a compound of formula (I) as
defined in claim 9, or a pharmaceutically acceptable salt
thereof, which process comprises:
- 20 i) treating a compound of formula (VII)



- wherein Y is $-(CH_2)_n-$; n, R1 and R2 are as defined in
claim 9; W and Z have, respectively, one the following
couple of meanings:
- 25 e) W is a dialkylamino group, and Z is a hydrogen atom;
f) W is a hydroxy group, and Z is a hydrogen atom, a C_1 -
 C_4 alkoxy carbonyl group or a methyl group;
c) Z is a C_1 - C_6 alkylthio or aryl- C_1 - C_6 alkylthio group,
and W is:
- 30 -i) a methylthio group,


- 142 -

- ii) a substituted or disubstituted amino group;
- iii) a group of general formula $-\text{CH}(\text{J})(\text{X})$ where J and X are, the same or different, electron withdrawing groups;
- iv) an alkyl or aryl group;
- 5 -v) an alkyl- or aryl-carbonyl group;
- vi) a cyano group or
- d) both Z and W are substituted or disubstituted amino groups;

with hydrazine in a suitable solvent to give a compound of
 10 general formula (I) wherein Y is a $-(\text{CH}_2)_n-$ group, n, R1 and R2 are as described above, and R3 is $\text{C}_1\text{-C}_6$ alkylthio or aryl $\text{C}_1\text{-C}_6$ alkylthio group, a substituted or disubstituted amino group; a group of the formula $-\text{CH}(\text{J})(\text{X})$ wherein X and J are, the same or different, electron withdrawing groups;
 15 a $\text{C}_1\text{-C}_6$ alkyl or aryl group; a $\text{C}_1\text{-C}_6$ alkyl- or aryl-carbonyl group; a cyano group and
 ii) optionally converting a compound of general formula (I) into a different compound of formula (I). if necessary separating a mixture of a compound of formula (I) wherein Y
 20 is a $-\text{CH}_2\text{-CH}_2-$ group and a compound of formula (I) wherein Y is a $-\text{CH=CH}-$ group and, if desired, converting a compound of formula (I) into a pharmaceutically acceptable salt thereof or converting a salt into the free compound (I).

13. A process for preparing a compound of formula (I) as
 25 defined in claim 9, wherein Y is a carbon-carbon double bond $-\text{C}=\text{C}-$, or a pharmaceutically acceptable salt thereof, which process comprises:

- i) treating with hydrazine a compound of formula (VIIa)



30 wherein Y is a carbon-carbon double bond $-\text{CH=CH}-$, R1 and R2 are as defined in claim 9, to give a compound of general

- 143 -


formula (I) wherein Y is a carbon-carbon double bond and R1, R2 are as described above, and R3 is hydrogen atom, and
 ii) optionally converting a compound of general formula (I) into a different compound of formula (I) and, if desired,
 5 converting a compound of formula (I) into a pharmaceutically acceptable salt thereof or converting a salt into the free compound (I).

14. A compound of formula VII or VIIa as defined in claims 12 or 13 with the proviso that when R2 is a hydrogen atom,
 10 and

i) W is dimethylamino and Z is a hydrogen atom, then R1 is not 7-chloro, hydrogen, 7-bromo atom, 7-cyclohexyl or 7-methyl group, or

ii) W is hydroxy and Z is a hydrogen atom,
 15 then R1 is not hydrogen, 7-methoxy group, 7-benzyloxy, or
 iii) W is hydroxy and Z is ethyloxycarbonyl group, then R1 is not hydrogen.

15. A process for preparing a compound of the formula (VII) or (VIIa) as defined in claim 14, which process comprises:
 20 either i) reacting a compound of formula (VI):



wherein Y, R1 and R2 are as above defined and the indole nitrogen is optionally protected with an appropriate protecting group, with any of the following:

- 25 - a dialkylacetale of dimethylformamide;
 - a carboxylic ester;
 - dimethyl trithiocarbonate and an alkyl iodide or bromide,

to give a compound of general formula (VII) wherein Y is
 30 -(CH₂)_n-; n, R1 and R2 are as above defined; W and Z

- 144 -

have, respectively, one of the following couple of meanings:

- a) W is a dialkylamino group, and Z is a hydrogen atom;
- b) W is a hydroxy group, and Z is a hydrogen atom, a C₁-C₄ alkoxy carbonyl group or a methyl group;
- 5 c) Z is a C₁-C₆ alkylthio or arylC₁-C₆ alkylthio group, and W is a methylthio group;


and iia) optionally reacting a compound of general formula (VII) where R₁, R₂ and Y are as described above and W and Z
10 are as defined under c) with any of the following:

- a') an aliphatic or aromatic primary or secondary amine;
- b') a compound of general formula W(CH₂)_nX where W and X are, the same or different, electron withdrawing groups;
- c') an organometallic compound of general formula RM,
15 where R is either an aliphatic or aromatic group, and M represents lithium or magnesium halide;
- d') an organometallic compound of general formula of (CH₃)₂CuLi₂B, where B is a suitable anion species;
- e') an inorganic cyanide;
- 20 to give a different compound of general formula (VII) where R₁, R₂ and Y are as defined above, while Z is a C₁-C₆ alkylthio or arylC₁-C₆ alkylthio group and W is
 - i) a substituted or disubstituted amino group;
 - ii) a group of general formula -CH(J)(X) where J and X
25 are, the same or different, electron withdrawing groups;
 - iii) an alkyl or aryl group;
 - iv) an alkyl- or aryl-carbonyl group;
 - v) a cyano group or

30 d) both Z and W are substituted or disubstituted amino groups,

or ii) reacting another compound of formula (VIa):

- 145 -



wherein Y is $-(CH_2)_2-$, R1 and R2 are as above defined, with $POCl_3$ in dimethylformamide, to give a compound of general formula (VIIa) as defined above.

- 5 16. A process according to claims 12 or 13 characterized in that the optional conversion of a compound of formula (I) into a different compound of formula I is carried out by reacting a compound of formula (I) as defined in claim 9 with a suitable activated solid support, then making the
- 10 desired functionality modifications, and cleaving the resultant compound so as to eliminate the solid support obtaining the desired compound of formula (I).
17. A library of two or more compounds of formula (I) as defined in claim 9, which can be obtained by converting one
- 15 or more compound of formula (I) supported onto a solid support of the formula (I) as described in claim 16.
18. A pharmaceutical composition comprising an effective amount of pyrazolo[3,4-a]carbazole derivative of formula (I) as defined in claim 9, and at least one
- 20 pharmaceutically acceptable excipient, carrier or diluent.
19. A pharmaceutical composition according to claim 18 further comprising one or more chemotherapeutic agents, as a combined preparation for simultaneous, separate or sequential use in anticancer therapy.
- 25 20. A product or kit comprising a compound of formula (I) as defined in claim 1 or a pharmaceutical composition thereof as defined in claim 18, and one or more chemotherapeutic agents, as a combined preparation for simultaneous, separate or sequential use in anticancer
- 30 therapy.

- 146 -

21. A compound of formula (I) as defined in claim 1 for use as a medicament.

22. Use of a compound of formula (I) as defined in claim 1 for the preparation of a medicament for the treatment of
5 tumors or cell proliferative disorders.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP2004/050071

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K31/4162 C07D487/04 C07D209/82 A61P25/00 A61P35/00
A61P37/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 00/27822 A (BASF AG ; DOYLE KEVIN J (GB); RAFFERTY PAUL (GB); HOCKLEY MICHAEL (GB)) 18 May 2000 (2000-05-18) page 1, lines 3-7 page 8, line 20- page 43, line 3-	1-22
A	WO 00/59901 A (BASF AG ; DOYLE KEVIN J (GB); RAFFERTY PAUL (GB); STEELE ROBERT W (GB)) 12 October 2000 (2000-10-12) page 1, lines 7-14 page 9, line 1- page 19, line 30- ----- -/--	1-22

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

Z document member of the same patent family

Date of the actual completion of the international search

14 July 2004

Date of mailing of the international search report

29/07/2004

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Heller, D

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP2004/050071

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	SEKAR, M. ET AL: "Synthesis, antimalarial and antibacterial activity of 1-chloro-2-formylcarbazole derivatives and pyrazolo[3,4-a]carbazole derivatives" INDIAN JOURNAL OF CHEMISTRY, SECTION B: ORGANIC CHEMISTRY INCLUDING MEDICINAL CHEMISTRY, 37B(3), 314-317 CODEN: IJSBDB; ISSN: 0376-4699, 1998, XP009033608 page 314, left-hand column, paragraph 2 Scheme I page 314	1,2,4,5, 7-11, 13-16, 18-22
X	SEKAR, M. ET AL: "Synthesis and antibacterial activity of 1-chloro-2-formyl- and pyrazolo[3,4-a]carbazole derivatives" RESEARCH JOURNAL OF CHEMISTRY AND ENVIRONMENT, 5(1), 31-33 CODEN: RJCEF7; ISSN: 0972-0626, 2001, XP001182290 page 31, left-hand column, paragraph 3 Scheme page 33	1,2,4,5, 7-11, 13-16, 18-22

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP2004/050071

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 0027822	A	18-05-2000	
		AU 762992 B2	10-07-2003
		AU 1909100 A	29-05-2000
		BG 105481 A	31-12-2001
		BR 9915132 A	07-08-2001
		CA 2350235 A1	18-05-2000
		CN 1335836 T	13-02-2002
		CZ 20011563 A3	12-02-2003
		EP 1127051 A2	29-08-2001
		HU 0200310 A2	28-11-2002
		ID 30132 A	08-11-2001
		JP 2003517447 T	27-05-2003
		NO 20012219 A	13-06-2001
		PL 348210 A1	06-05-2002
		SK 5282001 A3	07-01-2002
		TR 200102277 T2	21-01-2002
		WO 0027822 A2	18-05-2000
		US 6462036 B1	08-10-2002
		ZA 200103610 A	23-09-2002
WO 0059901	A	12-10-2000	
		AT 246684 T	15-08-2003
		AU 4037800 A	23-10-2000
		BG 106044 A	31-05-2002
		BR 0009561 A	16-04-2002
		CA 2368686 A1	12-10-2000
		CN 1368970 T	11-09-2002
		CZ 20013580 A3	13-03-2002
		DE 60004340 D1	11-09-2003
		DE 60004340 T2	09-06-2004
		DK 1165544 T3	01-12-2003
		EP 1165544 A1	02-01-2002
		ES 2207497 T3	01-06-2004
		HU 0201514 A2	28-08-2002
		JP 2002541150 T	03-12-2002
		NO 20014864 A	05-12-2001
		NZ 514269 A	31-10-2003
		PL 350891 A1	10-02-2003
		PT 1165544 T	31-12-2003
		SK 14112001 A3	04-04-2002
		TR 200103789 T2	22-04-2002
		WO 0059901 A1	12-10-2000
		US 6297238 B1	02-10-2001
		ZA 200107838 A	24-03-2003